Journal of Extracellular Vesicles ISSN : ( Print ) 2001 - 3078 ( Online ) Journal homepage : http : / / www . tandfonline . com / loi / zjev20 Minimal information for studies of extracellular vesicles 2018 ( MISEV2018 ) : a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines Clotilde Théry , Kenneth W Witwer , Elena Aikawa , Maria Jose Alcaraz , Johnathon D Anderson , Ramaroson Andriantsitohaina , Anna Antoniou , Tanina Arab , Fabienne Archer , Georgia K Atkin - Smith , D Craig Ayre , Jean - Marie Bach , Daniel Bachurski , Hossein Baharvand , Leonora Balaj , Shawn Baldacchino , Natalie N Bauer , Amy A Baxter , Mary Bebawy , Carla Beckham , Apolonija Bedina Zavec , Abderrahim Benmoussa , Anna C Berardi , Paolo Bergese , Ewa Bielska , Cherie Blenkiron , Sylwia Bobis - Wozowicz , Eric Boilard , Wilfrid Boireau , Antonella Bongiovanni , Francesc E Borràs , Steffi Bosch , Chantal M Boulanger , Xandra Breakefield , Andrew M Breglio , Meadhbh Á Brennan , David R Brigstock , Alain Brisson , Marike LD Broekman , Jacqueline F Bromberg , Paulina Bryl - Górecka , Shilpa Buch , Amy H Buck , Dylan Burger , Sara Busatto , Dominik Buschmann , Benedetta Bussolati , Edit I Buzás , James Bryan Byrd , Giovanni Camussi , David RF Carter , Sarah Caruso , Lawrence W Chamley , Yu - Ting Chang , Chihchen Chen , Shuai Chen , Lesley Cheng , Andrew R Chin , Aled Clayton , Stefano P Clerici , Alex Cocks , Emanuele Cocucci , Robert J Coffey , Anabela Cordeiro - da - Silva , Yvonne Couch , Frank AW Coumans , Beth Coyle , Rossella Crescitelli , Miria Ferreira Criado , Crislyn D’Souza - Schorey , Saumya Das , Amrita Datta Chaudhuri , Paola de Candia , Eliezer F De Santana Junior , Olivier De Wever , Hernando A del Portillo , Tanguy Demaret , Sarah Deville , Andrew Devitt , Bert Dhondt , Dolores Di Vizio , Lothar C Dieterich , Vincenza Dolo , Ana Paula Dominguez Rubio , Massimo Dominici , Mauricio R Dourado , Tom AP Driedonks , Filipe V Duarte , Heather M Duncan , Ramon M Eichenberger , Karin Ekström , Samir EL Andaloussi , Celine Elie - Caille , Uta Erdbrügger , Juan M Falcón - Pérez , Farah Fatima , Jason E Fish , Miguel Flores - Bellver , András Försönits , Annie Frelet - Barrand , Fabia Fricke , Gregor Fuhrmann , Susanne Gabrielsson , Ana Gámez - Valero , Chris Gardiner , Kathrin Gärtner , Raphael Gaudin , Yong Song Gho , Bernd Giebel , Caroline Gilbert , Mario Gimona , Ilaria Giusti , Deborah CI Goberdhan , André Görgens , Sharon M Gorski , David W Greening , Julia Christina Gross , Alice Gualerzi , Gopal N Gupta , Dakota Gustafson , Aase Handberg , Reka A Haraszti , Paul Harrison , Hargita Hegyesi , An Hendrix , Andrew F Hill , Fred H Hochberg , Karl F Hoffmann , Beth Holder , Harry Holthofer , Baharak Hosseinkhani , Guoku Hu , Yiyao Huang , Veronica Huber , Stuart Hunt , Ahmed Gamal - Eldin Ibrahim , Tsuneya Ikezu , Jameel M Inal , Mustafa Isin , Alena Ivanova , Hannah K Jackson , Soren Jacobsen , Steven M Jay , Muthuvel Jayachandran , Guido Jenster , Lanzhou Jiang , Suzanne M Johnson , Jennifer C Jones , Ambrose Jong , Tijana Jovanovic - Talisman , Stephanie Jung , Raghu Kalluri , Shin - ichi Kano , Sukhbir Kaur , Yumi Kawamura , Evan T Keller , Delaram Khamari , Elena Khomyakova , Anastasia Khvorova , Peter Kierulf , Kwang Pyo Kim , Thomas Kislinger , Mikael Klingeborn , David J Klinke II , Miroslaw Kornek , Maja M Kosanović , Árpád Ferenc Kovács , Eva - Maria Krämer - Albers , Susanne Krasemann , Mirja Krause , Igor V Kurochkin , Gina D Kusuma , Sören Kuypers , Saara Laitinen , Scott M Langevin , Lucia R Languino , Joanne Lannigan , Cecilia Lässer , Louise C Laurent , Gregory Lavieu , Elisa Lázaro - Ibáñez , Soazig Le Lay , Myung - Shin Lee , Yi Xin Fiona Lee , Debora S Lemos , Metka Lenassi , Aleksandra Leszczynska , Isaac TS Li , Ke Liao , Sten F Libregts , Erzsebet Ligeti , Rebecca Lim , Sai Kiang Lim , Aija Linē , Karen Linnemannstöns , Alicia Llorente , Catherine A Lombard , Magdalena J Lorenowicz , Ákos M Lörincz , Jan Lötvall , Jason Lovett , Michelle C Lowry , Xavier Loyer , Quan Lu , Barbara Lukomska , Taral R Lunavat , Sybren LN Maas , Harmeet Malhi , Antonio Marcilla , Jacopo Mariani , Javier Mariscal , Elena S Martens - Uzunova , Lorena Martin - Jaular , M Carmen Martinez , Vilma Regina Martins , Mathilde Mathieu , Suresh Mathivanan , Marco Maugeri , Lynda K McGinnis , Mark J McVey , David G Meckes Jr , Katie L Meehan , Inge Mertens , Valentina R Minciacchi , Andreas Möller , Malene Møller Jørgensen , Aizea Morales - Kastresana , Jess Morhayim , François Mullier , Maurizio Muraca , Luca Musante , Veronika Mussack , Dillon C Muth , Kathryn H Myburgh , Tanbir Najrana , Muhammad Nawaz , Irina Nazarenko , Peter Nejsum , Christian Neri , Tommaso Neri , Rienk Nieuwland , Leonardo Nimrichter , John P Nolan , Esther NM Nolte - ’t Hoen , Nicole Noren Hooten , Lorraine O’Driscoll , Tina O’Grady , Ana O’Loghlen , Takahiro Ochiya , Martin Olivier , Alberto Ortiz , Luis A Ortiz , Xabier Osteikoetxea , Ole Ostegaard , Matias Ostrowski , Jaesung Park , D . Michiel Pegtel , Hector Peinado , Francesca Perut , Michael W Pfaffl , Donald G Phinney , Bartijn CH Pieters , Ryan C Pink , David S Pisetsky , Elke Pogge von Strandmann , Iva Polakovicova , Ivan KH Poon , Bonita H Powell , Ilaria Prada , Lynn Pulliam , Peter Quesenberry , Annalisa Radeghieri , Robert L Raffai , Stefania Raimondo , Janusz Rak , Marcel I Ramirez , Graça Raposo , Morsi S Rayyan , Neta Regev - Rudzki , Franz L Ricklefs , Paul D Robbins , David D Roberts , Silvia C Rodrigues , Eva Rohde , Sophie Rome , Kasper MA Rouschop , Aurelia Rughetti , Ashley E Russell , Paula Saá , Susmita Sahoo , Edison Salas - Huenuleo , Catherine Sánchez , Julie A Saugstad , Meike J Saul , Raymond M Schiffelers , Raphael Schneider , Tine Hiorth Schøyen , Aaron Scott , Eriomina Shahaj , Shivani Sharma , Olga Shatnyeva , Faezeh Shekari , Ganesh Vilas Shelke , Ashok K Shetty , Kiyotaka Shiba , Pia R - M Siljander , Andreia M Silva , Agata Skowronek , Orman L Snyder II , Rodrigo Pedro Soares , Barbara W Sódar , Carolina Soekmadji , Javier Sotillo , Philip D Stahl , Willem Stoorvogel , Shannon L Stott , Erwin F Strasser , Simon Swift , Hidetoshi Tahara , Muneesh Tewari , Kate Timms , Swasti Tiwari , Rochelle Tixeira , Mercedes Tkach , Wei Seong Toh , Richard Tomasini , Ana Claudia Torrecilhas , Juan Pablo Tosar , Vasilis Toxavidis , Lorena Urbanelli , Pieter Vader , Bas WM van Balkom , Susanne G van der Grein , Jan Van Deun , Martijn JC van Herwijnen , Kendall Van Keuren - Jensen , Guillaume van Niel , Martin E van Royen , Andre J van Wijnen , M Helena Vasconcelos , Ivan J Vechetti Jr , Tiago D Veit , Laura J Vella , Émilie Velot , Frederik J Verweij , Beate Vestad , Jose L Viñas , Tamás Visnovitz , Krisztina V Vukman , Jessica Wahlgren , Dionysios C Watson , Marca HM Wauben , Alissa Weaver , Jason P Webber , Viktoria Weber , Ann M Wehman , Daniel J Weiss , Joshua A Welsh , Sebastian Wendt , Asa M Wheelock , Zoltán Wiener , Leonie Witte , Joy Wolfram , Angeliki Xagorari , Patricia Xander , Jing Xu , Xiaomei Yan , María Yáñez - Mó , Hang Yin , Yuana Yuana , Valentina Zappulli , Jana Zarubova , Vytautas Žėkas , Jian - ye Zhang , Zezhou Zhao , Lei Zheng , Alexander R Zheutlin , Antje M Zickler , Pascale Zimmermann , Angela M Zivkovic , Davide Zocco & Ewa K Zuba - Surma To cite this article : Clotilde Théry , Kenneth W Witwer , Elena Aikawa , Maria Jose Alcaraz , Johnathon D Anderson , Ramaroson Andriantsitohaina , Anna Antoniou , Tanina Arab , Fabienne Archer , Georgia K Atkin - Smith , D Craig Ayre , Jean - Marie Bach , Daniel Bachurski , Hossein Baharvand , Leonora Balaj , Shawn Baldacchino , Natalie N Bauer , Amy A Baxter , Mary Bebawy , Carla Beckham , Apolonija Bedina Zavec , Abderrahim Benmoussa , Anna C Berardi , Paolo Bergese , Ewa Bielska , Cherie Blenkiron , Sylwia Bobis - Wozowicz , Eric Boilard , Wilfrid Boireau , Antonella Bongiovanni , Francesc E Borràs , Steffi Bosch , Chantal M Boulanger , Xandra Breakefield , Andrew M Breglio , Meadhbh Á Brennan , David R Brigstock , Alain Brisson , Marike LD Broekman , Jacqueline F Bromberg , Paulina Bryl - Górecka , Shilpa Buch , Amy H Buck , Dylan Burger , Sara Busatto , Dominik Buschmann , Benedetta Bussolati , Edit I Buzás , James Bryan Byrd , Giovanni Camussi , David RF Carter , Sarah Caruso , Lawrence W Chamley , Yu - Ting Chang , Chihchen Chen , Shuai Chen , Lesley Cheng , Andrew R Chin , Aled Clayton , Stefano P Clerici , Alex Cocks , Emanuele Cocucci , Robert J Coffey , Anabela Cordeiro - da - Silva , Yvonne Couch , Frank AW Coumans , Beth Coyle , Rossella Crescitelli , Miria Ferreira Criado , Crislyn D’Souza - Schorey , Saumya Das , Amrita Datta Chaudhuri , Paola de Candia , Eliezer F De Santana Junior , Olivier De Wever , Hernando A del Portillo , Tanguy Demaret , Sarah Deville , Andrew Devitt , Bert Dhondt , Dolores Di Vizio , Lothar C Dieterich , Vincenza Dolo , Ana Paula Dominguez Rubio , Massimo Dominici , Mauricio R Dourado , Tom AP Driedonks , Filipe V Duarte , Heather M Duncan , Ramon M Eichenberger , Karin Ekström , Samir EL Andaloussi , Celine Elie - Caille , Uta Erdbrügger , Juan M Falcón - Pérez , Farah Fatima , Jason E Fish , Miguel Flores - Bellver , András Försönits , Annie Frelet - Barrand , Fabia Fricke , Gregor Fuhrmann , Susanne Gabrielsson , Ana Gámez - Valero , Chris Gardiner , Kathrin Gärtner , Raphael Gaudin , Yong Song Gho , Bernd Giebel , Caroline Gilbert , Mario Gimona , Ilaria Giusti , Deborah CI Goberdhan , André Görgens , Sharon M Gorski , David W Greening , Julia Christina Gross , Alice Gualerzi , Gopal N Gupta , Dakota Gustafson , Aase Handberg , Reka A Haraszti , Paul Harrison , Hargita Hegyesi , An Hendrix , Andrew F Hill , Fred H Hochberg , Karl F Hoffmann , Beth Holder , Harry Holthofer , Baharak Hosseinkhani , Guoku Hu , Yiyao Huang , Veronica Huber , Stuart Hunt , Ahmed Gamal - Eldin Ibrahim , Tsuneya Ikezu , Jameel M Inal , Mustafa Isin , Alena Ivanova , Hannah K Jackson , Soren Jacobsen , Steven M Jay , Muthuvel Jayachandran , Guido Jenster , Lanzhou Jiang , Suzanne M Johnson , Jennifer C Jones , Ambrose Jong , Tijana Jovanovic - Talisman , Stephanie Jung , Raghu Kalluri , Shin - ichi Kano , Sukhbir Kaur , Yumi Kawamura , Evan T Keller , Delaram Khamari , Elena Khomyakova , Anastasia Khvorova , Peter Kierulf , Kwang Pyo Kim , Thomas Kislinger , Mikael Klingeborn , David J Klinke II , Miroslaw Kornek , Maja M Kosanović , Árpád Ferenc Kovács , Eva - Maria Krämer - Albers , Susanne Krasemann , Mirja Krause , Igor V Kurochkin , Gina D Kusuma , Sören Kuypers , Saara Laitinen , Scott M Langevin , Lucia R Languino , Joanne Lannigan , Cecilia Lässer , Louise C Laurent , Gregory Lavieu , Elisa Lázaro - Ibáñez , Soazig Le Lay , Myung - Shin Lee , Yi Xin Fiona Lee , Debora S Lemos , Metka Lenassi , Aleksandra Leszczynska , Isaac TS Li , Ke Liao , Sten F Libregts , Erzsebet Ligeti , Rebecca Lim , Sai Kiang Lim , Aija Linē , Karen Linnemannstöns , Alicia Llorente , Catherine A Lombard , Magdalena J Lorenowicz , Ákos M Lörincz , Jan Lötvall , Jason Lovett , Michelle C Lowry , Xavier Loyer , Quan Lu , Barbara Lukomska , Taral R Lunavat , Sybren LN Maas , Harmeet Malhi , Antonio Marcilla , Jacopo Mariani , Javier Mariscal , Elena S Martens - Uzunova , Lorena Martin - Jaular , M Carmen Martinez , Vilma Regina Martins , Mathilde Mathieu , Suresh Mathivanan , Marco Maugeri , Lynda K McGinnis , Mark J McVey , David G Meckes Jr , Katie L Meehan , Inge Mertens , Valentina R Minciacchi , Andreas Möller , Malene Møller Jørgensen , Aizea Morales - Kastresana , Jess Morhayim , François Mullier , Maurizio Muraca , Luca Musante , Veronika Mussack , Dillon C Muth , Kathryn H Myburgh , Tanbir Najrana , Muhammad Nawaz , Irina Nazarenko , Peter Nejsum , Christian Neri , Tommaso Neri , Rienk Nieuwland , Leonardo Nimrichter , John P Nolan , Esther NM Nolte - ’t Hoen , Nicole Noren Hooten , Lorraine O’Driscoll , Tina O’Grady , Ana O’Loghlen , Takahiro Ochiya , Martin Olivier , Alberto Ortiz , Luis A Ortiz , Xabier Osteikoetxea , Ole Ostegaard , Matias Ostrowski , Jaesung Park , D . Michiel Pegtel , Hector Peinado , Francesca Perut , Michael W Pfaffl , Donald G Phinney , Bartijn CH Pieters , Ryan C Pink , David S Pisetsky , Elke Pogge von Strandmann , Iva Polakovicova , Ivan KH Poon , Bonita H Powell , Ilaria Prada , Lynn Pulliam , Peter Quesenberry , Annalisa Radeghieri , Robert L Raffai , Stefania Raimondo , Janusz Rak , Marcel I Ramirez , Graça Raposo , Morsi S Rayyan , Neta Regev - Rudzki , Franz L Ricklefs , Paul D Robbins , David D Roberts , Silvia C Rodrigues , Eva Rohde , Sophie Rome , Kasper MA Rouschop , Aurelia Rughetti , Ashley E Russell , Paula Saá , Susmita Sahoo , Edison Salas - Huenuleo , Catherine Sánchez , Julie A Saugstad , Meike J Saul , Raymond M Schiffelers , Raphael Schneider , Tine Hiorth Schøyen , Aaron Scott , Eriomina Shahaj , Shivani Sharma , Olga Shatnyeva , Faezeh Shekari , Ganesh Vilas Shelke , Ashok K Shetty , Kiyotaka Shiba , Pia R - M Siljander , Andreia M Silva , Agata Skowronek , Orman L Snyder II , Rodrigo Pedro Soares , Barbara W Sódar , Carolina Soekmadji , Javier Sotillo , Philip D Stahl , Willem Stoorvogel , Shannon L Stott , Erwin F Strasser , Simon Swift , Hidetoshi Tahara , Muneesh Tewari , Kate Timms , Swasti Tiwari , Rochelle Tixeira , Mercedes Tkach , Wei Seong Toh , Richard Tomasini , Ana Claudia Torrecilhas , Juan Pablo Tosar , Vasilis Toxavidis , Lorena Urbanelli , Pieter Vader , Bas WM van Balkom , Susanne G van der Grein , Jan Van Deun , Martijn JC van Herwijnen , Kendall Van Keuren - Jensen , Guillaume van Niel , Martin Full Terms & Conditions of access and use can be found at http : / / www . tandfonline . com / action / journalInformation ? journalCode = zjev20 E van Royen , Andre J van Wijnen , M Helena Vasconcelos , Ivan J Vechetti Jr , Tiago D Veit , Laura J Vella , Émilie Velot , Frederik J Verweij , Beate Vestad , Jose L Viñas , Tamás Visnovitz , Krisztina V Vukman , Jessica Wahlgren , Dionysios C Watson , Marca HM Wauben , Alissa Weaver , Jason P Webber , Viktoria Weber , Ann M Wehman , Daniel J Weiss , Joshua A Welsh , Sebastian Wendt , Asa M Wheelock , Zoltán Wiener , Leonie Witte , Joy Wolfram , Angeliki Xagorari , Patricia Xander , Jing Xu , Xiaomei Yan , María Yáñez - Mó , Hang Yin , Yuana Yuana , Valentina Zappulli , Jana Zarubova , Vytautas Žėkas , Jian - ye Zhang , Zezhou Zhao , Lei Zheng , Alexander R Zheutlin , Antje M Zickler , Pascale Zimmermann , Angela M Zivkovic , Davide Zocco & Ewa K Zuba - Surma ( 2018 ) Minimal information for studies of extracellular vesicles 2018 ( MISEV2018 ) : a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , Journal of Extracellular Vesicles , 7 : 1 , 1535750 , DOI : 10 . 1080 / 20013078 . 2018 . 1535750 To link to this article : https : / / doi . org / 10 . 1080 / 20013078 . 2018 . 1535750 © 2018 The Author ( s ) . Published by Informa UK Limited , trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles . Published online : 23 Nov 2018 . Submit your article to this journal Article views : 2571 View Crossmark data Minimal information for studies of extracellular vesicles 2018 ( MISEV2018 ) : a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines Clotilde Théry 103 * £ , Kenneth W Witwer 217 , 218 * & £ , Elena Aikawa 19 , 79 £ , Maria Jose Alcaraz 112 , Johnathon D Anderson 288 , Ramaroson Andriantsitohaina 97 , Anna Antoniou 70 , 265 , Tanina Arab 257 , Fabienne Archer 318 , Georgia K Atkin - Smith 131 , D Craig Ayre 15 , 158 , Jean - Marie Bach 254 , Daniel Bachurski 301 , Hossein Baharvand 195 , 353 , Leonora Balaj 143 , Shawn Baldacchino 321 , Natalie N Bauer 354 , Amy A Baxter 131 , Mary Bebawy 357 , Carla Beckham 350 , Apolonija Bedina Zavec 165 , Abderrahim Benmoussa 260 , Anna C Berardi 179 , Paolo Bergese 39 , 111 , 283 , Ewa Bielska 282 , Cherie Blenkiron 277 & , Sylwia Bobis - Wozowicz 119 , Eric Boilard 260 , Wilfrid Boireau 58 , Antonella Bongiovanni 106 , Francesc E Borràs 72 , 73 , 250 , Steffi Bosch 254 , Chantal M Boulanger 100 , 261 £ , Xandra Breakefield 140 , Andrew M Breglio 92 , 169 , Meadhbh Á Brennan 82 , 144 , 258 , David R Brigstock 174 , 221 , Alain Brisson 238 $ , Marike LD Broekman 78 , 134 , 142 , Jacqueline F Bromberg 155 , 379 , Paulina Bryl - Górecka 136 , Shilpa Buch 334 , Amy H Buck 305 , Dylan Burger 128 , 180 , 337 , Sara Busatto 148 , 283 , Dominik Buschmann 212 , Benedetta Bussolati 360 , Edit I Buzás 160 , 201 & £ , James Bryan Byrd 330 , Giovanni Camussi 359 £ , David RF Carter 181 , Sarah Caruso 131 , Lawrence W Chamley 279 , Yu - Ting Chang 170 , Amrita Datta Chaudhuri 218 , Chihchen Chen 171 , 172 , Shuai Chen 133 , Lesley Cheng 131 , Andrew R Chin 25 , Aled Clayton 23 , Stefano P Clerici 239 , Alex Cocks 23 , Emanuele Cocucci 220 , 222 £ , Robert J Coffey 373 , Anabela Cordeiro - da - Silva 346 , Yvonne Couch 340 , Frank AW Coumans 7 $ , Beth Coyle 227 , Rossella Crescitelli 308 , Miria Ferreira Criado 352 , Crislyn D ’ Souza - Schorey 335 , Saumya Das 141 , Paola de Candia 116 , Eliezer F De Santana Junior 225 , Olivier De Wever 22 , 75 , Hernando A del Portillo 101 , 104 , 117 , Tanguy Demaret 256 , Sarah Deville 262 , 377 , Andrew Devitt 12 , Bert Dhondt 22 , 74 , 75 , Dolores Di Vizio 25 & £ , Lothar C Dieterich 49 , Vincenza Dolo 315 , Ana Paula Dominguez Rubio 243 , Massimo Dominici 234 , 333 # , Mauricio R Dourado 298 , 338 , Tom AP Driedonks 369 , Filipe V Duarte 53 , Heather M Duncan 150 , 152 , Ramon M Eichenberger 120 , Karin Ekström 306 , Samir EL Andaloussi 51 , 127 , Celine Elie - Caille 58 , Uta Erdbrügger 366 & , Juan M Falcón - Pérez 32 , 94 & , Farah Fatima 351 , Jason E Fish 233 , 362 , Miguel Flores - Bellver 302 , András Försönits 201 , Annie Frelet - Barrand 58 , Fabia Fricke 68 , 267 , Gregor Fuhrmann 86 , 87 , 197 , Susanne Gabrielsson 126 , Ana Gámez - Valero 72 , 251 , Chris Gardiner 264 & , Kathrin Gärtner 85 , Raphael Gaudin 99 , 259 , Yong Song Gho 187 £ , Bernd Giebel 266 # , Caroline Gilbert 260 , Mario Gimona 183 , Ilaria Giusti 315 , Deborah CI Goberdhan 339 , André Görgens 51 , 123 , 266 $ , Sharon M Gorski 16 , 204 , David W Greening 131 , Julia Christina Gross 270 , 271 , Alice Gualerzi 115 , Gopal N Gupta 135 , Dakota Gustafson 362 , Aase Handberg 2 , 4 , Reka A Haraszti 325 , Paul Harrison 281 , Hargita Hegyesi 201 , An Hendrix 22 , 75 , Andrew F Hill 131 & £ , Fred H Hochberg 200 , 293 , Karl F Hoffmann 6 , Beth Holder 95 , 159 , Harry Holthofer 263 £ , Baharak Hosseinkhani 83 , Guoku Hu 334 , Yiyao Huang 162 , 217 , Veronica Huber 61 , Stuart Hunt 229 , Ahmed Gamal - Eldin Ibrahim 26 , Tsuneya Ikezu 18 , Jameel M Inal 313 , Mustafa Isin 118 , Alena Ivanova 69 , Hannah K Jackson 227 , Soren Jacobsen 38 , 304 , Steven M Jay 324 , Muthuvel Jayachandran 145 , Guido Jenster 47 , Lanzhou Jiang 131 , Suzanne M Johnson 322 , Jennifer C Jones 166 $ , Ambrose Jong 30 , 355 , Tijana Jovanovic - Talisman 34 , Stephanie Jung 71 , Raghu Kalluri 358 & , Shin - ichi Kano 219 , Sukhbir Kaur 167 , Yumi Kawamura 164 , 365 , Evan T Keller 327 , 331 , Delaram Khamari 201 , CONTACT Clotilde Théry Clotilde . Thery @ curie . fr Institut Curie / INSERM U932 , 26 rue d ’ Ulm , 75005 Paris , France ; Kenneth W Witwer kwitwer1 @ jhmi . edu 733 North Broadway , MRB 829 Baltimore , MD 21205 , USA * These authors are co - corresponding authors and contributed equally to this work . All authors , except for the corresponding authors , are listed alphabetically . This article was first drafted begining in late 2017 and finalized in September , 2018 with several rounds of feedback from the ISEV Executive Board and JEV Editorial Board . & The following authors are members ofthe 2016 - 2018 and / or 2018 - 2020 ISEV Board of Directors : Cherie Blenkiron , Edit I Buzas , Dolores Di Vizio , Uta Erdbrügger , Juan M Falcón - Pérez , Chris Gardiner , Andrew F Hill ( current President ) , Raghu Kalluri , Jan Lötvall ( past President ) , Malene Møller Jørgensen , Rienk Nieuwland , Lorraine O ’ Driscoll , SusmitaSahoo , CarolinaSoekmadji , HidetoshiTahara , AnaClaudiaTorrecilhas , MarcaHMWauben , AlissaWeaver , KennethWWitwer , Hang ( Hubert ) Yin , Lei Zheng . £ The following authors are Editors of the Journal of Extracellular Vesicles : Editors - in - Chief : Clotilde Théry , Peter Quesenberry , Yong Song Gho ; Associate Editors : Elena Aikawa , Chantal Boulanger , Edit I Buzas , Giovanni Camussi , Emanuele Cocucci , Dolores Di Vizio , Andrew F Hill , Harry Holthofer , Kwang Pyo Kim , Eva - Maria Krämer - Albers , Saara Laitinen , Cecilia Lässer , Suresh Mathivanan , Esther Nolte - ’ t Hoen , Takahiro Ochiya , Hector Peinado , Janusz Rak , Neta Regev - Rudzki , Raymond Schiffelers , Marca HM Wauben , Kenneth W Witwer . # AuthorswhoaremembersoftheInternationalSocietyforCellandGeneTherapy ( ISCT ) ExosomesScientificCommitteeincludeSaiKiangLim ( Co - Chair ) , BerndGiebel ( Co - Chair ) , Luis A Ortiz , Donald G Phinney and Daniel J Weiss ( ISCT Chief Scientific Officer ) . Massimo Dominici is Past President of ISCT . $ AuthorswhoaremembersofthejoinedISEV - ISAC ( InternationalSocietyforAdvancementofCytometry ) - ISTH ( InternationalSocietyonThrombosisandHaemostasis ) EV Flow Cytometry Working group are : Alain Brisson , Frank AW Coumans , André Görgens , Jennifer C Jones , Joanne Lannigan , Sten Libregts , François Mullier , Rienk Nieuwland , John P Nolan , Marca HM Wauben , Joshua A Welsh . JOURNAL OF EXTRACELLULAR VESICLES 2018 , VOL . 7 , 1535750 https : / / doi . org / 10 . 1080 / 20013078 . 2018 . 1535750 © 2018 The Author ( s ) . Published by Informa UK Limited , trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles . This is an Open Access article distributed under the terms of the Creative Commons Attribution - NonCommercial License ( http : / / creativecommons . org / licenses / by - nc / 4 . 0 / ) , which permits unrestricted non - commercial use , distribution , and reproduction in any medium , provided the original work is properly cited . Elena Khomyakova 45 , 56 , Anastasia Khvorova 325 , Peter Kierulf 178 , Kwang Pyo Kim 130 £ , Thomas Kislinger 188 , 363 , Mikael Klingeborn 43 , David J Klinke II 381 , 382 , Miroslaw Kornek 66 , 196 , Maja M Kosanovi ć 280 , Árpád Ferenc Kovács 201 , Eva - Maria Krämer - Albers 320 £ , Susanne Krasemann 273 , Mirja Krause 90 , Igor V Kurochkin 28 , Gina D Kusuma 90 , 156 , Sören Kuypers 84 , Saara Laitinen 59 £ , Scott M Langevin 33 , 300 , Lucia R Languino 232 , Joanne Lannigan 367 $ , Cecilia Lässer 308 £ , Louise C Laurent 294 , Gregory Lavieu 103 , Elisa Lázaro - Ibáñez 14 , Soazig Le Lay 97 , Myung - Shin Lee 50 , Yi Xin Fiona Lee 62 , Debora S Lemos 57 , Metka Lenassi 317 , Aleksandra Leszczynska 295 , Isaac TS Li 285 , Ke Liao 334 , Sten F Libregts 297 $ , Erzsebet Ligeti 202 , Rebecca Lim 90 , 156 , Sai Kiang Lim 107 # , Aija Lin ē 132 , Karen Linnemannstöns 270 , 271 , Alicia Llorente 177 , Catherine A Lombard 256 , Magdalena J Lorenowicz 370 , Ákos M Lörincz 202 , Jan Lötvall 308 & , Jason Lovett 210 , Michelle C Lowry 235 , Xavier Loyer 100 , 261 , Quan Lu 81 , Barbara Lukomska 157 , Taral R Lunavat 121 , Sybren LN Maas 371 , 372 , Harmeet Malhi 149 , Antonio Marcilla 252 , 253 , Jacopo Mariani 249 , Javier Mariscal 25 , Elena S Martens - Uzunova 47 , Lorena Martin - Jaular 103 , M Carmen Martinez 97 , Vilma Regina Martins 1 , Mathilde Mathieu 103 , Suresh Mathivanan 131 £ , Marco Maugeri 309 , Lynda K McGinnis 356 , Mark J McVey 203 , 361 , David G Meckes , Jr 60 , Katie L Meehan 223 , Inge Mertens 276 , 377 , Valentina R Minciacchi 63 , Andreas Möller 189 , Malene Møller Jørgensen 3 , 52 & , Aizea Morales - Kastresana 166 , Jess Morhayim 48 , François Mullier 161 , 255 $ , Maurizio Muraca 342 , Luca Musante 366 , Veronika Mussack 212 , Dillon C Muth 217 , Kathryn H Myburgh 210 , Tanbir Najrana 20 , Muhammad Nawaz 309 , Irina Nazarenko 67 , 154 , Peter Nejsum 5 , Christian Neri 205 , Tommaso Neri 345 , Rienk Nieuwland 7 & $ , Leonardo Nimrichter 247 , John P Nolan 200 $ , Esther NM Nolte - ’ t Hoen 369 £ , Nicole Noren Hooten 168 , Lorraine O ’ Driscoll 235 & , Tina O ’ Grady 316 , Ana O ’ Loghlen 190 , Takahiro Ochiya 163 £ , Martin Olivier 153 , Alberto Ortiz 93 , 206 , 242 , Luis A Ortiz 76 # , Xabier Osteikoetxea 13 , Ole Ostegaard 209 , 303 , Matias Ostrowski 286 , Jaesung Park 187 , D . Michiel Pegtel 11 , Hector Peinado 207 £ , Francesca Perut 114 , Michael W Pfaffl 212 , Donald G Phinney 224 # , Bartijn CH Pieters 191 , Ryan C Pink 181 , David S Pisetsky 42 , 44 , Elke Pogge von Strandmann 184 , Iva Polakovicova 185 , 186 , Ivan KH Poon 131 , Bonita H Powell 217 , Ilaria Prada 37 , Lynn Pulliam 296 , 375 , Peter Quesenberry 231 , Annalisa Radeghieri 39 , 283 , Robert L Raffai 41 , 296 , Stefania Raimondo 343 , Janusz Rak 151 , 153 £ , Marcel I Ramirez 110 , 245 , Graça Raposo 102 , Morsi S Rayyan 326 , Neta Regev - Rudzki 380 £ , Franz L Ricklefs 272 , Paul D Robbins 332 , David D Roberts 167 , Silvia C Rodrigues 36 , 53 , Eva Rohde 182 , 183 , 208 , Sophie Rome 319 , Kasper MA Rouschop 137 , Aurelia Rughetti 199 , Ashley E Russell 383 , Paula Saá 10 , Susmita Sahoo 91 & , Edison Salas - Huenuleo 8 , 299 , Catherine Sánchez 35 , Julie A Saugstad 175 , Meike J Saul 213 , Raymond M Schiffelers 275 £ , Raphael Schneider 362 , 364 , Tine Hiorth Schøyen 217 , Aaron Scott 284 , Eriomina Shahaj 61 , Shivani Sharma 289 , 291 , 292 , Olga Shatnyeva 14 , Faezeh Shekari 195 , Ganesh Vilas Shelke 307 , 308 , Ashok K Shetty 194 , 214 , Kiyotaka Shiba 21 , Pia R - M Siljander 311 , 312 , Andreia M Silva 96 , 348 , 349 , Agata Skowronek 138 , Orman L Snyder II 122 , Rodrigo Pedro Soares 193 , Barbara W Sódar 201 , Carolina Soekmadji 189 , 228 & , Javier Sotillo 120 , Philip D Stahl 378 , Willem Stoorvogel 369 , Shannon L Stott 80 , 139 , Erwin F Strasser 55 , Simon Swift 278 , Hidetoshi Tahara 88 & , Muneesh Tewari 327 , 328 , 329 , Kate Timms 323 , Swasti Tiwari 65 , 198 , Rochelle Tixeira 131 , Mercedes Tkach 103 , Wei Seong Toh 173 , Richard Tomasini 98 , Ana Claudia Torrecilhas 240 & , Juan Pablo Tosar 105 , 244 , Vasilis Toxavidis 17 , Lorena Urbanelli 344 , Pieter Vader 275 , Bas WM van Balkom 274 , Susanne G van der Grein 369 , Jan Van Deun 22 , 75 , Martijn JC van Herwijnen 369 , Kendall Van Keuren - Jensen 215 , Guillaume van Niel 27 , Martin E van Royen 46 , Andre J van Wijnen 146 , M Helena Vasconcelos 113 , 347 , 348 , Ivan J Vechetti Jr 314 , Tiago D Veit 248 , Laura J Vella 216 , 226 , Émilie Velot 237 , Frederik J Verweij 27 , Beate Vestad 176 , 192 , 336 , Jose L Viñas 128 , 180 , 337 , Tamás Visnovitz 201 , Krisztina V Vukman 201 , Jessica Wahlgren 310 , Dionysios C Watson 24 , 269 , Marca HM Wauben 369 & £ $ , Alissa Weaver 374 & , Jason P Webber 23 , Viktoria Weber 40 , Ann M Wehman 368 , Daniel J Weiss 230 # , Joshua A Welsh 166 $ , Sebastian Wendt 268 , Asa M Wheelock 125 , Zoltán Wiener 201 , Leonie Witte 270 , 271 , Joy Wolfram 31 , 89 , 147 , Angeliki Xagorari 64 , Patricia Xander 246 , Jing Xu 16 , 204 , Xiaomei Yan 384 , María Yáñez - Mó 29 , 241 , Hang Yin 236 & , Yuana Yuana 211 , Valentina Zappulli 341 , Jana Zarubova 108 , 109 , 290 , Vytautas Žė kas 376 , Jian - ye Zhang 77 , Zezhou Zhao 217 , Lei Zheng 162 & , Alexander R Zheutlin 326 , Antje M Zickler 124 , Pascale Zimmermann 9 , 129 , Angela M Zivkovic 287 , Davide Zocco 54 and Ewa K Zuba - Surma 119 1 A . C . Camargo Cancer Center , São Paulo , Brazil ; 2 Aalborg University Hospital , Department of Clinical Biochemistry , Aalborg , Denmark ; 3 Aalborg University Hospital , Department of Clinical Immunology , Aalborg , Denmark ; 4 Aalborg University , Clinical Institute , Aalborg , Denmark ; 5 Aarhus University , Department of Clinical Medicine , Aarhus , Denmark ; 6 Aberystwyth University , Institute of Biological , Environmental and Rural Sciences ( IBERS ) , Aberystwyth , United Kingdom ; 7 Academic Medical Centre of the University of Amsterdam , Department of Clinical Chemistry and Vesicle Observation Centre , Amsterdam , The Netherlands ; 8 Advanced Center for Chronic Diseases , Santiago , Chile ; 9 Aix - Marseille Université , Institut Paoli - Calmettes , INSERM U1068 , CNRS UMR7258 , Centre de Recherche en Cancérologie de Marseille , Marseille , France ; 10 American Red Cross , Scientific Affairs , Gaithersburg , MD , USA ; 11 Amsterdam University Medical Centers , Department of Pathology , Amsterdam , The Netherlands ; 12 Aston University , School of Life & Health Sciences , Birmingham , UK ; 13 AstraZeneca , Discovery Sciences , IMED Biotech Unit , Cambridge , UK ; 14 AstraZeneca , Discovery Sciences , IMED Biotech Unit , Gothenburg , Sweden ; 15 Atlantic Cancer Research Institute , Moncton , Canada ; 16 BC Cancer , Canada ’ s Michael Smith Genome Sciences Centre , Vancouver , Canada ; 17 Beth Israel Deaconess Medical Center , Boston , MA , USA ; 18 Boston University School of Medicine , Boston , MA , USA ; 19 Brigham and Women ’ s Hospital , Center for Interdisciplinary Cardiovascular Sciences , Boston , MA , USA ; 20 Brown University , Women and Infants Hospital , Providence , RI , USA ; 21 Cancer Institute of JFCR , Tokyo , Japan ; 22 Cancer Research Institute Ghent , Ghent , Belgium ; 23 Cardiff University , School of Medicine , Cardiff , UK ; 24 Case Western Reserve University , Department of Medicine , Cleveland , OH , USA ; 25 Cedars - Sinai Medical Center , Los 2 C . THÉRY AND K . W . WITWER Angeles , CA , USA ; 26 Cedars - Sinai Medical Center , Smidt Heart Institute , Los Angeles , CA , USA ; 27 Center for Psychiatry and Neuroscience , INSERM U894 , Paris , France ; 28 Central Research Laboratories , Sysmex Co . , Kobe , Japan ; 29 Centro de Biología Molecular Severo Ochoa , Instituto de Investigación Sanitaria la Princesa ( IIS - IP ) , Madrid , Spain ; 30 Children ’ s Hospital of Los Angeles , Los Angeles , CA , USA ; 31 Chinese Academy of Sciences , Wenzhou Institute of Biomaterials and Engineering , Wenzhou , China ; 32 CIC bioGUNE , CIBERehd , Exosomes Laboratory & Metabolomics Platform , Derio , Spain ; 33 Cincinnati Cancer Center , Cincinnati , OH , USA ; 34 City of Hope Comprehensive Cancer Center , Beckman Research Institute , Department of Molecular Medicine , Duarte , CA , USA ; 35 Clínica las Condes , Extracellular Vesicles in Personalized Medicine Group , Santiago , Chile ; 36 CNC , Coimbra , Portugal ; 37 CNR Institute of Neuroscience , Milan , Italy ; 38 Copenhagen Lupus and Vasculitis Clinic , Section 4242 - Rigshospitalet , Copenhagen , Denmark ; 39 CSGI - Research Center for Colloids and Nanoscience , Florence , Italy ; 40 Danube University Krems , Department for Biomedical Research and Christian Doppler Laboratory for Innovative Therapy Approaches in Sepsis , Krems an der Donau , Austria ; 41 Department of Veterans Affairs , San Francisco , CA , USA ; 42 Duke University Medical Center , Departments of Medicine and Immunology , Durham , NC , USA ; 43 Duke University , Department of Ophthalmology , Durham , NC , USA ; 44 Durham VAMC , Medical Research Service , Durham , NC , USA ; 45 École normale supérieure , Paris , France ; 46 Department of Pathology , Erasmus MC , Erasmus Optical Imaging Centre , Rotterdam , The Netherlands ; 47 Department of Urology , Rotterdam , The Netherlands ; 48 Erasmus MC , Rotterdam , The Netherlands ; 49 ETH Zurich , Institute of Pharmaceutical Sciences , Zurich , Switzerland ; 50 Eulji University , School of Medicine , Daejeon , South Korea ; 51 Evox Therapeutics Limited , Oxford , UK ; 52 EVSEARCH . DK , Denmark ; 53 Exogenus Therapeutics , Cantanhede , Portugal ; 54 Exosomics Siena SpA , Siena , Italy ; 55 FAU Erlangen - Nuremberg , Transfusion and Haemostaseology Department , Erlangen , Germany ; 56 Federal Research and Clinical Center of Physical - Chemical Medicine , Moscow , Russia ; 57 Federal University of Paraná , Department of Genetics , Human Molecular Genetics Laboratory , Curitiba , Brazil ; 58 FEMTO - ST Institute , UBFC , CNRS , ENSMM , UTBM , Besançon , France ; 59 Finnish Red Cross Blood Service , Research and Development , Helsinki , Finland ; 60 Florida State University College of Medicine , Department of Biomedical Sciences , Tallahassee , FL , USA ; 61 Fondazione IRCCS Istituto Nazionale dei Tumori , Unit of Immunotherapy of Human Tumors , Milan , Italy ; 62 Genome Institute of Singapore , A * STAR , Singapore ; 63 Georg - Speyer - Haus Institute for Tumor Biology and Experimental Therapy , Frankfurt , Germany ; 64 George Papanicolaou Hospital , Public Cord Blood Bank , Department of Haematology - BMT Unit , Thessaloniki , Greece ; 65 Georgetown University , Department of Medicine , Washington , DC , USA ; 66 German Armed Forces Central Hospital , Department of General , Visceral and Thoracic Surgery , Koblenz , Germany ; 67 German Cancer Consortium ( DKTK ) , Partner Site Freiburg and German Cancer Research Center ( DKFZ ) , Heidelberg , Germany ; 68 German Cancer Research Center ( DKFZ ) , Clinical Cooperation Unit Applied Tumor Biology , Heidelberg , Germany ; 69 German Cancer Research Center ( DKFZ ) , Division Signaling and Functional Genomics , Heidelberg , Germany ; 70 German Centre for Neurodegenerative Diseases ( DZNE ) , Bonn , Germany ; 71 German Research Center for Environmental Health , Institute for Virology , Munich , Germany ; 72 Germans Trias i Pujol Research Institute ( IGTP ) , Can Ruti Campus , REMAR - IVECAT Group , Badalona , Spain ; 73 Germans Trias i Pujol University Hospital , Nephrology Service , Badalona , Spain ; 74 Ghent University Hospital , Department of Urology , Ghent , Belgium ; 75 Ghent University , Department of Radiation Oncology and Experimental Cancer Research , Laboratory of Experimental Cancer Research , Ghent , Belgium ; 76 Graduate School of Public Health at the University of Pittsburgh , Division of Occupational and Environmental Medicine , Pittsburgh , PA , USA ; 77 Guangzhou Medical University , School of Pharmaceutical Sciences & the Fifth Affiliated Hospital , Key Laboratory of Molecular Target & Clinical Pharmacology , Guangzhou , China ; 78 Haaglanden Medical Center , Department of Neurosurgery , The Hague , The Netherlands ; 79 Harvard Medical School , Cardiovascular Medicine , Boston , MA , USA ; 80 Harvard Medical School , Department of Medicine , Boston , MA , USA ; 81 Harvard University , Harvard T . H . Chan School of Public Health , Boston , MA , USA ; 82 Harvard University , School of Engineering and Applied Sciences , Cambridge , MA , USA ; 83 Hasselt University , Biomedical Research Institute ( BIOMED ) , Department of Medicine and Life Sciences , Hasselt , Belgium ; 84 Hasselt University , Biomedical Research Institute ( BIOMED ) , Hasselt , Belgium ; 85 Helmholtz Center Munich German Research Center for Environmental Health , Research Unit Gene Vectors , Munich , Germany ; 86 Helmholtz - Centre for Infection Research , Braunschweig , Germany ; 87 Helmholtz - Institute for Pharmaceutical Research Saarland , Saarbrücken , Germany ; 88 Hiroshima University , Institute of Biomedical & Health Sciences , Department of Cellular and Molecular Biology , Hiroshima , Japan ; 89 Houston Methodist Research Institute , Department of Nanomedicine , Houston , TX , USA ; 90 Hudson Institute of Medical Research , Melbourne , Australia ; 91 Icahn School of Medicine at Mount Sinai , Department of Medicine , Cardiology , New York City , NY , USA ; 92 Icahn School of Medicine at Mount Sinai , New York City , NY , USA ; 93 IIS - Fundacion Jimenez Diaz - UAM , Department of Nephrology and Hypertension , Madrid , Spain ; 94 IKERBASQUE Research Science Foundation , Bilbao , Spain ; 95 Imperial College London , London , UK ; 96 INEB - Instituto de Engenharia Biomédica , Porto , Portugal ; 97 INSERM U1063 , Université d ’ Angers , CHU d ’ Angers , Angers , France ; 98 INSERM U1068 , Aix Marseille University , CNRS UMR7258 , Marseille , France ; 99 INSERM U1110 , Strasbourg , France ; 100 INSERM UMR - S 970 , Paris Cardiovascular Research Center , Paris , France ; 101 Institució Catalana de Recerca i Estudis Avançats ( ICREA ) , Barcelona , Spain ; 102 Institut Curie , CNRS UMR144 , PSL Research University , Paris , France ; 103 Institut Curie , INSERM U932 , PSL Research University , Paris , France ; 104 Institut d ’ Investigació Germans Trias i Pujol ( IGTP ) , PVREX group , Badalona , Spain ; 105 Institut Pasteur de Montevideo , Functional Genomics Unit , Montevideo , Uruguay ; 106 Institute of Biomedicine and Molecular Immunology ( IBIM ) , National Research Council ( CNR ) of Italy , Palermo , Italy ; 107 Institute of Medical Biology ( IMB ) , Agency for Science and Technology ( A * STAR ) , Singapore ; 108 Institute of Physiology CAS , Department of Biomaterials and Tissue Engineering , BIOCEV , Vestec , Czech Republic ; 109 Institute of Physiology CAS , Department of Biomaterials and Tissue Engineering , Prague , Czech Republic ; 110 Instituto Oswaldo Cruz , Rio de Janeiro , Brazil ; 111 INSTM - National Interuniversity Consortium of Materials Science and Technology , Florence , Italy ; 112 Interuniversity Research Institute for Molecular Recognition and Technological Development ( IDM ) , University of Valencia , Polytechnic University of Valencia , Valencia , Spain ; 113 IPATIMUP , Institute of Molecular Pathology and Immunology of the University of Porto , Porto , Portugal ; 114 IRCCS - Istituto Ortopedico Rizzoli , Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine , Bologna , Italy ; 115 IRCCS Fondazione Don Carlo Gnocchi , Laboratory of Nanomedicine and Clinical Biophotonics ( LABION ) , Milan , Italy ; 116 IRCCS MultiMedica , Milan , Italy ; 117 ISGlobal , Hospital Clínic - Universitat de Barcelona , PVREX Group , Barcelona , Spain ; 118 Istanbul University Oncology Institute , Basic Oncology Department , Istanbul , Turkey ; 119 Jagiellonian University , Faculty of Biochemistry , Biophysics and Biotechnology , Department of Cell Biology , Kraków , Poland ; 120 James Cook University , Australian Institute of Tropical Health and Medicine , Centre for Biodiscovery and Molecular Development of Therapeutics , Cairns , Australia ; 121 K . G . Jebsen Brain Tumor Research Centre , Department of Biomedicine , University of Bergen , Bergen , Norway ; 122 Kansas State University , College of Veterinary Medicine , Manhattan , KS , USA ; 123 Karolinska Institute , Clinical Research Center , Department of Laboratory Medicine , Stockholm , Sweden ; 124 Karolinska Institute , Clinical Research Center , Unit for Molecular Cell and Gene Therapy Science , Stockholm , Sweden ; 125 Karolinska Institute , Department of Medicine and Center for Molecular Medicine , Respiratory Medicine Unit , Stockholm , Sweden ; 126 Karolinska Institute , Department of Medicine Solna , Division for Immunology and Allergy , Stockholm , Sweden ; 127 Karolinska Institute , Stockholm , Sweden ; 128 Kidney Research Centre , Ottawa , Canada ; 129 KU Leuven ( Leuven University ) , Department of Human Genetics , Leuven , Belgium ; 130 Kyung Hee University , Department of Applied Chemistry , Yongin , Korea ; 131 La Trobe University , La Trobe Institute for Molecular JOURNAL OF EXTRACELLULAR VESICLES 3 Science , Department of Biochemistry and Genetics , Bundoora , Australia ; 132 Latvian Biomedical Research and Study Centre , Riga , Latvia ; 133 Leibniz Institute for Farm Animal Biology ( FBN ) , Institute of Reproductive Biology , Dummerstorf , Germany ; 134 Leiden University Medical Center , Department of Neurosurgery , Leiden , The Netherlands ; 135 Loyola University Chicago , Department of Urology , Maywood , IL , USA ; 136 Lund University , Department of Cardiology , Lund , Sweden ; 137 Maastricht University , GROW , School for Oncology and Developmental Biology , Maastricht Radiation Oncology ( MaastRO ) Lab , Maastricht , The Netherlands ; 138 Maria Sklodowska - Curie Institute - Oncology Center , Gliwice Branch , Gliwice , Poland ; 139 Massachusetts General Cancer Center , Boston , MA , USA ; 140 Massachusetts General Hospital and Neuroscience Program , Harvard Medical School , Department of Neurology and Radiology , Boston , MA , USA ; 141 Massachusetts General Hospital , Boston , MA , USA ; 142 Massachusetts General Hospital , Department of Neurology , Boston , MA , USA ; 143 Massachusetts General Hospital , Department of Neurosurgery , Boston , MA , USA ; 144 Massachusetts General Hospital , Harvard Medical School , Department of Neurology , Boston , MA , USA ; 145 Mayo Clinic , College of Medicine , Department of Physiology and Biomedical Engineering , Rochester , MN , USA ; 146 Mayo Clinic , Department of Orthopedic Surgery , Rochester , MN , USA ; 147 Mayo Clinic , Department of Transplantation Medicine / Department of Physiology and Biomedical Engineering , Jacksonville , FL , USA ; 148 Mayo Clinic , Department of Transplantation , Jacksonville , FL , USA ; 149 Mayo Clinic , Rochester , MN , USA ; 150 McGill University , Division of Experimental Medicine , Montreal , Canada ; 151 McGill University , Montreal , Canada ; 152 McGill University , The Research Institute of the McGill University Health Centre , Child Health and Human Development Program , Montreal , Canada ; 153 McGill University , The Research Institute of the McGill University Health Centre , Montreal , Canada ; 154 Medical Center - University of Freiburg , Faculty of Medicine , University of Freiburg , Institute for Infection Prevention and Hospital Epidemiology , Freiburg , Germany ; 155 Memorial Sloan Kettering Cancer Center , Department of Medicine , New York City , NY , USA ; 156 Monash University , Melbourne , Australia ; 157 Mossakowski Medical Research Centre , NeuroRepair Department , Warsaw , Poland ; 158 Mount Allison University , Department of Chemistry and Biochemistry , Sackville , Canada ; 159 MRC The Gambia , Fajara , The Gambia ; 160 MTA - SE Immuno - Proteogenomics Research Groups , Budapest , Hungary ; 161 Namur Thrombosis and Hemostasis Center ( NTHC ) , NARILIS , Namur , Belgium ; 162 Nanfang Hospital , Southern Medical University , Department of Clinical Laboratory Medicine , Guangzhou , China ; 163 National Cancer Center Research Institute , Division of Molecular and Cellular Medicine , Tokyo , Japan ; 164 National Cancer Center Research Institute , Tokyo , Japan ; 165 National Institute of Chemistry , Department of Molecular Biology and Nanobiotechnology , Ljubljana , Slovenia ; 166 National Institutes of Health , National Cancer Institute , Center for Cancer Research , Bethesda , MD , USA ; 167 National Institutes of Health , National Cancer Institute , Center for Cancer Research , Laboratory of Pathology , Bethesda , MD , USA ; 168 National Institutes of Health , National Institute on Aging , Baltimore , MD , USA ; 169 National Institutes of Health , National Institute on Deafness and Other Communication Disorders , Bethesda , MD , USA ; 170 National Taiwan University Hospital , Department of Internal Medicine , Taipei , Taiwan ; 171 National Tsing Hua University , Department of Power Mechanical Engineering , Hsinchu , Taiwan ; 172 National Tsing Hua University , Institute of Nanoengineering and Microsystems , Hsinchu , Taiwan ; 173 National University of Singapore , Faculty of Dentistry , Singapore ; 174 Nationwide Children ’ s Hospital , Columbus , OH , USA ; 175 Oregon Health & Science University , Department of Anesthesiology & Perioperative Medicine , Portland , OR , USA ; 176 Oslo University Hospital Rikshospitalet , Research Institute of Internal Medicine , Oslo , Norway ; 177 Oslo University Hospital - The Norwegian Radium Hospital , Institute for Cancer Research , Department of Molecular Cell Biology , Oslo , Norway ; 178 Oslo University Hospital , Department of Medical Biochemistry , Blood Cell Research Group , Oslo , Norway ; 179 Ospedale Santo Spirito , Pescara , Italy ; 180 Ottawa Hospital Research Institute , Ottawa , Canada ; 181 Oxford Brookes University , Department of Biological and Medical Sciences , Oxford , UK ; 182 Paracelsus Medical University , Department of Transfusion Medicine , Salzburg , Austria ; 183 Paracelsus Medical University , GMP Unit , Salzburg , Austria ; 184 Philipps University Marburg , Experimental Tumor Biology , Marburg , Germany ; 185 Pontificia Universidad Católica de Chile , Advanced Center for Chronic Diseases ( ACCDiS ) , Santiago , Chile ; 186 Pontificia Universidad Católica de Chile , Faculty of Medicine , Department of Hematology - Oncology , Santiago , Chile ; 187 POSTECH ( Pohang University of Science and Technology ) , Department of Life Sciences , Pohang , South Korea ; 188 Princess Margaret Cancer Centre , University Health Network , Toronto , Canada ; 189 QIMR Berghofer Medical Research Institute , Herston , Australia ; 190 Queen Mary University of London , Blizard Institute , Epigenetics & Cellular Senescence Group , London , UK ; 191 Radboud University Medical Center , Department of Rheumatology , Nijmegen , The Netherlands ; 192 Regional Research Network on Extracellular Vesicles , RRNEV , Oslo , Norway ; 193 René Rachou Institute / FIOCRUZ , Belo Horizonte , Brazil ; 194 Research Service , Olin E . Teague Veterans ’ Medical Center , Temple , TX , USA ; 195 Royan Institute for Stem Cell Biology and Technology , ACECR , Cell Science Research Center , Department of Stem Cells and Developmental Biology , Tehran , Iran ; 196 Saarland University Medical Center , Department of Medicine II , Homburg , Germany ; 197 Saarland University , Saarbrücken , Germany ; 198 Sanjay Gandhi Postgraduate Institute of Medical Sciences , Department of Molecular Medicine & Biotechnology , Lucknow , India ; 199 Sapienza University of Rome , Department of Experimental Medicine , Rome , Italy ; 200 Scintillon Institute , La Jolla , CA , USA ; 201 Semmelweis University , Department of Genetics , Cell - and Immunobiology , Budapest , Hungary ; 202 Semmelweis University , Department of Physiology , Budapest , Hungary ; 203 SickKids Hospital , Department of Anesthesia and Pain Medicine , Toronto , Canada ; 204 Simon Fraser University , Department of Molecular Biology and Biochemistry , Burnaby , Canada ; 205 Sorbonne Université , Centre National de la Recherche Scientifique , Research Unit Biology of Adaptation and Aging ( B2A ) , Team Compensation in Neurodegenerative and Aging ( Brain - C ) , Paris , France ; 206 Spanish Kidney Research Network , REDINREN , Madrid , Spain ; 207 Spanish National Cancer Research Center ( CNIO ) , Molecular Oncology Programme , Microenvironment and Metastasis Laboratory , Madrid , Spain ; 208 Spinal Cord Injury & Tissue Regeneration Center Salzburg ( SCI - TReCS ) , Salzburg , Austria ; 209 Statens Serum Institut , Department of Autoimmunology and Biomarkers , Copenhagen , Denmark ; 210 Stellenbosch University , Department of Physiological Sciences , Stellenbosch , South Africa ; 211 Technical University Eindhoven , Faculty Biomedical Technology , Eindhoven , The Netherlands ; 212 Technical University of Munich , TUM School of Life Sciences Weihenstephan , Division of Animal Physiology and Immunology , Freising , Germany ; 213 Technische Universität Darmstadt , Department of Biology , Darmstadt , Germany ; 214 Texas A & M University College of Medicine , Institute for Regenerative Medicine and Department of Molecular and Cellular Medicine , College Station , TX , USA ; 215 TGen , Neurogenomics Division , Phoenix , AZ , USA ; 216 The Florey Institute of Neuroscience and Mental Health , Melbourne , Australia ; 217 The Johns Hopkins University School of Medicine , Department of Molecular and Comparative Pathobiology , Baltimore , MD , USA ; 218 The Johns Hopkins University School of Medicine , Department of Neurology , Baltimore , MD , USA ; 219 The Johns Hopkins University School of Medicine , Department of Psychiatry and Behavioral Sciences , Baltimore , MD , USA ; 220 The Ohio State University , College of Pharmacy , Division of Pharmaceutics and Pharmaceutical Chemistry , Columbus , OH , USA ; 221 The Ohio State University , Columbus , OH , USA ; 222 The Ohio State University , Comprehensive Cancer Center , Columbus , OH , USA ; 223 The School of Biomedical Sciences , University of Western Australia , Perth , Australia ; 224 The Scripps Research Institute - Scripps Florida , Department of Molecular Medicine , Jupiter , FL , USA ; 225 The Sociedade Beneficente Israelita Brasileira Albert Einstein , São Paulo , Brazil ; 226 The University of Melbourne , The Department of Medicine , Melbourne , Australia ; 227 The University of Nottingham , School of Medicine , Children ’ s Brain Tumour Research Centre , Nottingham , UK ; 228 The University of Queensland , Brisbane , Australia ; 229 The University of Sheffield , Sheffield , UK ; 230 The University of Vermont Medical Center , Department of Medicine , Burlington , VT , USA ; 231 The Warren Alpert Medical School of Brown University , Department of Medicine , 4 C . THÉRY AND K . W . WITWER Providence , RI , USA ; 232 Thomas Jefferson University , Sidney Kimmel Medical School , Department of Cancer Biology , Philadelphia , PA , USA ; 233 Toronto General Hospital Research Institute , University Health Network , Toronto , Canada ; 234 TPM of Mirandola , Mirandola , Italy ; 235 Trinity College Dublin , School of Pharmacy and Pharmaceutical Sciences , Panoz Institute & Trinity Biomedical Sciences Institute , Dublin , Ireland ; 236 Tsinghua University , School of Pharmaceutical Sciences , Beijing , China ; 237 UMR 7365 CNRS - Université de Lorraine , Vand œ uvre - lès - Nancy , France ; 238 UMR - CBMN , CNRS - Université de Bordeaux , Bordeaux , France ; 239 UNICAMP , Institute of Biology , Campinas , Brazil ; 240 UNIFESP , Departamento de Ciências Farmacêuticas , Diadema , Brazil ; 241 Universidad Autónoma de Madrid , Departamento de Biología Molecular , Madrid , Spain ; 242 Universidad Autónoma de Madrid , School of Medicine , Department of Medicine , Madrid , Spain ; 243 Universidad de Buenos Aires , Facultad de Ciencias Exactas y Naturales , Departamento de Química Biológica , Buenos Aires , Argentina ; 244 Universidad de la República , Faculty of Science , Nuclear Research Center , Analytical Biochemistry Unit , Montevideo , Uruguay ; 245 Universidade Federal de Paraná , Paraná , Brazil ; 246 Universidade Federal de São Paulo Campus Diadema , Departamento de Ciências Farmacêuticas , Laboratório de Imunologia Celular e Bioquímica de Fungos e Protozoários , São Paulo , Brazil ; 247 Universidade Federal do Rio de Janeiro , Instituto de Microbiologia , Rio de Janeiro , Brazil ; 248 Universidade Federal do Rio Grande do Sul , Instituto de Ciências Básicas da Saúde , Departamento de Microbiologia , Imunologia e Parasitologia , Porto Alegre , Brazil ; 249 Università degli Studi di Milano , Department of Clinical Sciences and Community Health , EPIGET LAB , Milan , Italy ; 250 Universitat Autònoma de Barcelona , Department of Cell Biology , Physiology & Immunology , Barcelona , Spain ; 251 Universitat Autònoma de Barcelona , Hospital Universitari and Health Sciences Research Institute Germans Trias i Pujol , Department of Pathology , Barcelona , Spain ; 252 Universitat de València , Departament de Farmàcia i Tecnologia Farmacèutica i Parasitologia , Àrea de Parasitologia , Valencia , Spain ; 253 Universitat de València , Health Research Institute La Fe , Joint Research Unit on Endocrinology , Nutrition and Clinical Dietetics , Valencia , Spain ; 254 Université Bretagne Loire , Oniris , INRA , IECM , Nantes , France ; 255 Université Catholique de Louvain , CHU UCL Namur , Hematology - Hemostasis Laboratory , Yvoir , Belgium ; 256 Université Catholique de Louvain , Institut de Recherche Expérimentale et Clinique ( IREC ) , Laboratory of Pediatric Hepatology and Cell Therapy , Brussels , Belgium ; 257 Université de Lille , INSERM , U - 1192 , Laboratoire Protéomique , Réponse Inflammatoire et Spectrométrie de Masse - PRISM , Lille , France ; 258 Université de Nantes , INSERM UMR 1238 , Bone Sarcoma and Remodeling of Calcified Tissues , PhyOS , Nantes , France ; 259 Université de Strasbourg , Strasbourg , France ; 260 Université Laval , Centre de Recherche du CHU de Québec , Department of Infectious Diseases and Immunity , Quebec City , Canada ; 261 Université Paris Descartes , Sorbonne Paris Cité , Paris , France ; 262 Universiteit Hasselt , Diepenbeek , Belgium ; 263 University Clinic Eppendorf , Hamburg , Germany ; 264 University College London , London , UK ; 265 University Hospital Bonn ( UKB ) , Bonn , Germany ; 266 University Hospital Essen , University Duisburg - Essen , Institute for Transfusion Medicine , Essen , Germany ; 267 University Hospital Heidelberg , Institute of Pathology , Applied Tumor Biology , Heidelberg , Germany ; 268 University Hospital RWTH Aachen , Department of Thoracic and Cardiovascular Surgery , Aachen , Germany ; 269 University Hospitals Cleveland Medical Center , Department of Medicine , Cleveland , OH , USA ; 270 University Medical Center Göttingen , Developmental Biochemistry , Göttingen , Germany ; 271 University Medical Center Göttingen , Hematology and Oncology , Göttingen , Germany ; 272 University Medical Center Hamburg - Eppendorf , Department of Neurosurgery , Hamburg , Germany ; 273 University Medical Center Hamburg - Eppendorf , Institute of Neuropathology , Hamburg , Germany ; 274 University Medical Center Utrecht , Department of Nephrology and Hypertension , Utrecht , The Netherlands ; 275 University Medical Center Utrecht , Laboratory for Clinical Chemistry & Hematology , Utrecht , The Netherlands ; 276 University of Antwerp , Centre for Proteomics , Antwerp , Belgium ; 277 University of Auckland , Auckland , New Zealand ; 278 University of Auckland , Department of Molecular Medicine and Pathology , Auckland , New Zealand ; 279 University of Auckland , Department of Obstetrics and Gynaecology , Auckland , New Zealand ; 280 University of Belgrade , Institute for the Application of Nuclear Energy , INEP , Belgrade , Serbia ; 281 University of Birmingham , Birmingham , UK ; 282 University of Birmingham , Institute of Microbiology and Infection , Birmingham , UK ; 283 University of Brescia , Department of Molecular and Translational Medicine , Brescia , Italy ; 284 University of Bristol , Bristol , UK ; 285 University of British Columbia Okanagan , Kelowna , Canada ; 286 University of Buenos Aires , Instituto de Investigaciones Biomédicas en Retrovirus y SIDA ( INBIRS ) , Buenos Aires , Argentina ; 287 University of California , Davis , Department of Nutrition , Davis , CA , USA ; 288 University of California , Davis , Department of Otolaryngology , Davis , CA , USA ; 289 University of California , Los Angeles , California NanoSystems Institute , Los Angeles , CA , USA ; 290 University of California , Los Angeles , Department of Bioengineering , Los Angeles , CA , USA ; 291 University of California , Los Angeles , Department of Pathology and Laboratory Medicine , Los Angeles , CA , USA ; 292 University of California , Los Angeles , Jonsson Comprehensive Cancer Center , Los Angeles , CA , USA ; 293 University of California , San Diego , Department of Neurosurgery , La Jolla , CA , USA ; 294 University of California , San Diego , Department of Obstetrics , Gynecology , and Reproductive Sciences , La Jolla , CA , USA ; 295 University of California , San Diego , Department of Pediatrics , San Diego , CA , USA ; 296 University of California , San Francisco , CA , USA ; 297 University of Cambridge School of Clinical Medicine , Addenbrooke ’ s Hospital , Department of Medicine , Cambridge NIHR BRC Cell Phenotyping Hub , Cambridge , UK ; 298 University of Campinas , Piracicaba Dental School , Department of Oral Diagnosis , Piracicaba , Brazil ; 299 University of Chile , Faculty of Chemical and Pharmaceutical Science , Laboratory of Nanobiotechnology and Nanotoxicology , Santiago , Chile ; 300 University of Cincinnati College of Medicine , Cincinnati , OH , USA ; 301 University of Cologne , Department of Internal Medicine I , Cologne , Germany ; 302 University of Colorado , School of Medicine , Department of Ophthalmology , Cell Sight - Ocular Stem Cell and Regeneration Program , Aurora , CO , USA ; 303 University of Copenhagen , Faculty of Health and Medical Sciences , Novo Nordisk Foundation Center for Protein Research , Copenhagen , Denmark ; 304 University of Copenhagen , Institute of Clinical Medicine , Copenhagen , Denmark ; 305 University of Edinburgh , Institute of Immunology & Infection Research , Edinburgh , UK ; 306 University of Gothenburg , Institute of Clinical Sciences at Sahlgrenska Academy , Department of Biomaterials , Gothenburg , Sweden ; 307 University of Gothenburg , Institute of Clinical Sciences , Department of Surgery , Sahlgrenska Cancer Center , Gothenburg , Sweden ; 308 University of Gothenburg , Institute of Medicine at Sahlgrenska Academy , Krefting Research Centre , Gothenburg , Sweden ; 309 University of Gothenburg , Sahlgrenska Academy , Department of Rheumatology and Inflammation Research , Gothenburg , Sweden ; 310 University of Gothenburg , The Sahlgrenska Academy , Institute of Neuroscience and Physiology , Department of Psychiatry and Neurochemistry , Mölndal , Sweden ; 311 University of Helsinki , EV Core Facility , Helsinki , Finland ; 312 University of Helsinki , Faculty of Biological and Environmental Sciences , Molecular and Integrative Biosciences Research Programme , EV group , Helsinki , Finland ; 313 University of Hertfordshire , School of Life and Medical Sciences , Biosciences Research Group , Hatfield , UK ; 314 University of Kentucky , College of Medicine , Department of Physiology , Lexington , KY , USA ; 315 University of L ’ Aquila , Department of Life , Health and Environmental Sciences , L ’ Aquila , Italy ; 316 University of Liège , GIGA - R ( MBD ) , PSI Laboratory , Liège , Belgium ; 317 University of Ljubljana , Faculty of Medicine , Institute of Biochemistry , Ljubljana , Slovenia ; 318 University of Lyon , INRA , EPHE , UMR754 Viral Infections and Comparative Pathology , Lyon , France ; 319 University of Lyon , Lyon - Sud Faculty of Medicine , CarMeN Laboratory ( UMR INSERM 1060 - INRA 1397 ) , Pierre - Bénite , France ; 320 University of Mainz , Institute of Developmental Biology and Neurobiology , Mainz , Germany ; 321 University of Malta , Department of Pathology , Msida , Malta ; 322 University of Manchester , Division of Cancer Sciences , Manchester Cancer Research Centre , Manchester , UK ; 323 University of Manchester , Manchester , UK ; 324 University of Maryland , Fischell Department of Bioengineering , College Park , MD , USA ; 325 University of Massachusetts Medical School , RNA JOURNAL OF EXTRACELLULAR VESICLES 5 Therapeutics Institute , Worcester , MA , USA ; 326 University of Michigan Medical School , Ann Arbor , MI , USA ; 327 University of Michigan , Biointerfaces Institute , Ann Arbor , MI , USA ; 328 University of Michigan , Department of Biomedical Engineering , Ann Arbor , MI , USA ; 329 University of Michigan , Department of Internal Medicine - Hematology / Oncology Division , Ann Arbor , MI , USA ; 330 University of Michigan , Department of Medicine , Ann Arbor , MI , USA ; 331 University of Michigan , Department of Urology , Ann Arbor , MI , USA ; 332 University of Minnesota Medical School , Institute on the Biology of Aging and Metabolism , Department of Biochemistry , Molecular Biology and Biophysics , Minneapolis , MN , USA ; 333 University of Modena and Reggio Emilia , Division of Oncology , Modena , Italy ; 334 University of Nebraska Medical Center , Department of Pharmacology and Experimental Neuroscience , Omaha , NE , USA ; 335 University of Notre Dame , Department of Biological Sciences , Notre Dame , IN , USA ; 336 University of Oslo , Institute of Clinical Medicine , Oslo , Norway ; 337 University of Ottawa , Ottawa , Canada ; 338 University of Oulu , Faculty of Medicine , Cancer and Translational Medicine Research Unit , Oulu , Finland ; 339 University of Oxford , Department of Physiology , Anatomy and Genetics , Oxford , UK ; 340 University of Oxford , Radcliffe Department of Medicine , Acute Stroke Programme - Investigative Medicine , Oxford , UK ; 341 University of Padova , Department of Comparative Biomedicine and Food Science , Padova , Italy ; 342 University of Padova , Department of Women ’ s and Children ’ s Health , Padova , Italy ; 343 University of Palermo , Department of Biopathology and Medical Biotechnologies , Palermo , Italy ; 344 University of Perugia , Department of Chemistry , Biology and Biotechnology , Perugia , Italy ; 345 University of Pisa , Centro Dipartimentale di Biologia Cellulare Cardio - Respiratoria , Pisa , Italy ; 346 University of Porto , Faculty of Pharmacy ( FFUP ) , IBMC / I3S , Porto , Portugal ; 347 University of Porto , Faculty of Pharmacy ( FFUP ) , Porto , Portugal ; 348 University of Porto , i3S - Instituto de Investigação e Inovação em Saúde , Porto , Portugal ; 349 University of Porto , ICBAS - Instituto de Ciências Biomédicas Abel Salazar , Porto , Portugal ; 350 University of Rochester , Rochester , NY , USA ; 351 University of São Paulo , Ribeirão Preto Medical School , Department of Pathology and Forensic Medicine , Ribeirão Preto , Brazil ; 352 University of São Paulo , Ribeirão Preto Medical School , Ribeirão Preto , Brazil ; 353 University of Science and Culture , ACECR , Department of Developmental Biology , Tehran , Iran ; 354 University of South Alabama , Department of Pharmacology , Center for Lung Biology , Mobile , AL , USA ; 355 University of Southern California Keck School of Medicine , Los Angeles , CA , USA ; 356 University of Southern California , Los Angeles , CA , USA ; 357 University of Technology Sydney , Discipline of Pharmacy , Graduate School of Health , Sydney , Australia ; 358 University of Texas MD Anderson Cancer Center , Department of Cancer Biology , Metastasis Research Center , Houston , TX , USA ; 359 University of Torino , Department of Medical Sciences , Torino , Italy ; 360 University of Torino , Department of Molecular Biotechnology and Health Sciences , Torino , Italy ; 361 University of Toronto , Department of Anesthesia , Toronto , Canada ; 362 University of Toronto , Department of Laboratory Medicine and Pathobiology , Toronto , Canada ; 363 University of Toronto , Department of Medical Biophysics , Toronto , Canada ; 364 University of Toronto , Department of Medicine , Division of Neurology , Toronto , Canada ; 365 University of Tsukuba , Tsukuba , Japan ; 366 University of Virginia Health System , Department of Medicine , Division of Nephrology , Charlottesville , VA , USA ; 367 University of Virginia , Flow Cytometry Core , School of Medicine , Charlottesville , VA , USA ; 368 University of Würzburg , Rudolf Virchow Center , Würzburg , Germany ; 369 Utrecht University , Faculty of Veterinary Medicine , Department of Biochemistry and Cell Biology , Utrecht , The Netherlands ; 370 Utrecht University , University Medical Center Utrecht , Center for Molecular Medicine & Regenerative Medicine Center , Utrecht , The Netherlands ; 371 Utrecht University , University Medical Center Utrecht , Department of Neurosurgery , Brain Center Rudolf Magnus , Institute of Neurosciences , Utrecht , The Netherlands ; 372 Utrecht University , University Medical Center Utrecht , Department of Pathology , Utrecht , The Netherlands ; 373 Vanderbilt University Medical Center , Epithelial Biology Center , Department of Medicine , Nashville , TN , USA ; 374 Vanderbilt University School of Medicine , Department of Cell and Developmental Biology , Nashville , TN , USA ; 375 Veterans Affairs Medical Center , San Francisco , CA , USA ; 376 Vilnius University , Institute of Biomedical Sciences , Department of Physiology , Biochemistry , Microbiology and Laboratory Medicine , Vilnius , Lithuania ; 377 Vlaamse Instelling voor Technologisch Onderzoek ( VITO ) , Mol , Belgium ; 378 Washington University , Saint Louis , MO , USA ; 379 Weill Cornell Medicine , Department of Medicine , New York City , NY , USA ; 380 Weizmann Institute of Science , Department of Biomolecular Sciences , Rehovot , Israel ; 381 West Virginia University , Department of Chemical and Biomedical Engineering and WVU Cancer Institute , Morgantown , WV , USA ; 382 West Virginia University , Department of Microbiology Immunology and Cell Biology , Morgantown , WV , USA ; 383 West Virginia University , Morgantown , WV , USA ; 384 Xiamen University , Department of Chemical Biology , Xiamen , China ABSTRACT The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles ( EVs ) , a collective term covering various subtypes of cell - released , membranous structures , called exosomes , microvesicles , micropar - ticles , ectosomes , oncosomes , apoptotic bodies , and many other names . However , specific issues arise when working with these entities , whose size and amount often make them difficult to obtain as relatively pure preparations , and to characterize properly . The International Society for Extracellular Vesicles ( ISEV ) proposed Minimal Information for Studies of Extracellular Vesicles ( “ MISEV ” ) guidelines for the field in 2014 . We now update these “ MISEV2014 ” guidelines based on evolution of the collective knowledge in the last four years . An important point to consider is that ascribing a specific function to EVs in general , or to subtypes of EVs , requires reporting of specific information beyond mere description of function in a crude , potentially contaminated , and heterogeneous preparation . For example , claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally , given our still limited knowledge of their specific molecular machineries of biogenesis and release , as compared with other biophysically similar EVs . The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV - associated functional activities . Finally , a checklist is provided with summaries of key points . ARTICLE HISTORY Received 20 September 2018 Accepted 25 September 2018 KEYWORDS extracellular vesicles ; exosomes ; ectosomes ; microvesicles ; minimal information requirements ; guidelines ; standardization ; microparticles ; rigor ; reproducibility 6 C . THÉRY AND K . W . WITWER JOURNAL OF EXTRACELLULAR VESICLES 7 Table of Contents i . Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 ii . Note on applicability of MISEV2018 : species , cells , sample types , and experimental conditions . . . . . . . . . . . . . . . . . . . . . . . . 8 1 - Nomenclature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2 - Collection and pre - processing : pre - analytical variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2 - a ) Cell culture conditioned media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2 - b ) Biological fluids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 2 - c ) Tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 2 - d ) Storage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 3 - EV separation and concentration : How MISEV2014 evolves in 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Table 1 : Considerations for EV separation / enrichment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 4 - EV characterization : How MISEV2014 evolves in 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Table 2 : Steps of EV characterization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 4 - a ) Quantification of EVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 4 - b ) Characterization of EVs by their protein composition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 4 - b - 1 ) Selection of proteins for use as EV markers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Table 3 : Protein content - based EV characterization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 4 - b - 2 ) Methods to assess presence of proteins in EV preparations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 4 - b - 3 ) Non - protein components as markers of EVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 4 - c ) Single vesicle analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 4 - d ) New recommendation : determine the topology of EV - associated components . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 5 - Functional studies : How MISEV2014 evolves in 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Table 4 : EV - associated and EV - excluded biological activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 5 - a ) Determine the specific versus common functions of different types of EVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 5 - b ) Demonstrate that the activity is observed in the absence of direct cell - cell contact . . . . . . . . . . . . . . . . . . . . . . . . . . 23 5 - c ) Demonstrate that the activity is predominantly associated with EVs rather than with soluble mediators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 5 - d ) Demonstrate the specific association of the activity with EVs rather than with co - isolated components . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 5 - e ) Determine whether a function is specific to exosomes , as compared with other small EVs . . . . . . . . . . . . 25 5 - f ) How to attribute particular effects mediated by EVs to specific EV components . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 5 - g ) Consider whether an EV - dependent function is specific to a given EV source . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 6 - General considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 6 - a ) Reporting requirements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 6 - b ) Exceptions to compliance with MISEV guidelines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 7 - Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 8 - References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 9 - MISEV2018 Quick - Reference Checklist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 Introduction In 2014 , the ISEV board members published a Position Editorial detailing their recommendations , based on their own established expertise , on the “ minimal experimental requirements for definition of extracellular vesicles and their functions ” [ 1 ] . A list of minimal information for studies of extracellular vesicles ( MISEV or MISEV2014 ) was provided , covering extracellular vesicle ( EV ) separa - tion / isolation , characterization , and functional studies . The major goal of these recommendations was to sensi - tize researchers ( especially the rapidly growing numbers of scientists newly interested in EVs ) , as well as journal editors and reviewers , to experimental and reporting requirements specific to the EV field . The ISEV board highlighted the need to consider these issues when mak - ing strong conclusions on the involvement of EVs , or specific populations of EVs ( exosomes in particular ) , in any physiological or pathological situation , or when pro - posing EVs or their molecular cargo as biological mar - kers . By stimulating improved reliability and reproducibility of published EV results , the MISEV2014 authors hoped to further the promise of EVs as biomar - kers or for therapeutic applications even in the face of skepticism by some scientists outside the field . As evidenced by the increasing number of EV publica - tions in high - profile journals , proposing major roles of EVs in numerous physiological pathways from aging to cancer , infectious diseases to obesity , EV science has now clearly achieved widespread interest and enthusiasm well beyond the EV research community . However , the promotion of rigorous EV science is an ongoing process ; as EV experts within the ISEV community , we are still concerned to see that major conclusions in some articles are not sufficiently supported by the experiments performed or the informa - tion reported . We therefore aim to revise and renew the MISEV recommendations and to continue to work toward their wider acceptance and implementation . In this “ MISEV2018 ” update , a much larger group of ISEV scien - tists was involved through a community outreach ( the MISEV2018 Survey ) , striving for consensus on what is absolutely necessary , what should be done if possible , and how to cautiously interpret results if all recommendations for controls cannot be followed . We strongly believe that most of the MISEV2014 recommendations are still valid ; however , discoveries and developments within the field during the past four years necessitate certain amendments . This document explains how the 2014 recommendations evolved into MISEV2018 in Tables 1 , 2 and 4 ; provides suggestions for protein markers to validate the presence of EVs ( Table 3 ) ; and , to highlight the salient points , provides outlines of examplar approaches to address some of the most important experimental issues . Importantly , a 2 - page checklist summarizing the major aspects to follow in EV science is provided at the end of this article . The authors of MISEV2014 were careful to propose feasible experiments and controls for most experimental situations , but also to suggest alternatives for particular situations in which not all guidelines could be strictly followed , such as for limiting sample quantities . However , a recent survey of members of ISEV to lay the groundwork for MISEV2018 [ 2 ] showed that , while respondents agreed almost unanimously on the need for minimal require - ments , and a majority supported the MISEV2014 initiative and guidelines as published , almost a quarter of respon - dents found the guidelines too restrictive or too strong an imposition on the field . MISEV2018 thus provides clearer explanations of the need for each recommendation and highlights the extent of author consensus ( or lack thereof ) on each section . An initial draft of MISEV2018 was sub - mitted to the entire ISEV membership as a Survey asking for agreement / disagreement and comments on each sec - tion . The survey specified that , for agree / disagree ques - tions , > 20 % “ disagree ” responses would prompt acknowledgment of major dissent in the final document , while > 40 % “ disagree ” would prompt a focused survey or discussion of the ISEV board with selected survey respondents to redraft the relevant section . 329 responses were received , in which there was such broad agreement on the MISEV2018 draft that the 40 % threshold was not met for any section . Nevertheless , attempts were made to address as many comments as comprehensively as possible , and thus generate a semi - final version of this text . Finally , a last round of review was conducted by all previous con - tributors as well as ISEV and JEV board members and numerous additional long - standing EV experts . Although not all suggestions , references , and critiques could be included in the final product , we are confident that this document represents the views of EV scientists with broad and deep expertise . Consensus : > 99 % of MISEV2018 Survey respondents agreed with the introduction . It has been modified only slightly since the survey , mostly to convey the survey mechanism and results . Note on applicability of MISEV2018 : species , cells , sample types , and experimental conditions Does MISEV2018 apply to all EV studies , or only to some ? EVs appear to be produced by almost all organisms and cell types studied . Yet EV research to date has focused on mammalian EVs , chiefly those of human or mouse origin , and not all cell types or experimental conditions have been closely investigated . In this document , as in MISEV2014 , specific examples of molecular markers ( such as the mar - kers of EVs in Table 3 ) are based on studies of specific species , cells , and experimental conditions . Some may be broadly applicable , others less so . Nevertheless , the general principles of MISEV2018 apply to EVs produced by all organisms and all cells . The need to demonstrate presence ( or enrichment ) of EV markers and absence ( or depletion ) of putative contaminants , when contents or function of EVs are described , can be generalized to all species , cells , and conditions . We find ourselves at an exciting scientific frontier ; where such markers are not yet available , we encourage their development and publication , using the principles of this document as a guide . Additional specific examples may then be incorporated into future MISEV updates . Consensus : 93 % of MISEV2018 Survey respondents agreed that the examples in this document would be based on mammalian EVs . However , applicability to non - mammalian and non - eukaryotic EVs is now addressed . Nomenclature ISEV endorses “ extracellular vesicle ” ( EV ) as the generic term for particles naturally released from the cell that are 8 C . THÉRY AND K . W . WITWER delimited by a lipid bilayer and cannot replicate , i . e . do not contain a functional nucleus . Since consensus has not yet emerged on specific markers of EV subtypes , such as endo - some - origin “ exosomes ” and plasma membrane - derived “ ectosomes ” ( microparticles / microvesicles ) [ 3 , 4 ] assigning an EV to a particular biogenesis pathway remains extra - ordinarily difficult unless , e . g . the EV is caught in the act of release by live imaging techniques . Therefore , unless authors can establish specific markers of subcellular origin that are reliable within their experimental system ( s ) , authors are urged to consider use of operational terms for EV subtypes that refer to a ) physical characteristics of EVs , such as size ( “ small EVs ” ( sEVs ) and “ medium / large EVs ” ( m / lEVs ) , with ranges defined , for instance , respectively , < 100nm or < 200nm [ small ] , or > 200nm [ large and / or medium ] ) or density ( low , middle , high , with each range defined ) ; b ) biochemical composition ( CD63 + / CD81 + - EVs , Annexin A5 - stained EVs , etc . ) ; or c ) descriptions of conditions or cell of origin ( podocyte EVs , hypoxic EVs , large oncosomes , apoptotic bodies ) in the place of terms such as exosome and microvesicle that are historically burdened by both manifold , contradictory definitions and inaccurate expectations of unique biogenesis . If it is deemed unavoidable to use these or newly coined terms , they should be defined clearly and prominently at the beginning of each publication [ 5 ] . If confirmation of EV identity cannot be achieved according to the minimal requirements of this MISEV2018 publication , other terms such as extracellular particle ( EP ) might be more appropriate . Consensus : 94 % of MISEV2018 Survey respondents endorsed this nomenclature recommendation . The remainder were evenly split between dissent and a preference for no nomenclature recommendation . Collection and pre - processing : pre - analytical variables The first step to recover EVs is to harvest an EV - containing matrix , such as fluid from tissue culture or from an orga - nismal compartment . During this pre - analytical phase , an extended constellation of factors , including characteristics of the source , how the source material is manipulated and stored , and experimental conditions , can affect EV recov - ery . Therefore , it is crucial to plan collection and experi - mental procedures to maximize the number of known , reportable parameters , and then to report as many pre - analytical parameters as are known . Cell culture conditioned media For EV isolation / characterization from conditioned media ( an ISEV survey found that the majority of responding EV researchers studied conditioned medium [ 6 ] ) , basic char - acterization of the releasing cells and culture and harvesting conditions must be performed and reported . Some precau - tions , such as regular confirmation of cellular identity ( e . g . by short tandem repeat ( STR ) profiling or other methods ) [ 7 , 8 ] and identification of cell lineage and provenance including mode of immortalization [ 9 ] , are advisable for all cell studies . Especially important for EV studies is that the percent of dead cells at the time of EV harvest should be indicated , since even a small percentage of cell death could release cell membranes that outnumber true released EVs . Quantifying the percentage of apoptotic and necrotic cells may also be useful . ( Note , however , that when cells are treated with high concentrations of EVs , cell - adherent EVs positive for apoptotic markers may skew results [ 10 , 11 ] ) . Other relevant characteristics of the cells , including state of activation , malignancy , and senescence [ 12 , 13 ] , should be reported where applicable . Culture and harvesting conditions such as passage number ( or days in culture for suspension cells ) , seeding density [ 14 ] , density / confluence at harvest [ 14 ] , including any relevant post - confluence characteristics such as devel - opment of polarity [ 15 – 19 ] ( in that case , were EVs collected globally or separately , from the different parts of polarized cells ? ) , culture volume , culture vessel or bioreactor system ( if used [ 20 , 21 ] ) , surface coatings , oxygen or other gas tensions ( if they differ from standard cell culture ) [ 22 , 23 ] , stimulation and other treatments [ 24 – 30 ] , and frequency and intervals of harvest [ 14 ] should be given to allow replication [ 31 , 32 ] . Culture conditions prior to treatment - ( s ) , if any , should also be given . Note that EV recovery depends not only on EV release , but also on re - uptake by cells in culture , which may vary based on culture density and other conditions . Regular checks for contamination with Mycoplasma ( and possibly other microbes ) are needed , not only because of cellular responses to contam - ination , but also because contaminating species can release EVs [ 33 – 36 ] . Exact methods of medium collection should be given , as well ( e . g . decanting or pipetting from flasks , centrifugation of suspension cell cultures ) . The suggested parameters are of course non - inclusive , and others may be necessary to report for specific types of cells and experi - ments , including co - culture systems and organoid cul - tures [ 37 ] . All culture medium composition and preparation details should be provided in methods . This should be customary for cell culture studies , and is doubly impor - tant here since supplements like glucose [ 38 – 40 ] , anti - biotics [ 41 ] , and growth factors [ 42 ] can affect EV production and / or composition . Of special note are medium components that are likely to contain EVs , such as serum . EVs are ideally obtained from culture medium conditioned by cells in the absence of fetal calf JOURNAL OF EXTRACELLULAR VESICLES 9 serum ( FCS or FBS ) , serum from other species , or other complex products such as platelet lysate , pituitary extract , bile salts , and more , to avoid co - isolation of exogenous EVs . When use of these supplements is unavoidable , experiments should include a non - conditioned medium control to assess the contribution of the medium itself . However , depending on down - stream use , it may not be necessary or desirable to deplete EVs [ 43 , 44 ] . In the case of depletion , since nutrient or EV deprivation of cells that are normally cultured in serum - or lysate - containing medium can change cellular behavior and the nature and composi - tion of released EVs [ 45 , 46 ] , it is important to specify culture history ( how and when the switch to serum - free medium occurred , including acclimatization steps ) . Alternatively , cells can be exposed during the EV release period to medium that has been pre - depleted of EVs . Here , too , effects on cells and EVs may be expected [ 47 ] , and the methods and outcome of depletion vary greatly and should be reported . Several fairly efficient protocols are available , such as 100 , 000 x g ultracentrifugation of complete medium ( or of serum following at least 1 : 4 dilution ) for at least 18 hours [ 48 ] , centrifugation at enhanced speeds ( e . g . 200 , 000 x g [ 49 ] ) for shorter periods of time , or tan - gential flow filtration or other forms of ultrafiltration [ 50 ] . Ultracentrifugation at around 100k x g for a few hours or without dilution will not eliminate all EVs or EV - associated RNA [ 51 – 53 ] . Commercial “ exosome / EV - depleted ” serum and other supplements are avail - able from an increasing number of vendors . Since the method of depletion is usually not indicated , conse - quences on cell growth and EV release may not be predictable ; the exact source , method , and reference of depleted supplements should be given , and the “ exo - some - free ” nature of the product should be checked carefully before use [ 54 ] . Additionally , vendors are encouraged to report and benchmark the methods of depletion utilized in their products , while users should report product and lot numbers as well as any pooling of biologicals . Finally , medium preparation details , including heating ( heat inactivation ) or filtration steps , should be reported . For example , heat inactiva - tion of additives such as serum leads to formation of protein aggregates that may co - precipitate with EVs and thus also change the growth - supporting properties of the serum . Biological fluids Since more than 30 types of biofluids exist in mammals , and lavages of numerous compartments add to this num - ber ( despite not being true biofluids ) , MISEV2018 does not provide an exhaustive review of the literature on pre - analytical variables related to all biofluids . Each biological fluid presents specific biophysical and chemical character - istics that makes it different from culture conditioned medium , and this must be taken into account when isolating EVs . For instance , plasma and serum are more viscous than conditioned medium . Plasma and serum contain numerous non - EV lipidic structures ( low / very low / high density lipoproteins ) , milk is replete with fat - containing vesicles , urine with uromodulin ( Tamm - Horsfall protein ) , bronchoalveolar lavage with surfactant , all of which will be co - isolated to various degrees with EVs . In each case , specific precautions to separate EVs from these components may be required . While detailed biofluid - specific reporting guidelines are beyond the scope of this MISEV , we encourage development of such guidelines under the MISEV umbrella . For EV isolation / characterization from biofluids such as blood plasma , several previous ISEV posi - tion papers [ 55 , 56 ] and other publications ( for just a few of many examples , see [ 57 – 63 ] ) have listed reporting requirements that are important for stan - dardization , and these are still valid today , even if many questions remain about the effects of specific pre - analytical variables on different classes of EVs . Since many of these factors have been covered in these previous publications , we do not review them exhaustively here . To give examples of considera - tions for blood derivatives such as plasma : donor age , biological sex , current or previous pregnancy , menopause , pre / postprandial status ( fasting / non - fasting ) , time of day of collection ( Circadian varia - tions ) , exercise level and time of last exercise , diet , body mass index , specific infectious and non - infectious diseases , medications , and other factors may affect circulating EVs [ 64 , 65 ] . Similarly , tech - nical factors including fluid collection volume , first - tube discard , type of container ( s ) , time to proces - sing , choice of anticoagulant ( for blood plasma ) [ 66 – 68 ] , mixing or agitation , temperature ( storage and processing ) , description of transport ( if any ) , whether tube remained upright before processing , exact centrifugation or filtration procedures , degree of hemolysis , possible confirmation of platelet and lipoprotein depletion prior to storage [ 69 – 73 ] , and other parameters should be clearly indicated . Overall , except some that are specific of plasma / serum ( such as platelet removal and coagulation ) , the above listed technical details of collection con - dition apply to all biofluids and must be reported . Of course , it may be that not all variables have been recorded for archived samples , and this should be acknowledged where applicable . 10 C . THÉRY AND K . W . WITWER Tissue As a special case of pre - analytical issues , a rapidly increasing number of groups have reported isolation of tissue EVs . These studies may involve short - term culture of tissue explants [ 74 ] such as ex vivo tumors [ 75 ] , or placenta [ 76 , 77 ] , or extraction from whole tissues [ 78 – 84 ] . Many of the same considerations that apply for cellular and biofluids studies also apply here , including confirmation of provenance and condition . Especially for EV extraction from tissue , it is challen - ging to ensure that recovered vesicles are truly from the extracellular space , rather than being intracellular vesi - cles or artefactual particles released from cells broken during tissue harvest , processing ( e . g . mechanical dis - ruption ) , or storage ( including freezing ) . This may be especially challenging in a tissue like brain , where similar procedures are used to collect synaptosomes [ 85 ] . Even apparently pure tissue - derived EVs can con - tain endosome components , which could correspond to components of intracellular vesicles including unre - leased intraluminal vesicles of late endosomes / multi - vesicular bodies ( MVBs ) that are released artifactually during tissue processing . The recent awareness of these challenges has led researchers to perform gentle tissue disruption ( i . e . with the goal of separating EVs from cells and extracellular matrix , but not disrupting cells ) and several steps of further separation ( including den - sity gradients ) , followed by strict characterization of multiple negative markers , leading to more convincing tissue - derived EV preparations [ 79 ] . Use of genetically modified models to trace EV release from specific cells [ 83 ] is also a useful approach . More research is clearly needed and encouraged into the isolation , characteriza - tion , and function of tissue EVs , as compared with intracellular vesicles and / or non - vesicular extracellular particles ( EPs ) . Storage Storage and retrieval conditions of both the matrix ( e . g . biofluid , tissue , conditioned media ) and isolated EVs may affect EV characteristics , including stability , num - ber of particles , aggregation , and function [ 57 , 62 , 63 , 71 , 86 – 96 ] . In particular , highly purified EVs may be lost upon storage by adhering to the surfaces of the storage container . How were biofluids , tissues , or media prepared and stored ( type of storage container , temperature , etc . ) and for how long ? Were isolated EVs analyzed or used for experiments fresh , frozen / thawed , lyophilized and reconstituted , etc . ? If frozen , how was freezing and thawing performed ? In what buffer ( s ) were EVs stored ? For how long ? What , if any , cryo - protectant was used ? How many freeze - thaw cycles did each sample experience ? If EVs were processed and stored in some other manner , details should also be provided , along with the procedure to evaluate effects of storage method and time on EV activity and other properties , where applicable . Consensus : 96 % of MISEV2018 Survey respondents endorsed the pre - analytical variables section . Since 44 % of respondents also suggested at least one added literature citation or other amendment in more than 200 total comments , the section was revised to reflect as many of these suggestions as possible . However , bio - fluids - specific considerations and SOPs are beyond the current scope of MISEV ; only illustrative examples are provided . The MISEV2018 Survey comments evidenced particular interest in urine and milk , consistent with the “ Experts Meet ” sessions during ISEV2016 and the results of a previous ISEV survey ( which also highlighted cerebrospinal fluid ) [ 6 ] . Beginning with the blood EV roadmap announced at the ISEV2018 annual meeting [ 97 ] , development of more specific recommendations for individual biofluids and other matrices is encouraged . The overwhelming response to this section indeed demands additional research into the effects of pre - analytical variables on EV studies . EV separation and concentration : how MISEV2014 evolves in 2018 Absolute purification , or complete isolation of EVs from other entities , is an unrealistic goal ( as for many biological products ) . For this reason , and since the various combinations of EVs and media are colloids [ 98 ] , here we use the terms separation and concentra - tion . Separation ( colloquially referred to as purification or isolation ) of 1 ) EVs from other non - EV components of the matrix ( conditioned medium , biofluid , tissue ) and 2 ) the different types of EVs from each other , are achieved to various degrees by the different techniques available . Concentration is a means to increase num - bers of EVs per unit volume , with or without separa - tion . The term “ enrichment ” can refer to increasing concentration , i . e . EV counts relative to volume , or to increasing EV counts / markers relative to another com - ponent . The extent of separation or concentration can be assessed by characterization , which will be detailed in the next section . How pure should an EV preparation be ? The answer depends on the experimental question and EV end use , and often segregates by basic and clinical research . Highly purified EVs are needed to attribute a function or a biomarker to vesicles as compared with other particles . Less pure EVs may be required in other cases , such as when a biomarker is useful without pre - enrichment of EVs , or in certain JOURNAL OF EXTRACELLULAR VESICLES 11 therapeutic situations where function is paramount , not the definitive association of function with EVs . Of note , some presumed contaminants may co - isolate with EVs and may even contribute to EV function . Therefore , the choice of separation and concentration method must be informed by factors that may vary between studies such that there is no one - size - fits - all approach . More details on this issue ( function and co - isolated factors ) are given in section 5c - d ( p . 24 ) . At the end of 2015 , according to a worldwide ISEV survey [ 6 ] , differential ultracentrifugation was the most commonly used primary EV separation and concentra - tion technique , with various other techniques , such as density gradients , precipitation , filtration , size exclu - sion chromatography , and immunoisolation , used by 5 – 20 % of respondents each . Relative success of these different methods in terms of recovery and specificity to EVs ( as compared to non - vesicular components ) , or to EV subtypes , has been addressed in a previous ISEV Position Paper ( see Figure 1 of [ 56 ] ) , and is summar - ized in Table 1 below . To achieve better specificity of EV or EV subtype separation , most researchers use one or more additional techniques following the primary step , such as washing in EV - free buffer , ultrafiltration , application of density gradients ( velocity or flotation ) , or chromatography [ 6 , 99 – 102 ] . A variety of additional techniques or combinations of techniques have been or are currently being devel - oped , some of which may become more prominent in the coming years if they achieve better recovery or specificity than legacy methods ( and this must be demonstrated as in , e . g . [ 103 ] ) . Such methods include tangential flow filtration and variations thereon [ 21 , 104 – 110 ] , field - flow fractionation ( FFF ) [ 111 ] , asymmetric flow field - flow fractionation ( AFFF , A4F , or AF4 ) [ 112 – 114 ] , field - free viscoelastic flow [ 115 ] , alternating current electrophoretics [ 116 , 117 ] , acoustics [ 118 ] , variations on size exclusion chromatography ( SEC ) [ 100 , 119 – 121 ] , ion exchange chromatography [ 122 – 124 ] , microfiltration [ 125 ] , fluorescence - activated sorting [ 126 , 127 ] ( especially for larger EVs including large apoptotic bodies [ 128 ] and large onco - somes [ 129 ] ) , deterministic lateral displacement ( DLD ) arrays [ 130 ] , novel immunoisolation or other affinity isolation technologies [ 131 – 138 ] , including lipid affi - nity [ 139 ] , novel precipitation / combination techniques [ 140 – 142 ] , hydrostatic filtration dialysis [ 143 ] , high - throughput / high - pressure methods such as fast pro - tein / high perfomance liquid chromatography ( FPLC / HPLC ) that involve some form of chromatography [ 144 ] and a wide variety of microfluidics devices that harness one or more principles , including some of those mentioned above [ 145 – 153 ] . Of course , combi - nations of methods will continue to be used and may outperform single - method approaches . Table 1 summarizes the instructions given in MISEV2014 for EV isolation ( left column ) , and their updates in MISEV2018 ( right ) . Consensus : 93 % of MISEV2018 Survey respondents agreed with the original categorization of techniques by recovery and specificity in Section 3 and Table 1a ; numerous amendments have been made in response to almost 90 comments . 98 % agreed that reporting of all methods details should be mandated to allow reprodu - cibility . 97 % agreed with the statement of caution on proprietary kits . EV characterization : how MISEV2014 evolves in 2018 EV characterization by multiple , complementary techni - ques is important to assess the results of separation methods and to establish the likelihood that biomarkers or functions are associated with EVs and not other co - isolated materials . The need for guidelines for character - ization was emphasized by a consortium study led by Hendrix and colleagues [ 161 ] . These authors found that only about half of EV - related articles published within a five - year time period included positive markers of EVs , and only a small minority complemented positive with negative markers to track co - isolated non - EV com - ponents . ISEV recommends that each preparation of EVs be 1 ) defined by quantitative measures of the source of EVs ( e . g . number of secreting cells , volume of bio - fluid , mass of tissue ) ; 2 ) characterized to the extent possible to determine abundance of EVs ( total particle number and / or protein or lipid content ) ; 3 ) tested for presence of components associated with EV subtypes or EVs generically , depending on the specificity one wishes to achieve ; and 4 ) tested for the presence of non - vesicular , co - isolated components . Table 2 summarizes the instructions given in MISEV2014 for EV characterization , and their updates in MISEV2018 . These recommendations apply to EVs from all sources , including non - mammalian and non - eukaryotic cells and organisms . Quantification of EVs Since quantifying EVs themselves remains difficult ( see below ) , as minimal information , the total starting volume of biofluid , or , for conditioned medium , num - ber of cells or mass of tissue at the time of collecting , should be indicated for each experimental use . If the 12 C . THÉRY AND K . W . WITWER Table 1 . Considerations for EV separation / enrichment . Major recommendations of MISEV2014 . Validity and / or Update in 2018 a ) There is no single optimal separation method , so choose based on the downstream applications and scientific question . Separation of non - vesicular entities from EVs is not fully achieved by common EV isolation protocols , including centrifugation protocols or commercial kits that claim EV or “‘ exosome ’” purification . Still valid . Any newly developed or applied technique for EV isolation must indicate to which of the 4 recovery / specificity options below it aims , and provide characterization information ( see Table 2 ) to show the extent of success . Different methods may be positioned on a recovery vs specificity grid , ranging from low to high in each dimension . Note that the degree of specificity of a particular method might vary depending on the type of biofluid from which EVs are separated . 1 ) high recovery , low specificity : methods that recover the highest amount of extracellular material , whatever its vesicular or non - vesicular nature , i . e . whole or near - whole concentrated secretome . Examples of protocols include but are not limited to : precipitation kits / polymer ( PEG or others ) , low molecular weight cutoff centrifugal filters with no further separation step , and lengthy or very high speed ultracentrifugation without previous , lower - speed steps . 2 ) intermediate recovery , intermediate specificity : methods that recover mixed EVs along with some amount of free proteins , ribonucleoproteins , and lipoproteins , depending on the matrix . Examples of protocols : size - exclusion chromatography [ 154 , 155 ] , high molecular weight centrifugal filters [ 102 ] , differential ultracentrifugation using intermediate time / speed with or without wash , tangential flow filtration , and membrane - affinity columns [ 155 , 156 ] . 3 ) low recovery , high specificity : methods that recover a subtype ( or a few subtypes ) of EVs with as few non - vesicular components as possible . Subtypes of EVs can be separated by their size ( e . g . by filtration , which must be combined with another method such as SEC to eliminate non EV components ) , their density upon either flotation or pelleting in a density gradient , their surface protein , sugar , or lipid composition ( immuno - or other affinity isolation including flow cytometry for large particles ) , or other biophysical properties such as surface charge . Note that the designation of “ low recovery ” is relative to total EVs , and that high recovery of specific subtypes may be possible using these techniques . 4 ) high recovery and high specificity , which may not be achievable as of this writing . b ) Report all details of the method ( s ) for reproducibility Still valid . Methods reporting is now facilitated by the EV - TRACK knowledgebase [ 161 ] ( see also checklist , p . 42 ) . ISEV strongly recommends that authors deposit experimental details with EV - TRACK . Examples for classical techniques : centrifugation ( g - force , rotor , ultracentrifuge , adjusted k - factor , tube type , adaptor if relevant , time , temperature , and brake ) a ; gradients ( materials , densities , volumes , and whether top - down ( pelleting ) or bottom - up ( flotation ) gradients were done , further processing ) ; chromatography ( matrix nature , pore size , volume ; volume of loaded sample ; volume and number of fractions , type of the elution buffer ; further processing of fractions ) ; immunoaffinity ( antibody reference and amount per volume of fluid , particle number , or protein amount , incubation time and temperature , matrix , recovery ) . Necessary technical detail reporting may have to be established for newly developed techniques . b - d c ) MISEV2018 additional recommendation : Some protocols , including those associated with many commercial kits , may result in EV populations bound to or mixed with introduced components such as antibodies , beads , polymers , and more . These materials may affect downstream profiling or functional studies and may also render the EVs unusable for therapeutic applications . Particular care in performing functional experiments must be taken ( see Table 4 ) , with controls including procedural controls and possibly with further separation of EVs . e , f a For ultracentrifugation , the k factor can be determined from the rotor type , tube / adapter , and centrifuge speed : the k factor represents the relative pelleting efficiency of a given centrifuge rotor at maximum rotation speed ; for runs with a rotational speed lower than the maximum rotor - speed , the k factor has to be adjusted : k adj = k x ( maximum rotor speed / actual rotor speed ) 2 ; we recommend that all possible parameters be reported [ 157 , 201 ] . See also a web calculator based on a theoretical model of centrifugation and meant for conversion of protocol parameters between rotors [ 158 ] . b For filtration techniques , one must take care to remove cells and other large membranous structures prior to ultrafiltration ; otherwise , large structures may disintegrate and re - form as small vesicles after passing through the filter [ 159 ] . Reference numbers of all filters should be specified , as filter type has been found to influence recovery profoundly [ 102 ] . c SEC : the pore size of the matrix should be taken into account . For example , if the pore size excludes EVs > 70 nm in diameter , a population of vesicles may be excluded . d Both size exclusion chromatography ( SEC ) and density gradients may co - isolate EVs and certain lipoproteins . Sequential techniques may be needed to achieve separation [ 160 , 213 ] . e Note , however , continuing concerns about the specificity and effects on vesicles of certain precipitation techniques [ 103 , 278 ] . f This Table does not address several important considerations that are beyond the scope of these guidelines , such as ease of use , cost , and potential for Good Manufacturing Practice ( GMP ) production . JOURNAL OF EXTRACELLULAR VESICLES 13 Table 2 . Steps of EV characterization . Major recommendations of MISEV2014 . Validity and / or Update in 2018 a ) No recommendation on quantification New in MISEV2018 : As a rule , both the source of EVs and the EV preparation must be described quantitatively . Source : Number of cultured cells ( possibly an estimate , if adherent , as well as intervals of harvest , where applicable ) , total starting volume of biofluid , or weight / volume / size of tissue at the time of collection must be indicated for each experimental use . The appropriate parameters will vary by source , however ; e . g . for urine , volume alone may not be meaningful , and other parameters , such as creatinine level , might be reported . For the EV preparation , global quantification of EVs should be provided . There is no single perfect quantification method . The most commonly used are total protein amount and total particle number . Total lipid quantification could be also considered . None of these components are exclusively associated to EVs , though : proteins are also soluble , particles can be protein aggregates , and lipids are also present in lipoproteins . Thus , ratios of proteins : particles , lipids : particles or lipids : proteins should be reported along with global quantification estimates as a measure of purity and thus reliability of the quantity measure . b ) General characterization . Show : i . At least three positive protein markers of EVs , including at least one - transmembrane / lipid - bound protein - cytosolic protein ii . At least one negative protein marker Still valid but has evolved with increasing knowledge of the existence of different EV types . Table 3 gives categories of proteins to consider for characterization and some examples . At least one protein of each category 1 to 3 must be evaluated in any EV preparation ( at least each time pre - analytical and / or EV isolation conditions are modified ) . Analysis of proteins of categories 4 – 5 is recommended for studies that focus on one or more EV subtypes ( e . g . small EVs < 200 nm , vs larger EVs : category 4 ) , or that have identified a functional soluble factor in EVs ( category 5 ) . 1 . All EVs bear proteins associated with the membrane or outer membrane ( prokaryotic cells ) , or with plasma membrane and / or endosomes ( eukaryotic cells ) . To demonstrate the presence of a lipid bilayer in the material analysed , at least one transmembrane or GPI - anchored extracellular protein must be shown . Examples include mammalian proteins expressed ( nearly ) ubiquitously in all cell types ( 1a ) , and proteins specifically expressed in some cells ( 1b ) . 2 . In all EVs , the lipid bilayer encloses cytosolic material ( eukaryotic cells , Gram - positive bacteria ) or periplasmic material ( Gram - negative bacteria ) from the secreting cell . To demonstrate that the material analysed contains more than open cell fragments , at least one cytosolic / periplasmic protein with lipid or membrane protein - binding ability must be shown ( 2a ) . Other cytosolic proteins are more promiscuously associated with EVs and other structures and thus should be only optionally used as EV markers ( 2b ) . 3 . Purity controls include proteins found in most common co - isolated contaminants of EV preparations : depending on the source of EVs , expected contaminants from category 3a ( lipoproteins and serum - derived materials ) , or 3b ( urine ) , should be evaluated . 4 . Proteins present in subcellular compartments other than the plasma membrane and endosomes , which may be present in certain EV subtypes ( eukaryotic cells ) . 5 . Soluble extracellular proteins with functional activities ( cytokines , growth factors , extracellular matrix ) may be detected in EVs : their mode of association to EVs ( via a specific or promiscuous receptor ? Or internal ? ) should be determined . ( See Table 2 part d ) , below . c ) Characterization of single vesicles : use two different but complementary techniques , for example : i . electron or atomic force microscopy ( and show both close - up and wide - field ) ii . single particle analyzers ( not electron microscope - based ) Still valid , but has evolved with a rapidly increasing number of techniques used to analyze EVs . i . Techniques providing images of single EVs at high resolution , such as electron microscopy and related techniques , scanning - probe microscopy ( SPM ) including atomic - Force microscopy ( AFM ) , or super - resolution microscopy : these techniques are not interchangeable in the information they provide . When reporting results , both close - up and wide - field images must be provided . ii . Single particle analysis techniques that estimate biophysical features of EVs from other techniques than high - resolution images : size measured by resistive pulse sensing ( electric field displacement ) , or light scattering properties [ nanoparticle tracking analysis ( NTA ) , high resolution flow cytometry , multi - angle light scattering coupled to asymmetric flow field - flow fractionation ( AF4 ) ] ; or fluorescence properties [ fluorescence correlation spectroscopy ( FCS ) , high - resolution flow cytometry ] . Chemical composition measured by Raman spectroscopy . Other techniques are being developed that may combine these two categories but have not yet been widely used ( see 4c p . 20 ) . Whatever technique is used , all experimental details for both acquisition and analysis must be reported . Note that not all techniques are equally adapted to all EVs : large EVs ( > 400 nm ) and very small EVs ( < 50 nm ) are not well quantified by all NTA ; small EVs are not easy to detect by most common flow cytometers . Some large EVs ( and aggregates of small EVs ) can be imaged by light / fluorescence microscopy . EVs smaller than the refraction limit or resolution of a microscope can still be detected by fluorescence , but no structural information can be obtained , and a single EV cannot be distinguished from a small EV cluster purely based on structural details . d ) MISEV2018 additional characterization . We now recommend that the topology of EV - associated components be assessed , that is , whether a component is luminal or on / at the surface of EVs , at least for those required for a given EV - associated function . Topology may be particularly important for certain classes of biomolecules . Protease and nuclease digestions , detergent permeabilization , and antibodies to outer epitopes ( should bind ) or inner epitopes ( should not bind ) can be used to probe topology . 14 C . THÉRY AND K . W . WITWER latter is not possible , for instance due to culture con - ditions ( such as periodic collection in continuous bior - eactor - based cultures [ 162 ] ) , number of cells at initiation of culture , expected doubling time , and fre - quency of collection must be indicated . For some bio - logical fluids , like urine , the volume depends strongly on pre - analytical conditions ( especially intake of liquid by the donor ) , thus additional means of normalization should be considered , such as urinary creatinine , as routinely done in the clinic for albumin [ 163 ] . EVs have a particulate structure and contain pro - teins , lipids , nucleic acids , and other biomolecules . Quantification of each of these components can be used as a proxy for quantification of EVs , but none of these values is necessarily perfectly correlated with EV number . Particle number can be measured by light scattering technologies , such as nanoparticle tracking analysis ( NTA ) ; by standard flow cytometry for larger EVs [ 164 – 167 ] or high resolution flow cytometry for smal - ler EVs [ 127 , 168 – 176 ] ; by resistive pulse sensing ( RPS ) for a wide range of sizes , depending on pore size [ 177 ] ; by cryo - EM [ 174 ] ; by a platform combining surface plasmon resonance ( SPR ) with AFM [ 178 ] ; or by other techniques with similar capabilities . Accurate quantitation may be possible only within a certain con - centration and size range that varies by platform ; where possible , this range ( or the minimum and maximum diameter measured ) should be reported along with concentration . The method of volume determination in flow cytometry should be reported and potential swarming / coincidence artefacts controlled for [ 179 ] ; a more detailed guideline article on specifics of flow cytometry analysis of EVs is in preparation by mem - bers of ISEV , ISCT and ISAC . Some devices for particle quantification have the advantage of providing accurate sizing information amongst a complex mixture of par - ticles ( see Table 2 - c : single vesicle analysis ) . This is not the case for dynamic light scattering ( DLS ) , which is accurate only for monodisperse particle populations [ 180 ] . Particle counting by light scatter , RPS , and simi - lar techniques typically results in overestimation of EV counts since the techniques are not specific to EVs and also register co - isolated particles including lipoproteins and protein aggregates . Possibly , ongoing development of fluorescence capabilities of NTA devices may ulti - mately allow EV - specific measurement [ 181 ] , although assay sensitivity and the tendency of labeling antibodies and lipid dyes to form particles pose substantial hur - dles to such applications [ 127 , 182 ] . Additionally , par - ticle counting technologies may be biased towards certain particle size ranges ( especially 50 – 150 nm [ 183 , 184 ] ) because of pore sizes ( RPS ) , size of calibrator used , sensitivity ( for example , smaller parti - cles scatter less light ) , and ability to cope with multi - dispersity ( DLS versus NTA ) [ 185 ] . Finally , proprietary software used for analysis of data from each device may apply unknown selection and other processing of data , resulting in differences in absolute values obtained by different software or different versions of the same software ( see example in [ 183 ] ) . Total protein amount can be measured by various colorimetric assays [ Bradford or micro - bicinchonic acid ( BCA ) ] or fluorimetric assays , or by global protein stain on SDS - PAGE . The EV sample concentration must be within the linear range of the reference curve . However , protein quantification can result in overestimation due to co - isolated protein contaminants ( such as albumin from culture medium or plasma / serum ) , especially when the less specific methods of EV separation are used , or conversely can prove not sensitive enough if highly specific methods yield pure EVs . In addition , results may vary depending on the use or not of detergent to disrupt EVs and expose the entire protein content prior to performing the assay ; nature and concentration of the detergent must be indicated . Quantification of total lipids can be achieved , e . g . by sulfophosphovanilin assay [ 186 ] , by measuring fluorescence of phospholipid dyes that fluoresce only when incorporated into lipid bilayers , such as DiR [ 187 ] , or by total reflection Fourier - transform infrared spectroscopy [ 188 ] . However , the latter requires spe - cialized equipment , and the former two types of assays may be insufficiently sensitive for small amount of EVs . In addition , whether these techniques equally detect all EVs independent of their specific lipid com - position must still be established . Quantification of total RNA can be performed by global RNA assays including profiles obtained by capil - lary electrophoresis instruments ( see recommendations in Table 1 of [ 56 ] ) . Such measurements are difficult to recommend at this time for EV quantification or purity assays , though , since exRNAs associate in abundance with other circulating and potentially co - separating entities : chiefly ribonucleoproteins [ 189 , 190 ] , but also a range of particles including exomeres [ 112 ] and lipo - proteins [ 191 ] . RNA measurements remain , however , an important parameter to report in studies of extra - cellular RNA . Quantification of specific molecules . Other methods of EV quantification , like ELISA [ 192 ] bead - based flow cytometry [ 193 , 194 ] , aptamer - and carbon nanotube - based colorimetric assays [ 195 ] , and SPR on surfaces such as antibody - coated nanorods [ 178 , 196 , 197 ] , can be used to quantify the amount of one or more specific molecules in the EV preparation . These are generally JOURNAL OF EXTRACELLULAR VESICLES 15 proteins ( usually the tetraspanins CD9 , CD63 and / or CD81 , but sometimes tumor - specific proteins or other molecules such as lipids [ 139 ] ) and can be used to estimate the amount of EVs containing this particular component , rather than total EVs . These methods pro - vide additional information to the above methods and are in line with characterization recommended in part 4b ( p . 16 ) . Single and multiple measures and implications for purity . Quantification methods are the most informa - tive for EVs recovered by separation methods with the highest expected specificity ( Table 1a - category 3 ) , and for these preparations , one quantification method may suffice ; in contrast , more than one quantification should be used for EVs recovered from low - specificity methods . Importantly , ratios of the different quantifi - cation methods may provide useful measures of purity . For example , protein : particle ratio [ 198 , 199 ] , protein : lipid ratio [ 186 , 188 , 200 ] and RNA : particle [ 201 ] have been proposed as possible purity metrics , although their applicability across protein , lipid , RNA and par - ticle quantification methods remains to be established . Techniques that measure multiple parameters at once , such as colloidal nanoplasmonic assays or infrared ( IR ) spectroscopy [ 188 , 199 ] may be good optional methods , despite the need for specific sensors or other equipment . Absolute EV sizing and counting methods are currently imperfect and will require further improve - ment , aided by appropriate EV reference standards that are now in development [ 202 ] . Nevertheless , current methods can provide a reasonable indication of particles per volume and particle size distributions that are best interpreted when combined with gen - eral ( Table 2b ) and single - particle ( Table 2c ) characterization . Characterization of EVs by their protein composition Selection of proteins for use as EV markers . Since MISEV2014 , the growing recognition of the existence of many different types of EVs , of different sizes and cellular origins , has led to publication of several studies comparing the protein composition of at least two sub - types of EVs isolated from the same secreting cells . Some studies compared EVs recovered by medium speed centrifugation ( called large oncosomes [ 203 ] , ecto - somes [ 204 ] , microvesicles [ 205 ] , cell debris [ 206 ] , or large [ 207 ] or medium [ 208 ] EVs ) , with those recovered by 100 , 000 x g ultracentrifugation ( called exosomes in the first four studies , small EVs in the last two ) , and several of these applied additional separation in density gradients . Another study used differential filtration to separate large microvesicles retained by 0 . 65 micron filters , and small “ exosomes ” passing through 0 . 1 micron filters [ 209 ] . Others further separated the high speed pellet to identify subpopulations of small EVs bearing different surface markers such as A33 antigen ( GPA33 ) vs EPCAM [ 19 ] , lipid moieties binding Cholera Toxin , Annexin - V or Shiga Toxin [ 139 ] , or tetraspanins CD63 , CD9 , and / or CD81 [ 208 ] . EVs were also separated by floating at different densities within a sucrose gradient ( defined as high density “ HD - exo ” vs low density “ LD - exo ” ) [ 210 ] or eluting at differ - ent time points in asymmetric flow field - flow fractiona - tion ( AF4 ) ( small “ exo - S ” vs large “ exo - L ” ) [ 112 ] . These studies together provide a rich source of potential EV subtype - specific markers . However , since they were per - formed with different separation approaches and with different cellular sources of EVs , it is still not possible to propose specific and universal markers of one or the other type of EVs , let alone of MVB - derived “ exosomes ” as compared with other small EVs . Consequently , MISEV2018 does not propose mole - cular markers that could characterize specifically each EV subtype . Of note , although the ISEV board tried in MISEV2014 to propose general rules applying to all EVs , some suggestions of MISEV2014 were still biased by an “ exosome – oriented ” view of EVs . Specifically , Table 1 of MISEV2014 listed , as primary components to analyze in EVs , 2 categories of proteins present or enriched in EVs / exosomes ( membrane bound and cytosolic proteins ) , plus another global category of proteins « not expected in EVs / exosomes » ( such as mitochondria , Golgi , or nuclear proteins ) , and a last category of « contaminants » . In this updated version , MISEV2018 , reference to exosomes and the proteins expected or not in them ( the previously called “ nega - tive controls ” of “ exosome ” preparations ) have been deleted , reflecting an evolving understanding of the subtypes of EVs and their associations with other enti - ties . Incorporation of any given component of the cytoplasm or other cellular compartment into an EV is determined by 1 ) proximity to the budding mem - brane and size of the EV ( passive loading ) and 2 ) specific association with the membrane and any energy - dependent processes ( active loading ) . There are of course interactions between these two domains . Leaving aside the question of active loading , the larger the EV , the more likely any randomly selected mole - cular or organellar entity in the cell is to be incorpo - rated . Therefore , Golgi , endoplasmic reticulum , mitochondrial , or nuclear components may be excluded from small EVs ( < 200 nm ) that are presum - ably formed distant to these locations , or at least 16 C . THÉRY AND K . W . WITWER strongly depleted relative to the cell ( although we can - not exclude that particular components of such com - partments may end up in small EVs , especially in pathologic conditions that could affect incorporation ) . However , such proteins may be present in larger EVs , and even more so in a very large EV , ultimately the large oncosome [ 211 ] , which may be as large as some cells and contain by definition any and all components except for a whole , functional nucleus . A single nega - tive control for such large EVs may thus be elusive . Table 3 highlights three categories of markers that must be analysed in all bulk EV preparations to demonstrate the presence of EVs ( Categories 1 and 2 ) and assess their purity from common contaminants ( Category 3 ) , but no universal “ negative controls ” rele - vant to a particular subtype of EVs are suggested . The three main categories are : Category 1 : Transmembrane or GPI - anchored proteins localized at the external membrane of pro - karyotic cells , and plasma membrane and / or endosomes of eukaryotic cells represent hallmarks of any type of EVs : their pre - sence demonstrates the lipid - bilayer struc - ture specific of EVs , whether they bud directly off the plasma membrane or after transit through the endosomal pathway ; Category 2 : Presence of cytosolic proteins ( eukaryotic cells and Gram - positive bacteria ) or peri - plasmic proteins ( Gram - negative bac - teria ) demonstrates that the analysed preparation displays the structure of lipid bilayers enclosing intracellular mate - rial , as expected for any EV . Proteins pre - sumably actively incorporated into EVs are those with ability to bind to mem - branes or to cytosolic sequences of trans - membrane proteins . Others , like cytosolic enzymes or cytoskeletal proteins are more promiscuous EV components ; Category 3 : Some proteins are major constituents of non - EV structures often co - isolated with EVs . Evaluation of their presence helps to assess the degree of purity of the EV pre - paration . In biofluids like blood plasma , EVs have been reported to co - isolate with other particles , including lipoproteins [ 212 ] and a variety of non - integral pro - teins , such as albumin or soluble acetyl - cholinesterase . We therefore propose apolipoproteins A1 / 2 and B ( APOA1 / 2 , APOB ) , and albumin ( ALB ) as the best negative markers to date [ 213 ] for plasma / serum EVs , and EVs from cells cultured in the presence of bovine serum , or liver cells that secrete lipopro - teins , although it cannot be excluded that a fraction of such markers may be speci - fically associated with some EVs [ 214 ] . As another example , in urine , Tamm - Horsfall protein ( uromodulin / UMOD ) forms aggregates that co - precipitate with EVs unless the fluid is chemically treated [ 215 ] . Overall , however , since we cannot propose a threshold of abundance of these proteins in EV preparations below which acceptable purity is reached , we stress that it may be more appropriate to assay and report depletion than to expect a binary presence / absence of proposed negative markers . Category 4 : An additional category 4 ) of proteins should be evaluated if authors want to claim speci - ficity of their study to the small EV subtype - ( s ) : Proteins localized in / on intracellular compartments of eukaryotic secreting cells other than the plasma membrane and endo - somes ( i . e . components of the nucleus , mitochondria , endoplasmic reticulum , Golgi apparatus , autophagosomes , peroxi - somes ) are found in some types of EVs , but a priori not enriched in the smaller EVs ( approximately < 200 nm diameter ) of plasma membrane or endosomal origin . Category 5 : Finally , category 5 ) covers secreted or lumi - nal proteins that can associate with EVs by binding to specific ( e . g . growth factor receptors ) or to promiscuous ( e . g . proteo - glycan , lipid ) receptors on the EV surface : their identification in EV preparations should be accompanied by exploration of the cognate EV - associated receptor ( s ) . Methods to assess presence of proteins in EV prepara - tions . Several methods can be used to quantify pro - teins in or on EVs . Western blotting is the most commonly used , and it should be performed by loading side - by - side EV samples and source material lysates either in specified protein amount or in cell - equivalent amounts to determine if the analyzed pro - teins are enriched in EVs as compared with their pro - ducing cells . This comparison , however , can be easily performed only for analysis of EVs from cell culture conditioned medium ; it is more difficult for biofluids ( in which EVs may originate from cells in the fluid , but also from cells delimiting the fluid canals , and thus are JOURNAL OF EXTRACELLULAR VESICLES 17 T a b l e 3 . P r o t e i n c o n t e n t - b a s e d E V c h a r a c t e r i z a t i o n . A t l e a s t o n e p r o t e i n o f c a t e g o r i e s 1 a o r 1 b , 2 a ( o p t i o n a ll y 2 b ) , 3 a o r 3 b m u s t b e a n a l y s e d t o d e m o n s t r a t e t h e E V n a t u r e a n d t h e d e g r ee o f p u r i t y o f a n E V p r e p a r a t i o n . A n a l y s i s o f p r o t e i n s o f c a t e g o r y 4 i s r e q u i r e d w h e n c l a i m i n g s p e c i f i c a n a l y s i s o f s m a ll E V s , a n d o f c a t e g o r y 5 t o d o c u m e n t f u n c t i o n a l a c t i v i t i e s . E x a m p l e s o f p r o t e i n s c o mm o n l y f o u n d i n m a mm a l i a n c e ll - d e r i v e d E V s a r e p r o v i d e d , b u t o t h e r p r o t e i n s t h a t f a ll i n t o t h e p r o v i d e d c a t e g o r i e s c a n b e u s e d , p a r t i c u l a r l y f o r a n a l y s i s o f E V s f r o m p r o k a r y o t i c ( b a c t e r i a ) o r n o n - m a mm a l i a n e u k a r y o t i c s o u r c e s ( i n c l u d i n g p a r a s i t e s a n d p l a n t s ) . XX = h u m a n g e n e n a m e s . XX * o r XX * * u s e d f o r f a m i l i e s o f m u l t i p l e p r o t e i n s , f o r e x a m p l e f o r i n t e g r i n s : I T G A * i n d i c a t e s a n y i n t e g r i n a l p h a c h a i n . C a t e g o r y 1 - T r a n s m e m b r a n e o r G P I - a n c h o r e d p r o t e i n s a s s o c i a t e d t o p l a s m a m e m b r a n e a n d / o r e n d o s o m e s 2 - C y t o s o l i c p r o t e i n s r e c o v e r e d i n E V s 3 - M a j o r c o m p o n e n t s o f n o n - E V c o - i s o l a t e d s t r u c t u r e s 4 - T r a n s m e m b r a n e , l i p i d - b o u n d a n d s o l u b l e p r o t e i n s a ss o c i a t e d t o o t h e r i n t r a c e ll u l a r c o m p a r t m e n t s t h a n P M / e n d o s o m e s 5 - S e c r e t e d p r o t e i n s r e c o v e r e d w i t h E V s U s e f o r A ll E V s A ll E V s A ll E V s a s p u r i t y c o n t r o l S u b t y p e s o f E V s ( e . g . l a r g e o n c o s o m e s , l a r g e E V s ) a n d / o r p a t h o l o g i c / a t y p i c a l s t a t e F u n c t i o n a l c o m p o n e n t o f E V s : n ee d t o d e t e r m i n e t h e m o d e o f a ss o c i a t i o n w i t h E V s 1 a : n o n - t i ss u e s p e c i f i c . T e t r a s p a n i n s ( C D 63 , C D 81 , C D 82 ) ; o t h e r m u l t i - p a ss m e m b r a n e p r o t e i n s ( C D 47 ; h e t e r o t r i m e r i c G p r o t e i n s G N A * ) M H C c l a s s I ( H L A - A / B / C , H 2 - K / D / Q ) , I n t e g r i n s ( I T G A * / I T G B * ) , t r a n s f e rr i n r e c e p t o r ( T F R 2 ) ; L A M P 1 / 2 ; h e p a r a n s u l f a t e p r o t e o g l y c a n s i n c l u d i n g s y n d e c a n s ( S D C * ) ; E MM P R I N ( B S G ) ; A D A M 1 0 ; G P I - a n c h o r e d 5 ʹ n u c l e o t i d a s e C D 73 ( N T 5 E ) , c o m p l e m e n t - b i n d i n g p r o t e i n s C D 55 a n d C D 59 ; s o n i c h e d g e h o g ( S HH ) 2 a : w i t h l i p i d o r m e m b r a n e p r o t e i n - b i n d i n g a b i l i t y . E S C R T - I / II / III ( T S G 101 , C H M P * ) a n d a cc e ss o r y p r o t e i n s : A L I X ( P D C D 6 I P ) , V P S 4 A / B ; A RR D C 1 ; F l o t i ll i n s - 1 a n d 2 ( F L O T 1 / 2 ) ; c a v e o l i n s ( C A V * ) ; E H D * ; R H O A ; a nn e x i n s ( A N X A * ) ; H e a t s h o c k p r o t e i n s H S C 70 ( H S P A 8 ) , a n d H S P 84 ( H S P 90 A B 1 ) n o t e t h a t b o t h a r e a b u n d a n t a l s o i n e x o m e r e s ; A R F 6 ; s y n t e n i n ( S D C B P ) ; m i c r o t u b u l e - a ss o c i a t e d T a u ( M A P T , n e u r o n s ) 3 a : l i p o p r o t e i n s ( p r o d u c e d b y l i v e r , a b u n d a n t i n p l a s m a , s e r u m ) . A p o l i p o p r o t e i n s A 1 / 2 a n d B A P O A 1 / 2 , A P O B ; A P O B 100 ; a l b u m i n ( A L B ) 4 a : n u c l e u s . H i s t o n e s ( H I S T 1 H * * ) ; L a m i n A / C ( L M N A ) 5 a : C y t o k i n e s a n d g r o w t h f a c t o r s . e . g . T G F B 1 / 2 ; I F N G , V E G F A , F G F 1 / 2 , P D G F * , E G F , i n t e r l e u k i n s ( I L * ) … 1 b : c e ll / t i s s u e s p e c i f i c . S o m e T S P A N s : T S P A N 8 ( e p i t h e l i a l c e ll ) , C D 37 a n d C D 53 ( l e u k o c y t e s ) , C D 9 ( a b s e n t f r o m N K , B a n d s o m e M S C ) ; P E C A M 1 ( e n d o t h e l i a l c e ll s ) ; E RBB 2 ( b r e a s t c a n c e r ) ; E P C A M ( e p i t h e l i a l ) ; C D 90 ( T H Y 1 ) ( M S C s ) ; C D 45 ( P T P R C ) ( i mm u n e c e ll s ) , C D 41 ( I T G A 2 B ) o r C D 42 a ( G P 9 ) ( p l a t e l e t s ) ; G l y c o p h o r i n A ( G Y P A ) ( R B C ) ; C D 14 ( m o n o c y t e s ) , M H C c l a ss II ( H L A - D R / D P / D Q , H 2 - A * ) ; C D 3 * ( T c e ll s ) ; A c e t y l c h o l i n e s t e r a s e / A C h E - S ( n e u r o n s ) , A C h E - E ( e r y t h r o c y t e s ) ; a m y l o i d b e t a A 4 / A PP ( n e u r o n s ) ; m u l t i d r u g r e s i s t a n c e - a ss o c i a t e d p r o t e i n ( A B CC 1 ) 2 b : p r o m i s c u o u s i n c o r p o r a t i o n i n E V s ( a n d p o ss i b l y e x o m e r e s ) . H e a t s h o c k p r o t e i n H S P 70 ( H S P A 1 A ) , c y t o s k e l e t o n : a c t i n ( A C T * ) , t u b u l i n ( T U B * ) ; e n z y m e s ( G A P D H ) 3 b : p r o t e i n a n d p r o t e i n / n u c l e i c a c i d a gg r e g a t e s . T a mm - H o r s f a ll p r o t e i n ( U r o m o d u l i n / U M O D ) ( u r i n e ) ; r i b o s o m a l p r o t e i n s 4 b : m i t o c h o n d r i a I MM T , c y t o c h r o m e C ( C Y C 1 ) ; T O MM 20 5 b : a d h e s i o n a n d e x t r a c e ll u l a r m a t r i x p r o t e i n s . F i b r o n e c t i n ( F N 1 ) , C o ll a g e n ( C O L * * ) , M F G E 8 ; g a l e c t i n 3 - b i n d i n g p r o t e i n ( L G A L S 3 B P ) , C D 5 L ; f e t u i n - A ( A H S G ) 4 c : s e c r e t o r y p a t h w a y ( e n d o p l a s m i c r e t i c u l u m , G o l g i a pp a r a t u s ) c a l n e x i n ( C A N X ) ; G r p 94 ( H S P 90 B 1 ) ; B I P ( H S P A 5 ) , G M 130 ( G O L G A 2 ) 4 d : o t h e r s ( a u t o p h a g o s o m e s , c y t o s k e l e t o n … ) . A T G 9 A , A c t i n i n 1 / 4 ( A C T N 1 / 4 ) , c y t o k e r a t i n 18 ( K R T 18 ) 18 C . THÉRY AND K . W . WITWER difficult to attribute in bulk to any given cell type ) . Flow cytometry of EVs decorating beads or of bulk EV populations ( i . e . not designed to analyse single EVs ) can be used , but with care to use appropriate negative controls ( antibodies alone , isotype controls , etc ) [ 48 , 220 ] . Numerous multiplexing approaches have been developed to analyse simultaneously the presence of a pre - designated set of surface protein markers on EVs . For instance , one platform uses flow cytometry after capture on an array of 37 beads , each bearing a specific antibody [ 100 , 194 ] . Other approaches use fluorescence scanning [ 221 ] or surface plasmon resonance [ 222 , 223 ] to quantify EV binding to a surface coated with antibodies to different antigens . These methods are population - level , not single - EV techniques , since the final result is an arbitrary unit of signal for a given protein marker in the global EV population . Finally , mass spectrometry has become increasingly economical and accessible for many laboratories , allowing fingerprint - type assessment of many proteins at once . For an exhaustive review on the currently available methods of EV analysis , see [ 224 ] . Undoubtedly , new techniques and devices will become available , including commercially , in the near term . Besides the potential of such devices for diagnos - tic purposes based on amount and type of secreted EVs , one of the challenges associated with the use of such devices is whether they might allow sufficient quantities of specific EVs to be purified so that cargo ( RNAs , proteins ) content can be analysed on a profiling level . Non - protein components as markers of EVs . Although proteins are emphasized in the literature and here , phospholipids present in lipid bilayers are also poten - tial positive controls for the presence of EVs [ 225 , 226 ] , albeit non - specific as other particles ( lipo - proteins ) may also contain these . As an example , albeit one that may not be exposed on all EVs , outer leaflet phosphatidylserine ( PS ) can be evidenced indirectly by binding of fluorescently - labeled PS - binding proteins , such as Annexin V [ 139 , 167 ] or the C1C2 domain of lactadherin / MFGE8 [ 186 , 227 ] . Glycosphingolipids are similarly evidenced by binding of GM1 ganglioside [ 139 , 228 ] . Other lipids including cholesterol , sphingomyelin , ceramide , and phosphati - dyl - choline / ethanolamine / inositol can be detected by a variety of methods [ 225 ] including Raman spectro - scopy , which was recently used to analyze lipids in dried EVs [ 229 ] . However , in which ratio cholesterol , sphingomyelin , ceramide , and phosphatidyl - choline / ethanolamine / inositol are in EVs , and how this dif - fers from ratios found in lipoproteins is not yet estab - lished : additional comparative lipidomic studies of separated EVs and liproprotein subtypes may be informative . Alternatively , dyes that are activated by intra - cellular components can be used to label EVs . Calcein and CFSE are examples of cell permeant , non - fluorescent pro - dyes that are cleaved by intra - cytoplasmic enzymes , resulting in an impermeant fluorescent molecule ; labelling therefore theoreti - cally differentiates intact EVs from linearized mem - brane fragments , provided that the required enzymes are present in EVs [ 230 , 231 ] . Other tools , like a recently reported protein - and lipid - binding dye , di - 8 - ANEPPS [ 231 ] , may be worth evaluating for sensitivity and specificity . Additionally , appropriate negative controls are necessary in all studies , such as dye only and dye plus EV - depleted matrix . Text Box 1 . Example of a change from MISEV2014 as a paradigm for considering negative markers . Argonaute proteins , chiefly AGO2 , the most abundant family member in mammals , havebeenpreviouslyproposedasnegativemarkersofEVs . In bloodplasmaandperhaps otherfluids , most extracellularAGOis indeed found outside of EVs [ 189 , 190 , 216 ] . However , the canonical view of biogenesis of microRNAs ( miRNAs ) and their subsequent protection from degradation depends on AGO proteins . According to this reasoning , if a mature miRNA is detected , whether in cells , in EVs , or elsewhere , it is most likely protected by AGO ( although other associations have been reported [ 56 ] ) . Limits of detection of proteins versus amplified nucleic acids may have contributed to the interpretation that miRNAs are present in EVs without AGO protein . It is in any case now established that AGO can be found in mammalian [ 217 , 218 ] and non - mammalian [ 219 ] EVs , not just outside EVs . Text Box 2 . Example of a possible change from MISEV2018 in the future as markers of non - EV co - isolated components . The Lyden group recently reported that lipidic structures called “ exomeres ” contain lipids and a limited set of membrane - bound proteins , but do not feature a lipid bilayer and thus do not qualify as EVs . Exomeres were found to co - isolate with small EVs recovered from many cultured cell lines [ 112 ] but could be separated from EVs by AF4 ( which unfortunately is not implementable in some laboratories ) . It may be necessary to evaluate this potential contaminant in all EV preparations . Proteomic analyses of exomeres identified various proteins in Table 3 - category 2 , above : heat shock proteins ( HSPA8 , HSPA1A , HSP90AB1 ) , actin ( ACT * ) , tubulin ( TUB * ) , and GAPDH . Such proteins thus probably do not qualify as EV - specific components . In addition , a few proteins were identified exclusively in exomeres : hemoglobin ( HBA1 / A2 ) , IDH1 , MAT1A , transmembrane FAT4 ( protocadherin , transmembrane plasma membrane ) , and EXT1 / 2 ( exostosin , transmembrane , Golgi ) . Although this exhaustive study was performed with several cell lines , suggesting that the listed proteins are good candidates as specific markers of exomeres co - isolated with EVs , these results still have to be confirmed by other groups to reach validation and inclusion in the next update of the MISEV guidelines . JOURNAL OF EXTRACELLULAR VESICLES 19 Concerning nucleic acids , both DNA and RNA have been detected in EVs . RNA in EV preparations can be detected by dyes [ 232 ] , although some dyes may also detect non - EV - associated RNA . It is possi - ble that some nucleic acid species could serve as negative or positive markers of some EVs . For exam - ple , strictly nuclear RNAs might be identified as negative markers in the future , while RNA associated only with cytoplasmic complexes ( e . g . ribosomal RNAs or mitochondrial DNA ) [ 233 , 234 ] may be more likely to be present in certain EVs . However , several nuclear RNAs have been found in EVs , and a variety of data have been presented on specific versus non - specific incorporation of RNAs into EVs or subtypes of EVs [ 56 , 217 , 235 – 241 ] . More research is thus needed before specific recommendations can be made for using nucleic acids as specific markers of EVs or EV subtypes . Single vesicle analysis Quantification and global protein composition apply to bulk EV preparations . However , it is important to provide some information on the individual EVs pre - sent in such bulk preparations . Two different approaches provide different types of information : i . Techniques allowing visualization of single EVs at high resolution may provide information on both the structure and the composition of EVs , when combined with antibody - mediated detec - tion of EV components . However , they may be difficult to exploit in a quantitative manner , with analysis of sufficient number of EVs to reach statistical power . EVs with diameter larger than the diffraction limit of light ( ~ 200 nm ) can potentially be visua - lized as single EVs by regular fluorescence micro - scopy and regular flow cytometry . For EVs smaller than this limit , confocal microscopy can detect fluorescent dots , but these dots can correspond either to very bright vesicles with diameter smaller than 200 nm [ 242 ] , or to clusters of small dim vesicles , without the possibility to discriminate between the two [ 243 ] . All EVs can be analyzed by : electron microscopy or by other imaging techniques : SEM [ 244 ] , TEM by contrasting and embedding in a mixture of uranyl compounds and methylcellulose to maintain the bilayered morphology , cryo - EM [ 174 , 245 , 246 ] ; scan - ning - probe microscopy ( SPM ) including atomic force microscopy ( AFM ) [ 247 ] ; and super - resolution microscopy [ 248 , 249 ] . Note that these various techni - ques are not necessarily interchangeable or capable of providing images of comparable quality . For example , cryo - EM clearly shows the lipid - bilayer , preserves EV size better than the dehydrating conditions used to fix samples for TEM , and may be more quantitative , as all particles in a given volume can be imaged , not just those that adhere to a surface ( the grid ) . ii . Single particle analysis techniques that do not pro - vide high - resolution images but calculate biophysical parameters of single EVs can be used to quantify a large number of EVs with a higher statistical power than many single - EV techniques . For instance , size can be inferred from particle displacement pattern by nanoparticle tracking analysis [ 184 , 185 , 250 ] ; light scattering and / or fluorescence detection in high resolution flow cytometry [ 251 – 255 ] ; multi - angle light scattering combined with asymmetric flow field - flow fractionation ( AF4 - MALS ) [ 256 ] ; displa - cement of an electrical field in tunable resistive pulse sensing - based devices ; or fluorescence correlation spectroscopy ( FCS ) [ 257 – 259 ] . Chemical composi - tion can be evaluated by Raman tweezers micro - scopy [ 251 – 253 ] . Other recently developed technologies aim to combine the advantages of imaging with analysis of large numbers of events . They are , however , less commonly used in the EV field and require further validation in multiple laboratories . For instance , an imaging flow cytometer that captures images of single cells going through a fluidic chan - nel can be used , with a carefully designed set of controls and settings , to image EVs of all sizes after labeling with fluorescent lipids , proteins , or antibo - dies [ 260 , 261 ] . Another recently designed device involves capture of biotinylated EVs on a streptavidin surface , followed by successive rounds of staining with fluorescent antibodies , ima - ging , and quenching followed by additional rounds of labeling [ 262 ] . Another example uses single - particle interferometric reflectance imaging sensing of EVs captured on antibody - coated chips [ 263 , 264 ] , which can be accompanied by fluores - cence measurements . Whatever technique is used , all experimental details must be reported . These include the brand and version of the instrument and the software , the settings used for acquisition ( diluent buffer , camera , flow rate , threshold … ) and , for analysis , the precise process for EM or fluorescence microscopy and how the imaged areas were selected , as well as controls and calibration 20 C . THÉRY AND K . W . WITWER information where relevant . For flow cytometry , an ISTH working group has recently issued recommenda - tions [ 265 ] . Given the wide range of techniques and platforms available , many of which remain under development for EV applications , MISEV2018 cannot yet give precise protocol recommendations . New recommendation : determine the topology of EV - associated components Importantly , the luminal versus surface topology of var - ious EV - associated components , including nucleic acids , proteins , glycans , etc , is not entirely strictly determined . Theoretically , components localized in the cytosol of EV - secreting cells should be inside EVs , and hence protected from mild degradation by proteases or nucleases . While this protection is usually observed , some studies have unexpectedly found proteins [ 266 ] , RNAs [ 267 ] , and DNA [ 41 ] on the EV surface and sensitive to digestion . It is not yet clear whether this unexpected topology is due to debris from dead or dying cells , or is instead the outcome of as - yet unknown mechanisms of transport of intracellular compartments across membranes that could occur in some physio - or pathological conditions . Certainly , even a small degree of contamination with intracellular material ( with the reverse topology to EVs ) would complicate interpretation . Topology may also be important for function . A luminal active component would require mem - brane fusion or two membrane transport events to achieve function in a recipient cell , whereas if it is exposed at the surface of the EV , it may affect target cells without EV - cell fusion . As a result , we advise that the actual topology of putative active compo - nents be determined by performing mild digestions , permeabilizations , or antibody studies . To give an example , one might adopt and adapt methods devel - oped to assess protein insertion within the endoplas - mic reticulum [ 268 ] . Various protocols have also already been published in the EV community [ 56 , 217 , 242 , 266 , 269 , 270 ] . Example of a biochemical approach for assessing surface exposure of EV components ( see for instance use in [ 266 , 270 ] ) : for a given preparation of EVs , prepare four samples : ( 1 ) aliquot 1 is untreated ; ( 2 ) aliquot 2 is treated with a degrading enzyme alone , which should degrade only surface - exposed components ( e . g . proteins ) ; ( 3 ) aliquot 3 is treated with enzyme and detergent ( such as Triton X - 100 ) , which will ensure degra - dation of both surface and internal components ( to verify that enzymatic treatment worked ) . Note that detergents may also enhance enzy - matic digestion of certain molecules indepen - dently of permeabilization of membranes ; an alternative to detergent is saponin , which per - meabilizes membranes . ) ( 4 ) aliquot 4 is treated with detergent alone , to make sure that detergent does not affect the downstream analysis . For each sample , the cargo of interest is then ana - lyzed ( after careful neutralization of the enzyme ) by an appropriate method ( SDS - PAGE , RT - PCR , PCR … ) . Extinction of the signal within the enzyme - treated , detergent - untreated aliquot indicates surface exposure of the cargo . For RNA and DNA analysis , RNAse or DNAse must be used together with proteinase to allow access of nucleases to protein - shielded nucleic acids . Alternatively , the topology may be determined using flow cytometry and fluorescence microscopy with anti - bodies directed towards either external or cytoplasmic epitopes on EV membranes . Single vesicle characteriza - tion by EM or AFM coupled with immunolabeling could not only provide validation of surface - accessible targets or internal targets ( with permeabilization ) , but also aid in differentiating differences in topology among EVs of different sizes [ 247 ] . Consensus : 97 % of MISEV2018 Survey respondents endorsed the structure of the characterization section . The original version of Table 3 included more proposed markers of EV subtypes . However , although the responses ranged from 69 % to 93 % agreement on dis - creet categories of markers , some concern was commu - nicated about the universality of subtype - specific markers based on the existing evidence . As a result , the Table was thoroughly revised to focus on classes of markers that can be applied to all EVs , not just those from certain cell types or organisms . These revisions further establish the applicability of MISEV2018 to all EVs and EV sources . An original section on negative controls received 79 % agreement and 56 comments ; as a result , the approach to negative controls was substantially amended . 95 % of respondents agreed that the current focus on protein markers is justified ; however , lipids are now included . Although 13 respondents suggested that RNA markers could be used as generic or subtype EV mar - kers , and several mentioned post - translational modifi - cations , these comments were supported with limited or ( usually ) no references . Based on the limited endorse - ment of RNA markers and ongoing uncertainty about enrichment of RNAs in EVs , no specific recommenda - tions are made by MISEV2018 . Instead , further research is expected and encouraged . 92 % agreed with the topology recommendation ( 4c ) . JOURNAL OF EXTRACELLULAR VESICLES 21 Functional studies : how MISEV2014 evolves in 2018 Table 4 summarizes the previous and updated recom - mendations on functional analysis of EVs . More detailed justification for these recommendations and proposed protocols follows the Table . The goals of these recom - mendations are to avoid over - interpretations or classical artefacts when analyzing functions of EVs . It is important to consider several issues when attributing a functional activity to EVs in general , or an EV subtype in particular . We describe here the controls and processes that should be included in all functional studies , unless limited amounts make it impossible to perform them . For clinical applications , for instance , after a first step of pre - clinical validation following these recommendations , systematic analysis may not be possible ( see previous Position Paper on clinical applications ) [ 95 ] . Determine the specific versus common functions of different types of EVs An important point to keep in mind is that , when analyzing exclusively the function of a single type of EV ( for instance either small EVs or large EVs that have been called ectosomes , microvesicles or micropar - ticles in different studies ) , one may miss the most active EV subtype for the particular function studied . Even if a function is found in the concentrated small EV preparation , it could also be present , and even possibly more concentrated , in other EV subtypes that had been eliminated during the small EV isolation process : keeping large EVs ( e . g . “ microvesicles ” ) and comparing their activity to that of small EVs should be a first step in all functional studies . In addition , when a function found in EVs may be due to soluble mole - cules that may or may not associate specifically with EVs , one must consider the possibility that the EV - associated function is only a minor fraction of the non - EV - bound soluble protein . Comparing quantitatively the effects of EV fraction ( s ) , EV - depleted fraction ( s ) , and also the unfractionated initial fluid , will identify the relative contributions of each to total activity . Ideally , all functional studies of EVs recovered from any source ( biofluid , conditioned medium … ) could start by a crude separation of broad categories of EVs ( e . g . large versus small EVs versus EV - depleted frac - tion , separated by successive centrifugation , filtration , or chromatography ) . Importantly , to ascribe function to different categories of EVs , each fraction should be retained for side - by - side activity analysis . However , authors who wish to analyse the function of only one subtype of EVs can justify this choice by presenting Table 4 . EV - associated and EV - excluded biological activities . Major recommendations of MISEV2014 . Validity and / or Update in 2018 a ) Dose – response studies Still valid In addition : quantitative comparison of the activity of conditioned medium or biofluid 1 ) before , 2 ) after elimination of EVs , and 3 ) the EVs themselves , keeping in mind that the EV fraction may include co - isolated / contaminating materials . Additional suggested control : quantitative comparison of the activity of the targeted versus the “ discarded ” EV subtypes ( see part 1 below ) b ) Negative or background controls . For conditioned medium , negative control = complete medium that has not been conditioned by cells , but still processed in the same way as conditioned medium Still valid . For biofluids , negative controls of disease - associated functions = fluids from healthy , untreated or otherwise matched donors c ) Controls to assess influence of soluble or non - EV macromolecular components c - i . ) Density gradients or other rigorous separation method to show activity is intrinsic to EVs , not just associated or c - ii . ) EV depletion to remove activity or c - iii . ) EV / cell labelling ( e . g . fluorescent labelling , with careful interpretation ) Still valid . Increasingly , it is possible to separate EVs from non - EV components by multiple methods , e . g . density gradients and size exclusion chromatography . It is recommended that functional assays be performed after rigorous separations , comparing EV and non - EV fractions to identify what proportion of activity is associated with each fraction ( in case it is not EVs ) . If the activity is primarily associated with EVs , depleting the EVs should also deplete the activity . The refined separation must be performed at least for a set of biological replicates , but not necessarily systematically afterwards . Text Box 3 . As an aside , although we do not go into great detail on this point , many functional studies presume or investigate EV uptake . Time - courses and environmental determinants of EV uptake have been studied for some time [ 272 - 274 ] , but challenges exist [ 275 ] . Detection within the cell of signal from an EV - labeling dye or other entity does not necessarily mean that the EV or its cargo has been internalized . Some labeling substances are very long - lived , can exist separate from the presumably labeled entity , and can form EV - mimicking particles that are difficult to separate from EVs . Another potential artifact is that labeling EVs with lipophilic or surface - coating fluorophores may modify physicochemical characteristics of EVs , thus altering detection mode and / or uptake by target cells . Although we cannot yet make firm recommendations , we urge researchers to be aware of these issues and to consider that each specific EV - donor / EV - recipient pair may behave in a different manner . 22 C . THÉRY AND K . W . WITWER practical or theoretical reasons for selecting specifically this subtype for the particular experimental purpose , and further proceed with functional analyses . Before performing functional assays , it is advisable to determine whether EVs are detected in the different fractions , in terms of total proteins , or number of particles , or ratio of total nucleic acids ( RNA , DNA ) , or total lipids to particles ( i . e . substance x - to - particle ratios ) : if none of these EV - associated components are detectable , the “ empty ” fractions may be discarded for further functional tests , once a preliminary experiment has shown lack of activity . However , any change of conditions in generation of the biofluid from which EVs are isolated ( i . e . different culture conditions or treatment for the cells , different types of patients for biofluids ) should be followed by re - analysis of all EV categories . Example of an approach to compare activity of broad subcategories of EVs after separation by dif - ferential centrifugation ( see example of use in [ 220 ] ) From a given volume of conditioned medium : several low speed centrifugations , transferring supernatant into a new tube each time . The pellet contains cells . supernatant : 1x centrifugation at medium speed , to collect large EVs ( if mostly live cells ) , large apoptotic bodies , etc . , with the pellet largely devoid of cells supernatant : 1x centrifugation at intermediate speed to collect a pellet enriched in medium size EVs and / or aggregates of small EVs ( to be checked by EM ) supernatant : 1x centrifugation at high speed to col - lect a pellet enriched in small EVs . Each pellet is resuspended once in buffer / medium and re - centrifuged at the same speed ( = washed ) before resuspension in a given volume of buffer / medium . How to normalize amount of EVs used for comparative functional studies The most appropriate normalization strategy to com - pare quantitatively the functions of different EVs will depend on the scientific question . One can choose to normalize by either characteristics of the isolated EVs , or by the source material , or by co - isolated standards . Characteristics of isolated EVs would include particle counts , total amount of a biomolecule type in the EV sample ( e . g . proteins , nucleic acids , or lipids ) , and con - tent or activity of specific EV - associated molecules . Source characteristics include the amount of matrix from which the EVs were obtained ( initial volume of biofluid , initial mass of tissue , initial number of secreting cells , time of conditioning per cell , etc ) . Co - isolated standards would be traceable materials added into the matrix prior to separation [ 202 ] . Multiple normalization strategies can be pursued [ 120 ] , and , as emphasized elsewhere , dose - response studies are recommended regardless of normalization method . Unfortunately , there is no clear recommendation that can be made at this point on which normalization strategy is best . Instead , the choice of normalization must be reported and justified , and relevant details of alternative strategies should be provided . For example , when studying EVs obtained from some biofluids , e . g . blood derivatives , normalization by volume may be appropriate . For other fluids , such as lavage fluids and urine , initial volume is not easily compared between donors , so another strategy might be more appropriate . As another example , for in vitro studies , normalizing by levels of an EV component ( proteins , lipids , RNA ) , or by particle number may be appropriate , but the rationale should be provided , and information on the number of secreting cells should also be recorded and reported . The ISEV survey comments on this section evidenced broad disagreement about normalization strategy , parti - cularly on the relative merits of protein , nucleic acid , and lipid quantitation . Additional studies of normal - ization strategy should thus be encouraged . Demonstrate that the activity is observed in the absence of direct cell - cell contact Theoretically , an EV - associated function , like a soluble cytokine - dependent function , should be observed between two cells that are not in direct contact with each other . Therefore , it should be obtained when the EV - donor and an EV - recipient cell are cultured in vitro at a distance , through transwell co - culture systems or more sophisticated microfluidics - based culture devices , or by incubating the recipient cells with medium con - ditioned by the donor cells . However , the physiological relevance of optimal conditions of these co - cultures , in terms of respective numbers of EV - donor and – recipient cells , cannot be strictly determined . If such assays yield positive results , they prove that transfer of a signal occurs in a cell contact - independent manner , in which case the next necessary step ( next section p24 ) , is to distinguish EVs from soluble components . Lack of positive results at this step would suggest that cell - cell - contact is neces - sary for the exchange of signal , but it could still occur by exchange of membrane – enclosed signals by transfer of plasma membrane - derived vesicles ( like trogocyto - sis ) , or localized release of multivesicular body - derived vesicles at the cell - cell - contact ( e . g . an immune synapse ) . Thus , a negative result argues against signal - ing at a distance but does not conclusively disprove local involvement of EVs . JOURNAL OF EXTRACELLULAR VESICLES 23 Demonstrate that the activity is predominantly associated with EVs rather than with soluble mediators Typically , an EV - associated activity is explored by 1 ) separation and concentration of EVs from a biofluid or cell culture media , 2 ) application of EVs to a recipient cell or organism , and 3 ) observation of a readout phe - notype . However , to convincingly argue that a detected readout / function is EV - borne , it must be determined that the activity is specifically enriched in EVs ( possibly with non - EV components ) , and not instead due to low amounts of a highly active soluble molecule remaining non - specifically in the EV preparation . This point is particularly important when the proposed or suspected active molecule on EVs is a cytokine / growth factor / metabolite usually described as secreted in a soluble form . For this step , one must compare quantitatively the activity present in / on the EVs versus in the remain - ing EV - depleted biofluid , using the same amounts of materials in terms of initial volume of biofluid . When evaluating the relative importance of EVs and soluble mediators , it may be worth remembering that EVs and soluble mediators may have combinatorial ( e . g . syner - gistic ) effects on cells [ 275 , 276 ] . Example of an approach to determine the respec - tive contribution of EV - bound and soluble non - EV - associated factors ( see example of use in [ 200 ] ) : from a given volume of biofluid from which cells have been completely eliminated split supernatant into 2 equal parts ; keep one at 4°C while processing the other with the preferred protocol allowing extensive concentration of EVs , with separation from non - EV components , but without a need to separate EV subtypes ( see Table 1 ) . Make sure to recover the biofluid from which EVs have been separated . Compare activity of the total biofluid , the EV - containing pellet and the EV - depleted biofluid , using material coming from the same initial volume of biofluid . If the unprocessed supernatant must be concen - trated to display activity , the supernatant after centri - fugation must be concentrated in the same way , and the pellet can be resuspended in the same volume of concentrated fresh medium as concentrated superna - tant , before performing the functional assay . Demonstrate the specific association of the activity with EVs rather than with co - isolated components Especially when dealing with concentrated prepara - tions enriched in small EVs , one must keep in mind that such preparations potentially contain non - EV components ( ribonucleoprotein aggregates , lipopro - teins , exomeres , etc . ) . The proportion of such co - isolated components differs tremendously with the type of protocol used to separate EVs , with some ( like polymer - based concentration ) displaying particularly abundant contaminants , and also remnants of the pre - cipitating agent that can affect cell function [ 277 , 278 ] . In the case of cells infected experimentally or uninten - tionally ( e . g . mycoplasma ) with microbes , functional microbial factors may also be co - isolated with EVs . Therefore , the functional activity of an EV preparation may be borne by EVs , or by the additional compo - nents , or by a combination of both . One must deter - mine which of these three possibilities is the case . If small amounts of working materials do not make it possible to perform these additional investigations , the authors can explain this situation and interpret their data as activity present in EV - enriched preparations , rather than EV - specific activity . Examples of protocols to demonstrate specific association of the activity with EVs or a given EV subtype : From a concentrated EV preparation obtained by ( ultra ) centrifugation , or by centrifugal concentrator : Option 1 ) separate contaminants by upward flota - tion into a density gradient , where only lipid - enclosed structures float upward in the tube : analyze separately activity of each fraction of the gradient in the func - tional assay ; note that density gradient medium may have to be removed , because it can interfere with some functional assays . Alternatively , a control should be performed in which the chemical used for the density gradient is mixed with unseparated EVs . Option 2 ) separate soluble contaminants from EVs by SEC column , where EVs elute in the first fractions , whereas proteins and ribonucleoproteins and some lipoproteins are eluted later : analyze separately activity of each fraction ( or of pools of fractions containing EVs , intermediate , or free soluble components ) in the functional assay ; Option 3 ) compare activity of intact EVs with that of detergent - treated samples [ 279 ] . Detergent will destroy vesicular structures , without affecting other non - lipidic particles . Of course , this technique also has limitations : 1 . the effect of the same amount of detergent alone in the functional assay should be tested ( it could affect target cells ) ; 2 . there could be a few contaminants that are sensitive to detergents as well ( liposomes and some proteins ) . Option 4 ) immuno - isolate from half of the biofluid all EVs bearing a surface marker of interest ( for instance an integrin or a tetraspanin used to 24 C . THÉRY AND K . W . WITWER characterize the EVs , but not expected to be required for the observed activity ) , and use the specific EV - depleted supernatant in the functional assay , side - by - side with the other half of unprocessed biofluid , to determine if activity has been depleted ( hence was associated with the EVs of interest ) or not . Using the immuno - isolated EVs in the functional assay may com - plicate interpretation , since the immunoprecipitate will contain antibodies and beads used for isolation that may profoundly affect interaction of EVs with the target cells . Elimination of protein - bearing EVs by immunoisolation must be demonstrated by showing the amount of EV - associated protein in biofluid before ( all ) and after immuno - isolation ( none ) , and in the immuno - isolated sample ( all ) . Other options may arise from ongoing evolutions of the field . See section “ EV separation and concentra - tion ” p11 . As exemplified by AF4 [ 112 , 114 ] , combina - tions of ultrafiltration and SEC [ 280 ] , and tangential flow filtration combined with other filtration steps [ 106 ] , novel EV separation processes are constantly being developed and published . Determine whether a function is specific to exosomes , as compared with other small EVs As highlighted here , it is now clear that different types of EVs can present functional activities that are as important to explore as those elicited by late endo - some - derived exosomes . However , in the last decade , many studies have focused exclusively on demonstrat - ing association of a given function with exosomes . This section explains the technical limitations of such stu - dies , and why they are not sufficient to conclude , as is generally done , that exosomes have specific functions compared with other EVs . In particular , numerous approaches have been taken to inhibit or stimulate exosome secretion in loss - or gain - of - function experiments . For example , in mam - malian cells , exosome secretion has been decreased ( 100 % inhibition is almost never achieved ) by inhibit - ing neutral sphingomyelinases and ceramide genera - tion ( by shRNA , genetic editing , or drugs such as GW4869 , spiroepoxide , cambinol and others ) [ 281 – 284 ] ; inducing ISGylation , which promotes lysosomal degradation of MVB proteins [ 285 ] ; blocking Rab GTPases ( by expressing dominant - negative mutants or silencing or knocking out Rab27 , Rab11 , Rab35 , or others ) [ 286 – 288 ] , other small GTPases ( RAL - 1 [ 289 ] ) , SNARE proteins ( YKT6 [ 290 ] ) , upstream regulators of protein sorting into MVBs ( like SRC [ 291 ] ) , or cytos - keletal proteins ( cortactin [ 292 ] , microtubules [ 293 ] ) ; or using other drugs ( e . g . the sodium channel blocker amiloride [ 294 ] ) . Conversely , ionophores such as ionomycin ( calcium signaling ) or monensin ( sodium transport ) [ 295 , 296 ] , or drugs inhibiting endosomal acidification and / or autophagic degradation ( bafilomy - cin A1 [ 297 , 298 ] ) have been used to stimulate exosome secretion . Of note , drugs inhibiting EV uptake ( e . g . heparin [ 299 ] ) could lead to enhanced recovery of EVs , which could be misinterpreted as an increase of exosome release . A few studies have also proposed ways of modulat - ing secretion of plasma membrane - derived EVs in mammals : the ARRDC1 protein uses the ESCRT machinery to induce budding of small EVs at the PM , and its blocking or depletion inhibits secretion of such EVs [ 300 , 301 ] . Over - activation of ARF6 has been shown to increase release of PM - derived large EVs [ 302 ] . Modulation of cytoskeletal remodelers was reported to affect PM - derived EV release [ 303 – 305 ] , and depletion of DIAPH3 increased large oncosome release [ 306 ] . In prokaryotes , recent insights into the mechanisms of outer membrane vesicle formation [ 307 ] could suggest other molecules to test in eukar - yotic cells . These cell treatment approaches have great potential and deserve more development ; however , it is impor - tant to recognize several caveats . ( 1 ) Small EV – containing fractions potentially con - tain EVs originating from late endosomes ( “ exo - somes ” ) and others originating from the cell surface ( plasma membrane ) , with both classes sharing common molecular players , including the ESCRT components TSG101 , VPS4 , and / or Alix [ 308 – 310 ] . Therefore consequences of decreasing or increasing global secretion of het - erogeneous populations of small EVs should not be interpreted in terms of functional effects of exosomes , but rather of small EVs in general . ( 2 ) Tools described until now to block or enhance exosome secretion have not been well evaluated for their possible effect on secretion of other EVs . For instance , ionophores , such as ionomy - cin , are also potent inducers of large EV and microparticle secretion [ 207 , 311 ] . Conversely , in one study , inhibition of neutral sphingomyeli - nases was shown to enhance secretion of larger plasma membrane - derived EVs while decreasing that of small EVs [ 312 ] . Another example is monensin , often used to stimulate EV secretion , being an inhibitor of apoptotic body formation [ 167 ] . Therefore , it is likely that putative exo - some modulators will have different conse - quences in different cells and under different conditions , and it is important to carefully JOURNAL OF EXTRACELLULAR VESICLES 25 quantify the toxicity of each treatment in each experimental system , to exclude artefactual effects on EV recovery due to increased cell death . ( 3 ) Some EV release modulators affect other major intracellular pathways that might indirectly affect EV secretion and modify cell functions in general ( like general intracellular trafficking , secretory , or autophagy pathways ) . Consequently , not only EV amount , but also EV composition may be changed , together with changes in protein expression and physiol - ogy of the secreting cells . As an example , Rab27a inhibition also decreased secretion of some non - EV - bound soluble factors [ 313 , 314 ] . Another caveat to consider is that disrupting the secre - tion of one EV type may disrupt the production of other EV types , such that the functional EV type may be masked by the over - production of an antagonistic one , leading to an erroneous conclusion that the disrupted EV type is the functional EV . Therefore , demonstrating that only late endosome - derived exosomes bear an analyzed function remains challenging . Some previous studies managed to rescue an observed effect by re - introducing purified exosomes ( or rather small EV pellets ) into the functional in vitro or in vivo assays [ 292 , 313 , 314 ] . This approach is indeed recommended , with careful interpretation taking into account the degree of rescue and the required amount of EVs . Until we achieve unambiguous identification of speci - fic , unique biogenesis machineries affecting only a given subtype of EVs , we are left with trying to isolate EV subtypes after they have left the cell . For example , if multi - tetraspanin - bearing EVs are true exosomes in a particular cell system , an EV preparation could be depleted of such EVs and the activity quantified in comparison with that of an irrelevant IgG - or mock - depleted population . How to attribute particular effects mediated by EVs to specific EV components Many publications include knock - out or knock - down of a certain bioactive protein or RNA in the EV donor cell , after which the effects of the modified EV on target cells are compared with the effects of non - modified EVs . If the native effect of EVs is lost , the authors conclude that EV activity was due to the spe - cifically targeted protein or RNA . However , such a conclusion may or may not be valid in the absence of an extensive characterization of EVs released by the cells depleted for the targeted molecule . Indeed , dele - tion of the protein / RNA of interest may also lead to major alterations of the secreting cell , resulting in addi - tional changes to the quantity or molecular contents of EVs , which could also explain the changes in EV - induced effects on target cells . While a complete omics analyses of the modified EV population may be beyond the scope of many studies , there should be an awareness that other EV components may have chan - ged as well . At a minimum , a small - scale analysis of EV number or common EV - associated proteins in the modified and WT conditions must be performed . Finally , Direct EVs engineering ( e . g . to deplete the particular putative active molecule ) may overcome the issue of alterations in the secreting cells . However , possible loss / alteration of EV cargo due to EV manip - ulation may also occur . Consider whether an EV - dependent function is specific to a given EV source Finally , in all cases , one must be careful in claiming a specific function of EVs from a particular source : it is one thing to claim that the EV fraction from Cell X is potent ( versus other fractions ) , another to claim that Cell X EVs are potent versus those from other cells . For example , do my mesenchymal stromal cell ( MSC ) EVs do something special , or do milk EVs , urine EVs , cancer cell EVs do the same ? Of course , it will not be possible to compare EVs from all different sources , thus the final message must reflect this uncertainty . Consensus : This functional section had broad support ( > 94 % average for each subsection ) from MISEV2018 survey respondents and has been revised only mini - mally . The components of Table 4 , on EV - associated and - excluded activities , received an average 96 % endorsement . One of the least supported components of the functional section ( 90 % agreement ) was the ori - ginal normalization recommendation ( which are found in the function section but can be applied to character - ization and other sections as well ) . This part was sub - stantially revised based on the submitted comments . General considerations Reporting ISEV endorses the EV - TRACK knowledgebase as a facilitating and updatable tool for comprehensive reporting of EV experimental studies [ 161 ] . EV - TRACK invites submission of details on EV isolation and characterization via a multi - step online template , then associates each with a particular study or publica - tion and also returns an “ EV - METRIC ” as an aggregate 26 C . THÉRY AND K . W . WITWER measure of the level of detail provided . ISEV strongly encourages all authors to submit their experimental protocols on EV isolation and characterization to the EV - TRACK website ( evtrack . org ) , and to consider applying additional steps if they or reviewers / editors feel that the calculated metric is low . The important consideration is not obtaining a particular metric , which after all may vary widely between basic and clinical studies ; instead , the level of detail required for approved entries in EV - TRACK ensures that the trans - parency and reproducibility of procedures can be assessed . Furthermore , the knowledgebase can be revised and expanded as technologies and techniques develop , with input and assistance from the community . 1 Authors are also urged to submit EV profiling data to public databases such as those curated and maintained by the European Bioinformatics Institute , the US National Center for Biotechnology Information , and the Japanese Center for Information Biology . In addition , but not as a substitute , data may be submitted to field - specific databases such as EVpedia [ 315 , 316 ] , Vesiclepedia [ 317 ] ( formerly ExoCarta [ 318 ] ) , and the exRNA Atlas [ 319 ] . 2 Notes 1 . EV - TRACK submission and EV - METRIC calculation may assist with but do not replace appropriate peer review . Interestingly , respondents to the MISEV2018 Survey were split between advocating mandatory EV - TRACK submission and reporting and recognizing EV - TRACK as a valuable but optional tool . As a result , MISEV2018 strongly encourages but cannot mandate EV - TRACK submission , which most seem to acknowl - edge as highly valuable . 2 . The utility of field - specific databases was questioned by some respondents , who felt that data from studies ana - lysing EVs obtained through low - specificity methods renders these databases difficult to interpret in terms of specific association of a given molecule / sequence to EVs or an EV subtype . Submission to field - specific databases is thus important to update these resources , which are of value to identify different studies finding the same mole - cules , but not to demonstrate the exosomal nor EV nature of the analysed entities . It also does not substitute for deposition with publicly maintained repositories . Exceptions to compliance with MISEV guidelines Some situations may arise in which strict adherence to the MISEV guidelines is difficult . Not all biofluids , for example lacrimal fluid , are available in sufficient volume to separate EVs and perform multiple tests with each sample ; also , only limited numbers of EVs may be harvested from small numbers of patient - derived cells , small organoids , and more . In such cases , multiple samples might be pooled to establish the reliability of the separation method ( s ) and charac - terize EVs before further characterization or functional studies are performed with individuals samples . If even this solution is impractical , authors should indicate the limit of detection of each applied EV characterization technology and demonstrate that the available material falls below this limit . However , applying this “ escape clause ” means that EVs cannot be rigorously demon - strated , requiring that authors mention ( and reviewers insist on ) the caveats of alternative interpretations , i . e . that EVs may contribute , but not necessarily exclu - sively , to an observed phenomenon or molecular signature . Consensus : Section 6a ( reporting requirements ) was supported by 89 % of MISEV2018 Survey respondents . The comments were split between those who wanted more reliance on EV - TRACK and those who found EV - TRACK submissions to be time - consuming or otherwise cumbersome . 99 % of respondents agreed with mention - ing exceptions to compliance in 6b . Conclusions Major points of MISEV2018 ( see MISEV2018 quick - reference checklist , p42 ) : ( 1 ) “ Extracellular vesicle ” is the preferred generic term for the subject of our investigations , and subtypes should be defined by physical and bio - chemical characteristics and / or conditions / sources . When other terms are used , careful definition is required . ( 2 ) A growing number of separation techniques and combinations thereof are available , variously balancing recovery and specificity . In all cases , the EV separation and / or isolation procedure must be reported in detail , to allow a reliable replication . ( 3 ) As EV characterization evolves , protein and lipid markers continue to be highly useful to demon - strate presence of the generic structure of EVs . Markers chosen for characterization of EVs may differ based on cells of origin ( including mamma - lian vs non - mammalian vs non - eukaryotic cells ) , and whether claims are generic to all kinds of EVs , or instead specific to subtypes of EVs ( 4 - b p16 , Table 2 , Table 3 ) . Further , newly identified EV - associated components must be validated by 1 ) showing their specific association with EVs or sub - types and 2 ) if functionally relevant : topology in / outside EVs of the functional molecule ( 4 - d p . 21 ) . JOURNAL OF EXTRACELLULAR VESICLES 27 ( 4 ) Function . Demonstration that a function is asso - ciated specifically with EVs released from the cell ( Table 4 ) requires demonstration that the function occurs without cell - cell contact ( 5 - b p22 ) and is not present ( or is present to a substantially reduced extent ) in the soluble , non - EV - associated secreted factors ( 5 - c , d p23 - 24 ) . Demonstration that a function is specific to exosomes ( EVs of endosomal origin ) , as compared with other types of small EVs , is not recommended as a major point of any EV study due to the issues elaborated in section 5 - e p25 . However , if authors wish to make this point , the currently proposed exosome - specific tools cannot be taken for granted , and several controls should be performed to evaluate their action on other EVs , on secretion of non - EV products , and on the general physiology of secret - ing cells . Additional techniques for separation of these vesicles and / or genetic tools specifically affecting their secretion , may become available in the future ( 5 - e p25 ) . ( 5 ) The EV - TRACK knowledgebase is endorsed by ISEV to showcase and enhance rigor and repro - ducibility in EV studies , consistent with the MISEV guidelines . ( 6 ) Finally , there are exceptions to every rule . MISEV2018 is meant to guide and improve the field , not stifle it . If MISEV recommendations and requirements cannot be met , authors will then need to explain their unique situation and describe their attempts to meet the guidelines and the reason for failure . These guidelines will also continue to evolve . Consensus : 89 % of ISEV2018 Survey respondents had no major changes ; 29 comments were taken into account in revisions of this section . Acknowledgments The authors are grateful to all respondents to the various surveys that supported the MISEV2018 effort , including those who only partially completed the surveys or completed the surveys but declined authorship . They also thank all community members who offered feedback . Disclosure statement No potential conflict of interest was reported by the authors . In addition , they declare that they took responsibility for avoiding any introduction of possible conflicting material into the text . For example all names of companies and trademarks were avoided in the main text to reduce the likelihood of preferential treatment to specific services or products of for - profit entities . Funding Funding is listed only for the corresponding authors . CT ’ s laboratory is funded by INSERM , Institut Curie , Ministry of Education , and grants from INCa ( INCA - 11548 ) , French National Research Agency ( ANR - 10 - IDEX - 0001 - 02 PSL * and ANR - 11 - LABX - 0043 ) , SIDACTION ( 17 - 1 - AAE - 1138 ) , Fondation ARC ( PGA1 RF20180206962 , PJA 20171206453 ) . KWW and CT receive support from NIDA ( DA040385 ) . KWW is also supported in part by NIA AG057430 , NIDA DA047807 and NIMH MH118164 . Authors ’ contributions CT and KWW led the manuscript drafting team , prepared the online surveys , analyzed survey results and other input , communicated with authors and prospective authors , and prepared all revisions . All other authors contributed as spe - cified in the text and in footnotes to the author affiliations . All authors reviewed and approved the final draft of the manuscript . ORCID Clotilde Théry http : / / orcid . org / 0000 - 0001 - 8294 - 6884 Kenneth W Witwer http : / / orcid . org / 0000 - 0003 - 1664 - 4233 References References , especially those provided to illustrate methods and approaches , are representative only , and are not meant to be a comprehensive review of the literature . Most references were derived from suggestions provided in the MISEV2018 Survey results . Each reference was checked by multiple authors . Citation implies deemed relevance of scientific content and not an endorsement by the authors or ISEV of any particular journal or editorial practice . [ 1 ] Lotvall J , Hill AF , Hochberg F , et al . Minimal experi - mental requirements for definition of extracellular vesicles and their functions : a position statement from the international society for extracellular vesicles . J Extracell Vesicles . 2014 ; 3 : 26913 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25536934 [ 2 ] Witwer KW , Soekmadji C , Hill AF , et al . Updating the MISEV minimal requirements for extracellular vesicle studies : building bridges to reproducibility . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1396823 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1396823 [ 3 ] Stein JM , Luzio JP Ectocytosis caused by sublytic auto - logous complement attack on human neutrophils . The sorting of endogenous plasma - membrane proteins and lipids into shed vesicles . Biochem J . 1991 ; 274 28 C . THÉRY AND K . W . WITWER ( Pt 2 ) : 381 – 386 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 1848755 [ 4 ] Cocucci E , Meldolesi J Ectosomes and exosomes : shed - ding the confusion between extracellular vesicles . Trends Cell Biol . 2015 ; 25 ( 6 ) : 364 – 372 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25683921 [ 5 ] Gould SJ , Raposo G As we wait : coping with an imperfect nomenclature for extracellular vesicles . J Extracell Vesicles . 2013 ; 2 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 24009890 [ 6 ] Gardiner C , Di Vizio D , Sahoo S , et al . Techniques used for the isolation and characterization of extracel - lular vesicles : results of a worldwide survey . J Extracell Vesicles . 2016 ; 5 : 32945 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27802845 [ 7 ] Rojas A The imperative authentication of cell lines . Antimicrob Agents Chemother . 2017 ; 61 ( 11 ) : e01823 – 17 . Available from : http : / / aac . asm . org / lookup / doi / 10 . 1128 / AAC . 01823 - 17 [ 8 ] Reid Y , Storts D , Riss T , et al . Authentication of human cell lines by STR DNA profiling analysis [ Internet ] . Assay Guidance Manual . 2004 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 23805434 [ 9 ] Chen TS , Arslan F , Yin Y , et al . Enabling a robust scalable manufacturing process for therapeutic exo - somes through oncogenic immortalization of human ESC - derived MSCs . J Transl Med . 2011 ; 9 ( 1 ) : 47 . Available from : http : / / translational - medicine . biomed central . com / articles / 10 . 1186 / 1479 - 5876 - 9 - 47 [ 10 ] Lima LG , Chammas R , Monteiro RQ , et al . Tumor - derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine - dependent manner . Cancer Lett . 2009 ; 283 ( 2 ) : 168 – 175 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0304383509002420 [ 11 ] Frey B , Gaipl US The immune functions of phosphati - dylserine in membranes of dying cells and microvesicles . Semin Immunopathol . 2011 ; 33 ( 5 ) : 497 – 516 . Available from : http : / / link . springer . com / 10 . 1007 / s00281 - 010 - 0228 - 6 [ 12 ] Roseblade A , Luk F , Ung A , et al . Targeting micro - particle biogenesis : a novel approach to the circumven - tion of cancer multidrug resistance . Curr Cancer Drug Targets . 2015 ; 15 ( 3 ) : 205 – 214 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25714701 [ 13 ] Takasugi M Emerging roles of extracellular vesicles in cellular senescence and aging . Aging Cell . 2018 ; 17 ( 2 ) : e12734 . [ 14 ] Patel DB , Gray KM , Santharam Y , et al . Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell - derived extracel - lular vesicles . Bioeng Transl Med . 2017 ; 2 ( 2 ) : 170 – 179 . [ 15 ] Dang VD , Jella KK , Ragheb RRT , et al . Lipidomic and proteomic analysis of exosomes from mouse cortical collecting duct cells . FASEB J . 2017 ; 31 ( 12 ) : 5399 – 5408 . Available from : http : / / www . fasebj . org / doi / 10 . 1096 / fj . 201700417R [ 16 ] Klingeborn M , Dismuke WM , Skiba NP , et al . Directional exosome proteomes reflect polarity - specific functions in retinal pigmented epithelium monolayers . Sci Rep . 2017 ; 7 ( 1 ) : 4901 . Available from : http : / / www . nat ure . com / articles / s41598 - 017 - 05102 - 9 [ 17 ] Mittelbrunn M , Vicente - Manzanares M , Sánchez - Madrid F Organizing polarized delivery of exosomes at synapses . Traffic . 2015 ; 16 ( 4 ) : 327 – 337 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25614958 [ 18 ] van Niel G , Raposo G , Candalh C , et al . Intestinal epithelial cells secrete exosome - like vesicles . Gastroenterology . 2001 ; 121 ( 2 ) : 337 – 349 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 11487543 [ 19 ] Tauro BJ , Greening DW , Mathias RA , et al . Two dis - tinct populations of exosomes are released from LIM1863 colon carcinoma cell - derived organoids . Mol Cell Proteomics . 2013 ; 12 ( 3 ) : 587 – 598 . Available from : http : / / www . mcponline . org / lookup / doi / 10 . 1074 / mcp . M112 . 021303 [ 20 ] Yan IK , Shukla N , Borrelli DA , et al . Use of a hollow fiber bioreactor to collect extracellular vesicles from cells in culture . Methods Mol Biol . 2018 ; 1740 : 35 – 41 . Available from : http : / / link . springer . com / 10 . 1007 / 978 - 1 - 4939 - 7652 - 2 _ 4 [ 21 ] Watson DC , Yung BC , Bergamaschi C , et al . Scalable , cGMP - compatible purification of extracellular vesicles carrying bioactive human heterodimeric IL - 15 / lactad - herin complexes . J Extracell Vesicles . 2018 ; 7 ( 1 ) : 1442088 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 29535850 [ 22 ] Lowry MC , O ’ Driscoll L Can hi - jacking hypoxia inhi - bit extracellular vesicles in cancer ? Drug Discov Today . 2018 ; 23 ( 6 ) : 1267 – 1273 . Available from : https : / / linkin ghub . elsevier . com / retrieve / pii / S1359644617303252 [ 23 ] Mitchell MD , Peiris HN , Kobayashi M , et al . Placental exosomes in normal and complicated pregnancy . Am J Obstet Gynecol . 2015 ; 213 ( 4Suppl ) : S173 – 81 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0002937815007176 [ 24 ] de Jong OG , Verhaar MC , Chen Y , et al . Cellular stress conditions are reflected in the protein and RNA con - tent of endothelial cell - derived exosomes . J Extracell Vesicles . 2012 ; 1 ( 1 ) : 18396 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v1i0 . 18396 [ 25 ] Stratton D , Moore C , Antwi - Baffour S , et al . Microvesicles released constitutively from prostate cancer cells differ biochemically and functionally to stimulated microvesicles released through sublytic C5b - 9 . Biochem Biophys Res Commun . 2015 ; 460 ( 3 ) : 589 – 595 . Available from : http : / / linkinghub . else vier . com / retrieve / pii / S0006291X15005203 [ 26 ] Dozio V , Sanchez J - C Characterisation of extracellular vesicle - subsets derived from brain endothelial cells and analysis of their protein cargo modulation after TNF exposure . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1302705 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1302705 [ 27 ] Taylor J , Jaiswal R , Bebawy M Calcium - calpain depen - dent pathways regulate vesiculation in malignant breast cells . Curr Cancer Drug Targets . 2017 ; 17 ( 5 ) : 486 – 494 . Available from : http : / / www . eurekaselect . com / node / 146745 / article [ 28 ] Mostefai HA , Agouni A , Carusio N , et al . Phosphatidylinositol 3 - kinase and xanthine oxidase regulate nitric oxide and reactive oxygen species pro - ductions by apoptotic lymphocyte microparticles in endothelial cells . J Immunol . 2008 ; 180 ( 7 ) : 5028 – 5035 . JOURNAL OF EXTRACELLULAR VESICLES 29 Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 18354228 [ 29 ] Agouni A , Mostefai HA , Porro C , et al . Sonic hedge - hog carried by microparticles corrects endothelial injury through nitric oxide release . FASEB J . 2007 ; 21 ( 11 ) : 2735 – 2741 . Available from : http : / / www . fasebj . org / doi / 10 . 1096 / fj . 07 - 8079com [ 30 ] Soekmadji C , Riches JD , Russell PJ , et al . Modulation of paracrine signaling by CD9 positive small extracel - lular vesicles mediates cellular growth of androgen deprived prostate cancer . Oncotarget . 2017 ; 8 ( 32 ) : 52237 – 52255 . Available from : http : / / www . oncotar get . com / fulltext / 11111 [ 31 ] Saari H , Lázaro - Ibáñez E , Viitala T , et al . Microvesicle - and exosome - mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells . J Control Release . 2015 ; 220 ( PtB ) : 727 – 737 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0168365915301322 [ 32 ] Lázaro - Ibáñez E , Neuvonen M , Takatalo M , et al . Metastatic state of parent cells influences the uptake and functionality of prostate cancer cell - derived extra - cellular vesicles . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1354645 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1354645 [ 33 ] Chernov VM , Mouzykantov AA , Baranova NB , et al . Extracellular membrane vesicles secreted by myco - plasma acholeplasma laidlawii PG8 are enriched in virulence proteins . J Proteomics . 2014 ; 110 : 117 – 128 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S1874391914003819 [ 34 ] Corral - Vázquez C , Aguilar - quesada R , Catalina P , et al . Cell lines authentication and mycoplasma detec - tion as minimun quality control of cell lines in biobanking . Cell Tissue Bank . 2017 ; 18 ( 2 ) : 271 – 280 . Available from : http : / / link . springer . com / 10 . 1007 / s10561 - 017 - 9617 - 6 [ 35 ] Yang C , Chalasani G , Ng Y - H , et al . Exosomes released from mycoplasma infected tumor cells activate inhibi - tory B cells . PLoS One . 2012 ; 7 ( 4 ) : e36138 . Available from : http : / / dx . plos . org / 10 . 1371 / journal . pone . 0036138 [ 36 ] Quah BJC , O ’ Neill HC Mycoplasma contaminants pre - sent in exosome preparations induce polyclonal B cell responses . J Leukoc Biol . 2007 ; 82 ( 5 ) : 1070 – 1082 . [ 37 ] Mathivanan S , Lim JW , Tauro BJ , et al . Proteomics analysis of A33 immunoaffinity - purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue - specific protein signature . Mol Cell Proteomics . 2010 ; 9 ( 2 ) : 197 – 208 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 19837982 [ 38 ] Burger D , Turner M , Xiao F , et al . High glucose increases the formation and pro - oxidative activity of endothelial microparticles . Diabetologia . 2017 ; 60 ( 9 ) : 1791 – 1800 . Available from : http : / / link . springer . com / 10 . 1007 / s00125 - 017 - 4331 - 2 [ 39 ] Thom SR , Bhopale VM , Yu K , et al . Neutrophil microparticle production and inflammasome activa - tion by hyperglycemia due to cytoskeletal instability . J Biol Chem . 2017 ; 292 ( 44 ) : 18312 – 18324 . Available from : http : / / www . jbc . org / lookup / doi / 10 . 1074 / jbc . M117 . 802629 [ 40 ] Rice GE , Scholz - Romero K , Sweeney E , et al . The effect of glucose on the release and bioactivity of exosomes from first trimester trophoblast cells . J Clin Endocrinol Metab . 2015 ; 100 ( 10 ) : E1280 – 8 . Available from : https : / / academic . oup . com / jcem / article - lookup / doi / 10 . 1210 / jc . 2015 - 2270 [ 41 ] Németh A , Orgovan N , Sódar BW , et al . Antibiotic - induced release of small extracellular vesicles ( exo - somes ) with surface - associated DNA . Sci Rep . 2017 ; 7 ( 1 ) : 8202 . Available from : http : / / www . nature . com / arti cles / s41598 - 017 - 08392 - 1 [ 42 ] Zhou X , Zhang W , Yao Q , et al . Exosome production and its regulation of EGFR during wound healing in renal tubular cells . Am J Physiol Renal Physiol . 2017 ; 312 ( 6 ) : F963 – 70 . Available from : http : / / www . phy siology . org / doi / 10 . 1152 / ajprenal . 00078 . 2017 [ 43 ] Pachler K , Lener T , Streif D , et al . A good manufactur - ing practice - grade standard protocol for exclusively human mesenchymal stromal cell - derived extracellular vesicles . Cytotherapy . 2017 ; 19 ( 4 ) : 458 – 472 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S1465324917300038 [ 44 ] Saury C , Lardenois A , Schleder C , et al . Human serum and platelet lysate are appropriate xeno - free alterna - tives for clinical - grade production of human MuStem cell batches . Stem Cell Res Ther . 2018 ; 9 ( 1 ) : 128 . Available from : https : / / stemcellres . biomedcentral . com / articles / 10 . 1186 / s13287 - 018 - 0852 - y [ 45 ] Li J , Lee Y , Johansson HJ , et al . Serum - free culture alters the quantity and protein composition of neuroblastoma - derived extracellular vesicles . J Extracell Vesicles . 2015 ; 4 ( 1 ) : 26883 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v4 . 26883 [ 46 ] Beninson LA , Fleshner M Exosomes in fetal bovine serum dampen primary macrophage IL - 1 β response to lipopolysaccharide ( LPS ) challenge . Immunol Lett . 2015 ; 163 ( 2 ) : 187 – 192 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25455591 [ 47 ] Eitan E , Zhang S , Witwer KW , et al . Extracellular vesicle - depleted fetal bovine and human sera have reduced capacity to support cell growth . J Extracell Vesicles . 2015 ; 4 : 26373 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25819213 [ 48 ] Théry C , Amigorena S , Raposo G , et al . Isolation and characterization of exosomes from cell culture super - natants and biological fluids . In : Current protocols in cell biology . Hoboken , NJ , USA : John Wiley & Sons , Inc . ; 2006 . p . Unit 3 . 22 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 18228490 [ 49 ] van Balkom BWM , de Jong OG , Smits M , et al . Endothelial cells require miR - 214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells . Blood . 2013 ; 121 ( 19 ) : 3997 – 4006 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 23532734 [ 50 ] Kornilov R , Puhka M , Mannerström B , et al . Efficient ultrafiltration - based protocol to deplete extracellular vesicles from fetal bovine serum . J Extracell Vesicles . 2018 ; 7 ( 1 ) : 1422674 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1422674 30 C . THÉRY AND K . W . WITWER [ 51 ] Wei Z , Batagov AO , Carter DRF , et al . Fetal bovine serum RNA interferes with the cell culture derived extracellular RNA . Sci Rep . 2016 ; 6 : 31175 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27503761 [ 52 ] Shelke GV , Lässer C , Gho YS , et al . Importance of exosome depletion protocols to eliminate functional and RNA - containing extracellular vesicles from fetal bovine serum . J Extracell Vesicles . 2014 ; 3 : 24783 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25317276 [ 53 ] Tosar JP , Cayota A , Eitan E , et al . Ribonucleic arte - facts : are some extracellular RNA discoveries driven by cell culture medium components ? J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1272832 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 28326168 [ 54 ] Kaur S , Singh SP , Elkahloun AG , et al . CD47 - dependent immunomodulatory and angiogenic activ - ities of extracellular vesicles produced by T cells . Matrix Biol . 2014 ; 37 : 49 – 59 . Available from : http : / / lin kinghub . elsevier . com / retrieve / pii / S0945053X14000924 [ 55 ] Witwer KW , Buzas EI , Bemis LT , et al . Standardization of sample collection , isolation and analysis methods in extracellular vesicle research : an ISEV position paper . J Extracell Vesicles . 2013 ; 2 : 20360 . [ 56 ] Mateescu B , Kowal EJK , van Balkom BWM , Bartel S , Bhattacharyya SN , Buzàs EI , et al . Obstacles and opportunities in the functional analysis of extracellular vesicle RNA - An ISEV Position Paper . J Extracell Vesicles . 2017 ; 6 : 1286095 . [ 57 ] Bæk R , Søndergaard EKL , Varming K , et al . The impact of various preanalytical treatments on the phe - notype of small extracellular vesicles in blood analyzed by protein microarray . J Immunol Meth . 2016 ; 438 : 11 – 20 . Available from : http : / / linkinghub . else vier . com / retrieve / pii / S0022175916301624 [ 58 ] Barteneva NS , Fasler - Kan E , Bernimoulin M , et al . Circulating microparticles : square the circle . BMC Cell Biol . 2013 ; 14 ( 1 ) : 23 . Available from : http : / / bmccell biol . biomedcentral . com / articles / 10 . 1186 / 1471 - 2121 - 14 - 23 [ 59 ] Mullier F , Bailly N , Chatelain C , et al . Pre - analytical issues in the measurement of circulating microparti - cles : current recommendations and pending questions . J Thromb Haemost . 2013 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 23410207 [ 60 ] Lacroix R , Judicone C , Poncelet P , et al . Impact of pre - analytical parameters on the measurement of cir - culating microparticles : towards standardization of protocol . J Thromb Haemost . 2012 ; 10 ( 3 ) : 437 – 446 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 22212198 [ 61 ] Coumans FAW , Brisson AR , Buzas EI , et al . Methodological guidelines to study extracellular vesicles . Circ Res . 2017 ; 120 ( 10 ) : 1632 – 1648 . Available from : http : / / circres . ahajournals . org / lookup / doi / 10 . 1161 / CIRCRESAHA . 117 . 309417 [ 62 ] Yuana Y , Bertina RM , Osanto S Pre - analytical and analytical issues in the analysis of blood microparticles . Thromb Haemost . 2011 ; 105 ( 3 ) : 396 – 408 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 21174005 [ 63 ] Yuana Y , Böing AN , Grootemaat AE , et al . Handling and storage of human body fluids for analysis of extra - cellular vesicles . J Extracell Vesicles . 2015 ; 4 : 29260 . [ 64 ] Robbins PD Extracellular vesicles and aging . Stem Cell Investig . 2017 ; 4 ( 12 ) : 98 . Available from : http : / / sci . amegroups . com / article / view / 17758 / 18069 [ 65 ] Danielson KM , Estanislau J , Tigges J , et al . Diurnal variations of circulating extracellular vesicles measured by nano flow cytometry . PLoS One . 2016 ; 11 ( 1 ) : e0144678 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26745887 [ 66 ] Fendl B , Weiss R , Fischer MB , et al . Characterization of extracellular vesicles in whole blood : influence of pre - analytical parameters and visualization of vesicle - cell interactions using imaging flow cytometry . Biochem Biophys Res Commun . 2016 ; 478 ( 1 ) : 168 – 173 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0006291X16311950 [ 67 ] Wisgrill L , Lamm C , Hartmann J , et al . Peripheral blood microvesicles secretion is influenced by storage time , temperature , and anticoagulants . Cytometry A . 2016 ; 89 ( 7 ) : 663 – 672 . [ 68 ] György B , Pálóczi K , Kovács A , et al . Improved circu - lating microparticle analysis in acid - citrate dextrose ( ACD ) anticoagulant tube . Thromb Res . 2014 ; 133 ( 2 ) : 285 – 292 . Available from : http : / / linkinghub . else vier . com / retrieve / pii / S004938481300546X [ 69 ] Mitchell AJ , Gray WD , Hayek SS , et al . Platelets con - found the measurement of extracellular miRNA in archived plasma . Sci Rep . 2016 ; 6 ( 1 ) : 32651 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27623086 [ 70 ] Cheng HH , Yi HS , Kim Y , et al . Plasma processing conditions substantially influence circulating microRNA biomarker levels . PLoS One . 2013 ; 8 ( 6 ) : e64795 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 23762257 [ 71 ] Muller L , Hong C - S , Stolz DB , et al . Isolation of biologically - active exosomes from human plasma . J Immunol Meth . 2014 ; 411 : 55 – 65 . [ 72 ] Ayers L , Kohler M , Harrison P , et al . Measurement of circulating cell - derived microparticles by flow cytome - try : sources of variability within the assay . Thromb Res . 2011 ; 127 ( 4 ) : 370 – 377 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 21257195 [ 73 ] Heijnen HF , Schiel AE , Fijnheer R , et al . Activated platelets release two types of membrane vesicles : microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha - granules . Blood . 1999 ; 94 ( 11 ) : 3791 – 3799 . [ 74 ] Mincheva - Nilsson L , Baranov V , Nagaeva O , et al . Isolation and characterization of exosomes from cul - tures of tissue explants and cell lines . Curr Protoc Immunol . 2016 ; 115 : 14 . 42 . 1 – 14 . 42 . 21 . [ 75 ] Lunavat TR , Cheng L , Einarsdottir BO , et al . BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells . Proc Natl Acad Sci U S A . 2017 ; 114 ( 29 ) : E5930 – 9 . Available from : http : / / www . pnas . org / lookup / doi / 10 . 1073 / pnas . 1705206114 [ 76 ] Gupta AK , Rusterholz C , Huppertz B , et al . A comparative study of the effect of three different syncytiotrophoblast micro - particles preparations on JOURNAL OF EXTRACELLULAR VESICLES 31 endothelial cells . Placenta . 2005 ; 26 ( 1 ) : 59 – 66 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0143400404001080 [ 77 ] Holder BS , Tower CL , Forbes K , et al . Immune cell activation by trophoblast - derived microvesicles is mediated by syncytin 1 . Immunology . 2012 ; 136 ( 2 ) : 184 – 191 . [ 78 ] Perez - Gonzalez R , Gauthier SA , Kumar A , et al . The exosome secretory pathway transports amyloid precur - sor protein carboxyl - terminal fragments from the cell into the brain extracellular space . J Biol Chem . 2012 ; 287 ( 51 ) : 43108 – 43115 . Available from : http : / / www . jbc . org / lookup / doi / 10 . 1074 / jbc . M112 . 404467 [ 79 ] Vella LJ , Scicluna BJ , Cheng L , et al . A rigorous method to enrich for exosomes from brain tissue . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1348885 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 28804598 [ 80 ] Deng ZB , Poliakov A , Hardy RW , et al . Adipose tissue exosome - like vesicles mediate activation of macrophage - induced insulin resistance . Diabetes . 2009 ; 58 ( 11 ) : 2498 – 2505 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 19675137 [ 81 ] Wang GJ , Liu Y , Qin A , et al . Thymus exosomes - like particles induce regulatory T cells . J Immunol . 2008 ; 181 ( 8 ) : 5242 – 5248 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 18832678 [ 82 ] Kranendonk MEG , Visseren FLJ , van Balkom BWM , et al . Human adipocyte extracellular vesicles in reci - procal signaling between adipocytes and macrophages . Obesity ( Silver Spring ) . 2014 ; 22 ( 5 ) : 1296 – 1308 . [ 83 ] Loyer X , Zlatanova I , Devue C , et al . Intra - cardiac release of extracellular vesicles shapes inflammation following myocardial infarction . Circ Res . 2018 ; 123 ( 1 ) : 100 – 106 . Available from : http : / / circres . ahajour nals . org / lookup / doi / 10 . 1161 / CIRCRESAHA . 117 . 311326 [ 84 ] Leroyer AS , Ebrahimian TG , Cochain C , et al . Microparticles from ischemic muscle promotes post - natal vasculogenesis . Circulation . 2009 ; 119 ( 21 ) : 2808 – 2817 . Available from : http : / / circ . ahajour nals . org / cgi / doi / 10 . 1161 / CIRCULATIONAHA . 108 . 816710 [ 85 ] Michaelis ML , Jiang L , Michaelis EK Isolation of synaptosomes , synaptic plasma membranes , and synaptic junctional complexes . In : Methods in mole - cular biology . Clifton , NJ . 2017 . p . 107 – 119 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27943187 [ 86 ] Zhou H , Yuen PS , Pisitkun T , et al . Collection , storage , preservation , and normalization of human urinary exosomes for biomarker discovery . Kidney Int . 2006 ; 69 ( 8 ) : 1471 – 1476 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 16501490 [ 87 ] Vila - Liante V , Sánchez - López V , Martínez - Sales V , et al . Impact of sample processing on the measurement of circulating microparticles : storage and centrifuga - tion parameters . Clin Chem Lab Med . 2016 ; 54 ( 11 ) : 1759 – 1767 . Available from : https : / / www . degruy ter . com / view / j / cclm . 2016 . 54 . issue - 11 / cclm - 2016 - 0036 / cclm - 2016 - 0036 . xml [ 88 ] Kriebardis AG , Antonelou MH , Georgatzakou HT , et al . Microparticles variability in fresh frozen plasma : preparation protocol and storage time effects . Blood Transfus . 2016 ; 14 ( 2 ) : 228 – 237 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27136430 [ 89 ] L ő rincz ÁM , Timár CI , Marosvári KA , et al . Effect of storage on physical and functional properties of extra - cellular vesicles derived from neutrophilic granulocytes . J Extracell Vesicles . 2014 ; 3 ( 1 ) : 25465 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v3 . 25465 [ 90 ] Bosch S , de Beaurepaire L , Allard M , et al . Trehalose prevents aggregation of exosomes and cryodamage . Sci Rep . 2016 ; 6 ( 1 ) : 36162 . Available from : http : / / www . nat ure . com / articles / srep36162 [ 91 ] Maroto R , Zhao Y , Jamaluddin M , et al . Effects of storage temperature on airway exosome integrity for diagnostic and functional analyses . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1359478 . Available from : https : / / www . tand fonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1359478 [ 92 ] Jin Y , Chen K , Wang Z , et al . DNA in serum extra - cellular vesicles is stable under different storage conditions . BMC Cancer . 2016 ; 16 ( 1 ) : 753 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27662833 [ 93 ] Jeyaram A , Jay SM . Preservation and storage stability of extracellular vesicles for therapeutic applications . Aaps J . 2017 ; 20 ( 1 ) : 1 . Available from : http : / / link . springer . com / 10 . 1208 / s12248 - 017 - 0160 - y [ 94 ] Trummer A , De Rop C , Tiede A , et al . Recovery and composition of microparticles after snap - freezing depends on thawing temperature . Blood Coagul Fibrinolysis . 2009 ; 20 ( 1 ) : 52 – 56 . Available from : https : / / insights . ovid . com / crossref ? an = 00001721 - 200901000 - 00010 [ 95 ] Lener T , Gimona M , Aigner L , et al . Applying extra - cellular vesicles based therapeutics in clinical trials - an ISEV position paper . J Extracell Vesicles . 2015 ; 4 : 30087 . Available from : http : / / www . pubmedcentral . nih . gov / articlerender . fcgi ? artid = 4698466 & tool = pmcentrez & ren dertype = abstract [ 96 ] Reiner AT , Witwer KW , Van Balkom BWM , et al . Concise review : developing best - practice models for the therapeutic use of extracellular vesicles . Stem Cells Transl Med . 2017 ; 6 ( 8 ) . [ 97 ] Clayton A , Buschmann D , Byrd JB , et al . Summary of the ISEV workshop on extracellular vesicles as disease biomarkers , held in Birmingham , UK , during December 2017 . J Extracell Vesicles . 2018 ; 7 ( 1 ) : 1473707 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2018 . 1473707 [ 98 ] Montis C , Zendrini A , Valle F , et al . Size distribution of extracellular vesicles by optical correlation techniques . Colloids Surf B Biointerfaces . 2017 ; 158 : 331 – 338 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S092777651730406X [ 99 ] Morales - Kastresana A , Telford B , Musich TA , et al . Labeling extracellular vesicles for nanoscale flow cytometry . Sci Rep . 2017 ; 7 ( 1 ) : 1878 . Available from : http : / / www . nature . com / articles / s41598 - 017 - 01731 - 2 [ 100 ] Corso G , Mäger I , Lee Y , et al . Reproducible and scalable purification of extracellular vesicles using combined bind - elute and size exclusion chromatography . Sci Rep . 2017 ; 7 ( 1 ) : 11561 . Available from : http : / / www . nature . com / articles / s41598 - 017 - 10646 - x 32 C . THÉRY AND K . W . WITWER [ 101 ] Welton JL , Webber JP , Botos L - A , et al . Ready - made chromatography columns for extracellular vesicle iso - lation from plasma . J Extracell Vesicles . 2015 ; 4 : 27269 . Available from : http : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v4 . 27269 [ 102 ] Vergauwen G , Dhondt B , Van Deun J , et al . Confounding factors of ultrafiltration and protein ana - lysis in extracellular vesicle research . Sci Rep . 2017 ; 7 ( 1 ) : 2704 . Available from : http : / / www . nature . com / arti cles / s41598 - 017 - 02599 - y [ 103 ] Lobb RJ , Becker M , Wen SW , et al . Optimized exo - some isolation protocol for cell culture supernatant and human plasma . J Extracell Vesicles . 2015 ; 4 : 27031 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v4 . 27031 [ 104 ] Tan CY , Lai RC , Wong W , et al . Mesenchymal stem cell - derived exosomes promote hepatic regeneration in drug - induced liver injury models . Stem Cell Res Ther . 2014 ; 5 ( 3 ) : 76 . Available from : http : / / stemcellres . com / content / 5 / 3 / 76 [ 105 ] Jong AY , Wu C - H , Li J , et al . Large - scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1294368 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1294368 [ 106 ] Heinemann ML , Ilmer M , Silva LP , et al . Benchtop isolation and characterization of functional exosomes by sequential filtration . J Chromatogr A . 2014 ; 1371 : 125 – 135 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0021967314015908 [ 107 ] Heinemann ML , Vykoukal J Sequential filtration : A gentle method for the isolation of functional extra - cellular vesicles . In : Methods in molecular biology . Clifton , NJ . 2017 . p . 33 – 41 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 28828646 [ 108 ] Wei Z , Batagov AO , Schinelli S , et al . Coding and noncoding landscape of extracellular RNA released by human glioma stem cells . Nat Commun . 2017 ; 8 ( 1 ) : 1145 . Available from : http : / / www . nature . com / arti cles / s41467 - 017 - 01196 - x [ 109 ] Lamparski HG , Metha - Damani A , Yao JY , et al . Production and characterization of clinical grade exo - somes derived from dendritic cells . J Immunol Meth . 2002 ; 270 ( 2 ) : 211 – 226 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 12379326 [ 110 ] Escudier B , Dorval T , Chaput N , et al . Vaccination of metastatic melanoma patients with autologous dendri - tic cell ( DC ) derived - exosomes : results of thefirst phase I clinical trial . J Transl Med . 2005 ; 3 ( 1 ) : 10 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 15740633 [ 111 ] Roda B , Zattoni A , Reschiglian P , et al . Field - flow fractionation in bioanalysis : A review of recent trends . Anal Chim Acta . 2009 ; 635 ( 2 ) : 132 – 143 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0003267009000865 [ 112 ] Zhang H , Freitas D , Kim HS , et al . Identification of distinct nanoparticles and subsets of extracellular vesi - cles by asymmetric flow field - flow fractionation . Nat Cell Biol . 2018 ; 20 ( 3 ) : 332 – 343 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 29459780 [ 113 ] Yang JS , Lee JC , Byeon SK , et al . Size dependent lipidomic analysis of urinary exosomes from patients with prostate cancer by flow field - flow fractionation and nanoflow liquid chromatography - tandem mass spectrometry . Anal Chem . 2017 ; 89 ( 4 ) : 2488 – 2496 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acs . ana lchem . 6b04634 [ 114 ] Agarwal K , Saji M , Lazaroff SM , et al . Analysis of exosome release as a cellular response to MAPK path - way inhibition . Langmuir . 2015 ; 31 ( 19 ) : 5440 – 5448 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25915504 [ 115 ] Liu C , Guo J , Tian F , et al . Field - free isolation of exosomes from extracellular vesicles by microfluidic viscoelastic flows . ACS Nano . 2017 ; 11 ( 7 ) : 6968 – 6976 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acs nano . 7b02277 [ 116 ] Ibsen SD , Wright J , Lewis JM , et al . Rapid isolation and detection of exosomes and associated biomarkers from plasma . ACS Nano . 2017 ; 11 ( 7 ) : 6641 – 6651 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acs nano . 7b00549 [ 117 ] Lewis JM , Vyas AD , Qiu Y , et al . Integrated analysis of exosomal protein biomarkers on alternating current electrokinetic chips enables rapid detection of pancrea - tic cancer in patient blood . ACS Nano . 2018 ; 12 ( 4 ) : 3311 – 3320 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acsnano . 7b08199 [ 118 ] Lee K , Shao H , Weissleder R , et al . Acoustic purifica - tion of extracellular microvesicles . ACS Nano . 2015 ; 9 ( 3 ) : 2321 – 2327 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / nn506538f [ 119 ] Satzer P , Wellhoefer M , Jungbauer A . Continuous separation of protein loaded nanoparticles by simu - lated moving bed chromatography . J Chromatogr A . 2014 ; 1349 : 44 – 49 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0021967314006979 [ 120 ] Mol EA , Goumans M - J , Doevendans PA , et al . Higher functionality of extracellular vesicles isolated using size - exclusion chromatography compared to ultracentrifugation . Nanomedicine . 2017 ; 13 ( 6 ) : 2061 – 2065 . Available from : http : / / linkinghub . else vier . com / retrieve / pii / S1549963417300540 [ 121 ] de Menezes - Neto A , Sáez MJF , Lozano - Ramos I , et al . Size - exclusion chromatography as a stand - alone metho - dology identifies novel markers in mass spectrometry analyses of plasma - derived vesicles from healthy individuals . J Extracell Vesicles . 2015 ; 4 : 27378 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26154623 [ 122 ] Kosanovi ć M , Milutinovi ć B , Go č S , et al . Ion - exchange chromatography purification of extracellular vesicles . Biotechniques . 2017 ; 63 ( 2 ) : 65 – 71 . Available from : https : / / www . future - science . com / doi / 10 . 2144 / 000114575 [ 123 ] Heath N , Grant L , De Oliveira TM , et al . Rapid isolation and enrichment of extracellular vesicle preparations using anion exchange chromatography . Sci Rep . 2018 ; 8 ( 1 ) : 5730 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 29636530 [ 124 ] Kim D , Nishida H , An SY , et al . Chromatographically isolated CD63 + CD81 + extracellular vesicles from JOURNAL OF EXTRACELLULAR VESICLES 33 mesenchymal stromal cells rescue cognitive impair - ments after TBI . Proc Natl Acad Sci . 2016 ; 113 ( 1 ) : 170 – 175 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26699510 [ 125 ] Merchant ML , Powell DW , Wilkey DW , et al . Microfiltration isolation of human urinary exosomes for characterization by MS . PROTEOMICS - Clin Appl . 2010 ; 4 ( 1 ) : 84 – 96 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 21137018 [ 126 ] Higginbotham JN , Zhang Q , Jeppesen DK , et al . Identification and characterization of EGF receptor in individual exosomes by fluorescence - activated vesicle sorting . J Extracell Vesicles . 2016 ; 5 : 29254 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27345057 [ 127 ] Groot Kormelink T , Arkesteijn GJA , Nauwelaers FA , et al . Prerequisites for the analysis and sorting of extra - cellular vesicle subpopulations by high - resolution flow cytometry . Cytometry A . 2016 ; 89 ( 2 ) : 135 – 147 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25688721 [ 128 ] Atkin - Smith GK , Paone S , Zanker DJ , et al . Isolation of cell type - specific apoptotic bodies by fluorescence - activated cell sorting . Sci Rep . 2017 ; 7 : 39846 . Available from : http : / / www . nature . com / articles / srep39846 [ 129 ] Minciacchi VR , Spinelli C , Reis - Sobreiro M , et al . MYC mediates large oncosome - induced fibroblast reprogramming in prostate cancer . Cancer Res . 2017 ; 77 ( 9 ) : 2306 – 2317 . Available from : http : / / can cerres . aacrjournals . org / lookup / doi / 10 . 1158 / 0008 - 5472 . CAN - 16 - 2942 [ 130 ] Wunsch BH , Smith JT , Gifford SM , et al . Nanoscale lateral displacement arrays for the separation of exo - somes and colloids down to 20 nm . Nat Nanotechnol . 2016 ; 11 ( 11 ) : 936 – 940 . Available from : http : / / www . nat ure . com / articles / nnano . 2016 . 134 [ 131 ] Echevarria J , Royo F , Pazos R , et al . Microarray - based identification of lectins for the purification of human urinary extracellular vesicles directly from urine samples . Chembiochem . 2014 ; 15 ( 11 ) : 1621 – 1626 . [ 132 ] Ghosh A , Davey M , Chute IC , et al . Rapid isolation of extracellular vesicles from cell culture and biological fluids using a synthetic peptide with specific affinity for heat shock proteins . PLoS One . 2014 ; 9 ( 10 ) : e110443 . Available from : http : / / dx . plos . org / 10 . 1371 / journal . pone . 0110443 [ 133 ] Balaj L , Atai NA , Chen W , et al . Heparin affinity purification of extracellular vesicles . Sci Rep . 2015 ; 5 : 10266 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25988257 [ 134 ] Fang X , Duan Y , Adkins GB , et al . Highly efficient exosome isolation and protein analysis by an inte - grated nanomaterial - based platform . Anal Chem . 2018 ; 90 ( 4 ) : 2787 – 2795 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acs . analchem . 7b04861 [ 135 ] Sharma P , Ludwig S , Muller L , et al . Immunoaffinity - based isolation of melanoma cell - derived exosomes from plasma of patients with melanoma . J Extracell Vesicles . 2018 ; 7 ( 1 ) : 1435138 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2018 . 1435138 [ 136 ] Brett SI , Lucien F , Guo C , et al . Immunoaffinity based methods are superior to kits for purification of prostate derived extracellular vesicles from plasma samples . Prostate . 2017 ; 77 ( 13 ) : 1335 – 1343 . [ 137 ] Nakai W , Yoshida T , Diez D , et al . A novel affinity - based method for the isolation of highly pur - ified extracellular vesicles . Sci Rep . 2016 ; 6 ( 1 ) : 33935 . Available from : http : / / www . nature . com / articles / srep33935 [ 138 ] Welton JL , Loveless S , Stone T , et al . Cerebrospinal fluid extracellular vesicle enrichment for protein bio - marker discovery in neurological disease ; multiple sclerosis . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1369805 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1369805 [ 139 ] Lai RC , Tan SS , Yeo RWY , et al . MSC secretes at least 3 EV types each with a unique permutation of mem - brane lipid , protein and RNA . J Extracell Vesicles . 2016 ; 5 ( 1 ) : 29828 . Available from : https : / / www . tandfon line . com / doi / full / 10 . 3402 / jev . v5 . 29828 [ 140 ] Gallart - Palau X , Serra A , Wong ASW , et al . Extracellular vesicles are rapidly purified from human plasma by PRotein Organic Solvent PRecipitation ( PROSPR ) . Sci Rep . 2015 ; 5 ( 1 ) : 14664 . Available from : http : / / www . nature . com / articles / srep14664 [ 141 ] Shin H , Han C , Labuz JM , et al . High - yield isolation of extracellular vesicles using aqueous two - phase system . Sci Rep . 2015 ; 5 ( 1 ) : 13103 . Available from : http : / / www . nature . com / articles / srep13103 [ 142 ] Hurwitz SN , Nkosi D , Conlon MM , et al . CD63 reg - ulates epstein - barr virus LMP1 exosomal packaging , enhancement of vesicle production , and noncanonical NF - κ B signaling . J Virol . 2017 ; 91 ( 5 ) : e02251 – 16 . Available from : http : / / jvi . asm . org / lookup / doi / 10 . 1128 / JVI . 02251 - 16 [ 143 ] Musante L , Tataruch D , Gu D , et al . A simplified method to recover urinary vesicles for clinical applica - tions , and sample banking . Sci Rep . 2014 ; 4 ( 1 ) : 7532 . Available from : http : / / www . nature . com / articles / srep07532 [ 144 ] Sedykh SE , Purvinish LV , Monogarov AS , et al . Purified horse milk exosomes contain an unpredictable small number of major proteins . Biochim Open . 2017 ; 4 : 61 – 72 . Available from : http : / / linkinghub . else vier . com / retrieve / pii / S2214008517300056 [ 145 ] Contreras - Naranjo JC , Wu H - J , Ugaz VM Microfluidics for exosome isolation and analysis : enabling liquid biopsy for personalized medicine . Lab Chip . 2017 ; 17 ( 21 ) : 3558 – 3577 . [ 146 ] Wu M , Ouyang Y , Wang Z , et al . Isolation of exo - somes from whole blood by integrating acoustics and microfluidics . Proc Natl Acad Sci U S A . 2017 ; 114 ( 40 ) : 10584 – 10589 . Available from : http : / / www . pnas . org / lookup / doi / 10 . 1073 / pnas . 1709210114 [ 147 ] Chen C , Skog J , Hsu CH , et al . Microfluidic isolation and transcriptome analysis of serum microvesicles . Lab Chip . 2010 / 02 / 04 . 2010 ; 10 ( 4 ) : 505 – 511 . [ 148 ] Liang L - G , Kong M - Q , Zhou S , et al . An integrated double - filtration microfluidic device for isolation , enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer . Sci Rep . 2017 ; 7 : 46224 . Available from : http : / / www . nature . com / articles / srep46224 34 C . THÉRY AND K . W . WITWER [ 149 ] Shin S , Han D , Park MC , et al . Separation of extra - cellular nanovesicles and apoptotic bodies from cancer cell culture broth using tunable microfluidic systems . Sci Rep . 2017 ; 7 ( 1 ) : 9907 . Available from : http : / / www . nature . com / articles / s41598 - 017 - 08826 - w [ 150 ] Yasui T , Yanagida T , Ito S , et al . Unveiling massive numbers of cancer - related urinary - microRNA candi - dates via nanowires . Sci Adv . 2017 ; 3 ( 12 ) : e1701133 . Available from : http : / / advances . sciencemag . org / lookup / doi / 10 . 1126 / sciadv . 1701133 [ 151 ] Zhao Z , Yang Y , Zeng Y , et al . A microfluidic exo - search chip for multiplexed exosome detection towards blood - based ovarian cancer diagnosis . Lab Chip . 2016 ; 16 ( 3 ) : 489 – 496 . [ 152 ] Wang Z , Wu H , Fine D , et al . Ciliated micropillars for the microfluidic - based isolation of nanoscale lipid vesicles . Lab Chip . 2013 ; 13 ( 15 ) : 2879 – 2882 . [ 153 ] Reátegui E , van der Vos KE , Lai CP , et al . Engineered nanointerfaces for microfluidic isolation and molecu - lar profiling of tumor - specific extracellular vesicles . Nat Commun . 2018 ; 9 ( 1 ) : 175 . Available from : http : / / www . nature . com / articles / s41467 - 017 - 02261 - 1 [ 154 ] Böing AN , van der Pol E , Grootemaat AE , et al . Single - step isolation of extracellular vesicles by size - exclusion chromatography . J Extracell Vesicles . 2014 ; 3 : 23430 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v3 . 23430 [ 155 ] Stranska R , Gysbrechts L , Wouters J , et al . Comparison of membrane affinity - based method with size - exclusion chromatography for isolation of exosome - like vesicles from human plasma . J Transl Med . 2018 ; 16 ( 1 ) : 1 . Available from : https : / / translational - medicine . biomed central . com / articles / 10 . 1186 / s12967 - 017 - 1374 - 6 [ 156 ] Enderle D , Spiel A , Coticchia CM , et al . Characterization of RNA from exosomes and other extracellular vesicles isolated by a novel spin column - based method . PLoS One . 2015 ; 10 ( 8 ) : e0136133 . Available from : http : / / dx . plos . org / 10 . 1371 / journal . pone . 0136133 [ 157 ] Jeppesen DK , Hvam ML , Primdahl - Bengtson B , et al . Comparative analysis of discrete exosome fractions obtained by differential centrifugation . J Extracell Vesicles . 2014 ; 3 : 25011 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25396408 [ 158 ] Livshits MA , Khomyakova E , Evtushenko EG , et al . Isolation of exosomes by differential centrifugation : theoretical analysis of a commonly used protocol . Sci Rep . 2015 ; 5 ( 1 ) : 17319 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26616523 [ 159 ] Jang SC , Kim OY , Yoon CM , et al . Bioinspired exosome - mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors . ACS Nano . 2013 ; 7 ( 9 ) : 7698 – 7710 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / nn402232g [ 160 ] Li K , Wong DK , Hong KY , et al . Cushioned - density gradient ultracentrifugation ( C - DGUC ) : a refined and high performance method for the isolation , character - ization , and use of exosomes . Methods Mol Biol . 2018 ; 1740 : 69 – 83 . Available from : http : / / link . springer . com / 10 . 1007 / 978 - 1 - 4939 - 7652 - 2 _ 7 [ 161 ] Van Deun J , Mestdagh P , Agostinis P , et al . EV - TRACK : transparent reporting and centralizing knowledge in extracellular vesicle research . Nat Methods . 2017 ; 14 ( 3 ) : 228 – 232 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 28245209 [ 162 ] Mitchell JP , Court J , Mason MD , et al . Increased exosome production from tumour cell cultures using the integra celline culture system . J Immunol Meth . 2008 ; 335 ( 1 – 2 ) : 98 – 105 . Available from : http : / / l i n k i n g h u b . e l s e v i e r . c o m / r e t r i e v e / p i i / S0022175908000926 [ 163 ] Ortiz A , Sanchez - Niño MD , Sanz AB The meaning of urinary creatinine concentration . Kidney Int . 2011 ; 79 ( 7 ) : 791 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0085253815548849 [ 164 ] Cointe S , Judicone C , Robert S , et al . Standardization of microparticle enumeration across different flow cytometry platforms : results of a multicenter collabora - tive workshop . J Thromb Haemost . 2017 ; 15 ( 1 ) : 187 – 193 . [ 165 ] Krishnan SR , Luk F , Brown RD , et al . Isolation of human CD138 ( + ) microparticles from the plasma of patients with multiple myeloma . Neoplasia . 2016 ; 18 ( 1 ) : 25 – 32 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S1476558615001566 [ 166 ] McVey MJ , Spring CM , Semple JW , et al . Microparticles as biomarkers of lung disease : enumera - tion in biological fluids using lipid bilayer microspheres . Am J Physiol Lung Cell Mol Physiol . 2016 ; 310 ( 9 ) : L802 – 14 . Available from : http : / / www . phy siology . org / doi / 10 . 1152 / ajplung . 00369 . 2015 [ 167 ] Atkin - Smith GK , Tixeira R , Paone S , et al . A novel mechanism of generating extracellular vesicles during apoptosis via a beads - on - a - string membrane structure . Nat Commun . 2015 ; 6 : 7439 . Available from : http : / / www . nature . com / doifinder / 10 . 1038 / ncomms8439 [ 168 ] van der Vlist EJ , Nolte - ’ T Hoen EN , Stoorvogel W , et al . Fluorescent labeling of nano - sized vesicles released by cells and subsequent quantitative and qua - litative analysis by high - resolution flow cytometry . Nat Protoc . 2012 / 06 / 23 . 2012 ; 7 ( 7 ) : 1311 – 1326 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 22722367 [ 169 ] van der Pol E , van Gemert MJ , Sturk A , et al . Single vs . swarm detection of microparticles and exosomes by flow cytometry . J Thromb Haemost . 2012 / 03 / 08 . 2012 ; 10 ( 5 ) : 919 – 930 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 22394434 [ 170 ] Pospichalova V , Svoboda J , Dave Z , et al . Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer . J Extracell Vesicles . 2015 ; 4 ( 1 ) : 25530 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v4 . 25530 [ 171 ] Tian Y , Ma L , Gong M , et al . Protein profiling and sizing of extracellular vesicles from colorectal cancer patients via flow cytometry . ACS Nano . 2018 ; 12 ( 1 ) : 671 – 680 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acsnano . 7b07782 [ 172 ] McVey MJ , Spring CM , Kuebler WM . Improved resolution in extracellular vesicle populations using 405 instead of 488 nm side scatter . J Extracell Vesicles . 2018 ; 7 ( 1 ) : 1454776 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2018 . 1454776 JOURNAL OF EXTRACELLULAR VESICLES 35 [ 173 ] Nolan JP , Stoner SA . A trigger channel threshold arti - fact in nanoparticle analysis . Cytometry A . 2013 ; 83 ( 3 ) : 301 – 305 . [ 174 ] Arraud N , Linares R , Tan S , et al . Extracellular vesicles from blood plasma : determination of their morphol - ogy , size , phenotype and concentration . J Thromb Haemost . 2014 ; 12 ( 5 ) : 614 – 627 . [ 175 ] Arraud N , Gounou C , Linares R , et al . A simple flow cytometry method improves the detection of phosphatidylserine - exposing extracellular vesicles . J Thromb Haemost . 2015 ; 13 ( 2 ) : 237 – 247 . [ 176 ] Maas SLN , de Vrij J , van der Vlist EJ , et al . Possibilities and limitations of current technologies for quantifica - tion of biological extracellular vesicles and synthetic mimics . J Control Release . 2015 ; 200 : 87 – 96 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0168365914008384 [ 177 ] de Vrij J , Maas SL , van Nispen M , et al . Quantification of nanosized extracellular membrane vesicles with scanning ion occlusion sensing . Nanomedicine ( Lond ) . 2013 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 23384702 [ 178 ] Obeid S , Ceroi A , Mourey G , et al . Development of a NanoBioAnalytical platform for on - chip qualification and quantification of platelet - derived microparticles . Biosens Bioelectron . 2017 ; 93 : 250 – 259 . Available from : https : / / linkinghub . elsevier . com / retrieve / pii / S0956566316308569 [ 179 ] Libregts SFWM , Arkesteijn GJA , Németh A , et al . Flow cytometric analysis of extracellular vesicle subsets in plasma : impact of swarm by particles of non - interest . J Thromb Haemost . 2018 ; 16 ( 7 ) : 1423 – 1436 . [ 180 ] van der Pol E , Hoekstra AG , Sturk A , et al . Optical and non - optical methods for detection and characteriza - tion of microparticles and exosomes . J Thromb Haemost . 2010 ; 8 ( 12 ) : 2596 – 2607 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 20880256 [ 181 ] Carnell - Morris P , Tannetta D , Siupa A , et al . Analysis of extracellular vesicles using fluorescence nanoparticle tracking analysis . Methods Mol Biol . 2017 ; 1660 : 153 – 173 . Available from : http : / / link . springer . com / 10 . 1007 / 978 - 1 - 4939 - 7253 - 1 _ 13 [ 182 ] Takov K , Yellon DM , Davidson SM Confounding fac - tors in vesicle uptake studies using fluorescent lipophi - lic membrane dyes . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1388731 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 29184625 [ 183 ] van der Pol E , Coumans FAW , Grootemaat AE , et al . Particle size distribution of exosomes and microvesi - cles determined by transmission electron microscopy , flow cytometry , nanoparticle tracking analysis , and resistive pulse sensing . J Thromb Haemost . 2014 ; 12 ( 7 ) : 1182 – 1192 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 24818656 [ 184 ] Dragovic RA , Gardiner C , Brooks AS , et al . Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis . Nanomedicine . 2011 ; 7 ( 6 ) : 780 – 788 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 21601655 [ 185 ] Gardiner C , Ferreira YJ , Dragovic RA , et al . Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis . J Extracell Vesicles . 2013 ; 2 : 19671 . Available from : [ 186 ] Osteikoetxea X , Balogh A , Szabó - Taylor K , et al . Improved characterization of EV preparations based on protein to lipid ratio and lipid properties . PLoS One . 2015 ; 10 ( 3 ) : e0121184 . Available from : http : / / dx . plos . org / 10 . 1371 / journal . pone . 0121184 [ 187 ] Benmoussa A , Ly S , Shan ST , et al . A subset of extra - cellular vesicles carries the bulk of microRNAs in commercial dairy cow ’ s milk . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1401897 . Available from : https : / / www . tand fonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1401897 [ 188 ] Mihály J , Deák R , Szigyártó IC , et al . Characterization of extracellular vesicles by IR spectroscopy : fast and simple classification based on amide and CH stretch - ing vibrations . Biochim Biophys Acta . 2017 ; 1859 ( 3 ) : 459 – 466 . Available from : http : / / linkinghub . else vier . com / retrieve / pii / S000527361630390X [ 189 ] Turchinovich A , Weiz L , Langheinz A , et al . Characterization of extracellular circulating microRNA . Nucleic Acids Res . 2011 ; 39 ( 16 ) : 7223 – 7233 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 21609964 [ 190 ] Arroyo JD , Chevillet JR , Kroh EM , et al . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma . Proc Natl Acad Sci U S A . 2011 ; 108 ( 12 ) : 5003 – 5008 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 21383194 [ 191 ] Vickers KC , Palmisano BT , Shoucri BM , et al . MicroRNAs are transported in plasma and delivered to recipient cells by high - density lipoproteins . Nat Cell Biol . 2011 ; 13 ( 4 ) : 423 – 433 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 21423178 [ 192 ] Duijvesz D , Versluis CYL , van der Fels CAM , et al . Immuno - based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer . Int J Cancer . 2015 ; 137 ( 12 ) : 2869 – 2878 . [ 193 ] Suárez H , Gámez - Valero A , Reyes R , et al . A bead - assisted flow cytometry method for the semi - quantitative analysis of extracellular vesicles . Sci Rep . 2017 ; 7 ( 1 ) : 11271 . Available from : http : / / www . nat ure . com / articles / s41598 - 017 - 11249 - 2 [ 194 ] Koliha N , Wiencek Y , Heider U , et al . A novel multi - plex bead - based platform highlights the diversity of extracellular vesicles . J Extracell Vesicles . 2016 ; 5 : 29975 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26901056 [ 195 ] Xia Y , Liu M , Wang L , et al . A visible and colorimetric aptasensor based on DNA - capped single - walled car - bon nanotubes for detection of exosomes . Biosens Bioelectron . 2017 ; 92 : 8 – 15 . Available from : http : / / linkin ghub . elsevier . com / retrieve / pii / S0956566317300635 [ 196 ] Liang K , Liu F , Fan J , et al . Nanoplasmonic quantifica - tion of tumor - derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring . Nat Biomed Eng . 2017 ; 1 ( 4 ) : 0021 . Available from : http : / / www . nature . com / articles / s41551 - 016 - 0021 [ 197 ] Rupert DLM , Lässer C , Eldh M , et al . Determination of exosome concentration in solution using surface plas - mon resonance spectroscopy . Anal Chem . 2014 ; 86 ( 12 ) : 5929 – 5936 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / ac500931f 36 C . THÉRY AND K . W . WITWER [ 198 ] Webber J , Clayton A How pure are your vesicles ? J Extracell Vesicles . 2013 ; 2 : 19861 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 24009896 [ 199 ] Maiolo D , Paolini L , Di Noto G , et al . Colorimetric nanoplasmonic assay to determine purity and titrate extracellular vesicles . Anal Chem . 2015 ; 87 ( 8 ) : 4168 – 4176 . Available from : http : / / pubs . acs . org / doi / abs / 10 . 1021 / ac504861d [ 200 ] Lai RC , Arslan F , Lee MM , et al . Exosome secreted by MSC reduces myocardial ischemia / reperfusion injury . Stem Cell Res . 2010 ; 4 ( 3 ) : 214 – 222 . [ 201 ] CvjetkovicA , LotvallJ , LasserCTheinfluenceofrotortype and centrifugation time on the yield and purity of extra - cellular vesicles . J Extracell Vesicles . 2014 ; 3 : 23111 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 24678386 [ 202 ] Valkonen S , van der Pol E , Böing A , et al . Biological reference materials for extracellular vesicle studies . Eur J Pharm Sci . 2017 ; 98 : 4 – 16 . Available from : http : / / lin kinghub . elsevier . com / retrieve / pii / S0928098716303578 [ 203 ] Minciacchi VR , You S , Spinelli C , et al . Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor - derived extracellular vesicles . Oncotarget . 2015 ; 6 ( 13 ) : 11327 – 11341 . Available from : http : / / www . oncotarget . com / fulltext / 3598 [ 204 ] Keerthikumar S , Gangoda L , Liem M , et al . Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes . Oncotarget . 2015 ; 6 ( 17 ) : 15375 – 15396 . Available from : http : / / www . oncotar get . com / fulltext / 3801 [ 205 ] Haraszti RA , Didiot M - C , Sapp E , et al . High - resolution proteomic and lipidomic analysis of exo - somes and microvesicles from different cell sources . J Extracell Vesicles . 2016 ; 5 ( 1 ) : 32570 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v5 . 32570 [ 206 ] Clark DJ , Fondrie WE , Liao Z , et al . Redefining the breast cancer exosome proteome by tandem mass tag quantita - tive proteomics and multivariate cluster analysis . Anal Chem . 2015 ; 87 ( 20 ) : 10462 – 10469 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acs . analchem . 5b02586 [ 207 ] Durcin M , Fleury A , Taillebois E , et al . Characterisation of adipocyte - derived extracellular vesicle subtypes iden - tifies distinct protein and lipid signatures for large and small extracellular vesicles . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1305677 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1305677 [ 208 ] Kowal J , Arras G , Colombo M , et al . Proteomic com - parison defines novel markers to characterize hetero - geneous populations of extracellular vesicle subtypes . Proc Natl Acad Sci . 2016 ; 113 ( 8 ) : E968 – 77 . Available from : http : / / www . pnas . org / lookup / doi / 10 . 1073 / pnas . 1521230113 [ 209 ] Xu R , Greening DW , Rai A , et al . Highly - purified exosomes and shed microvesicles isolated from the human colon cancer cell line LIM1863 by sequential centrifugal ultrafiltration are biochemically and func - tionally distinct . Methods . 2015 ; 87 : 11 – 25 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S1046202315001541 [ 210 ] Willms E , Johansson HJ , Mäger I , et al . Cells release subpopulations of exosomes with distinct molecular and biological properties . Sci Rep . 2016 ; 6 ( 1 ) : 22519 . Available from : http : / / www . nature . com / articles / srep22519 [ 211 ] Meehan B , Rak J , Di Vizio D Oncosomes - large and small : what are they , where they came from ? J Extracell Vesicles . 2016 ; 5 : 33109 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27680302 [ 212 ] Sódar BW , Kittel Á , Pálóczi K , et al . Low - density lipoprotein mimics blood plasma - derived exosomes and microvesicles during isolation and detection . Sci Rep . 2016 ; 6 : 24316 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27087061 [ 213 ] Karimi N , Cvjetkovic A , Jang SC , et al . Detailed ana - lysis of the plasma extracellular vesicle proteome after separation from lipoproteins . Cell Mol Life Sci . 2018 ; 75 ( 15 ) : 2873 – 2886 . Available from : http : / / link . springer . com / 10 . 1007 / s00018 - 018 - 2773 - 4 [ 214 ] Østergaard O , Nielsen CT , Iversen LV , et al . Quantitative proteome profiling of normal human cir - culating microparticles . J Proteome Res . 2012 ; 11 ( 4 ) : 2154 – 2163 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / pr200901p [ 215 ] Musante L , Saraswat M , Duriez E , et al . Biochemical and physical characterisation of urinary nanovesicles following CHAPS treatment . PLoS One . 2012 ; 7 ( 7 ) : e37279 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 22808001 [ 216 ] Van Deun J , Mestdagh P , Sormunen R , et al . The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling . J Extracell Vesicles . 2014 ; 3 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25317274 [ 217 ] McKenzie AJ , Hoshino D , Hong NH , et al . KRAS - MEK Signaling Controls Ago2 Sorting into Exosomes . Cell Rep . 2016 ; 15 ( 5 ) : 978 – 987 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27117408 [ 218 ] Melo SAA , Sugimoto H , O ’ Connell JT , et al . Cancer exosomes perform cell - independent microRNA bio - genesis and promote tumorigenesis . Cancer Cell . 2014 ; 26 ( 5 ) : 707 – 721 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25446899 [ 219 ] Buck AH , Coakley G , Simbari F , et al . Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity . Nat Commun . 2014 ; 5 ( 1 ) : 5488 . Available from : http : / / www . nature . com / articles / ncomms6488 [ 220 ] Tkach M , Kowal J , Zucchetti AE , et al . Qualitative differences in T - cell activation by dendritic cell - derived extracellular vesicle subtypes . Embo J . 2017 ; 36 ( 20 ) : 3012 – 3028 . Available from : http : / / emboj . embopress . org / lookup / doi / 10 . 15252 / embj . 201696003 [ 221 ] Jorgensen MM , Baek R , Varming K Potentials and capabilities of the Extracellular Vesicle ( EV ) Array . J Extracell Vesicles . 2015 ; 4 : 26048 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25862471 [ 222 ] Gool EL , Stojanovic I , Schasfoort RBM , et al . Surface plasmon resonance is an analytically sensitive method for antigen profiling of extracellular vesicles . Clin Chem . 2017 ; 63 ( 10 ) : 1633 – 1641 . Available from : http : / / www . clin chem . org / lookup / doi / 10 . 1373 / clinchem . 2016 . 271049 [ 223 ] Zhu L , Wang K , Cui J , et al . Label - free quantitative detection of tumor - derived exosomes through surface JOURNAL OF EXTRACELLULAR VESICLES 37 plasmon resonance imaging . Anal Chem . 2014 ; 86 ( 17 ) : 8857 – 8864 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / ac5023056 [ 224 ] Shao H , Im H , Castro CM , et al . New technologies for analysis of extracellular vesicles . Chem Rev . 2018 ; 118 ( 4 ) : 1917 – 1950 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acs . chemrev . 7b00534 [ 225 ] Skotland T , Sandvig K , Llorente A Lipids in exosomes : current knowledge and the way forward . Prog Lipid Res . 2017 ; 66 : 30 – 41 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0163782716300492 [ 226 ] Record M , Carayon K , Poirot M , et al . Exosomes as new vesicular lipid transporters involved in cell - cell commu - nication and various pathophysiologies . Biochim Biophys Acta . 2014 ; 1841 ( 1 ) : 108 – 120 . Available from : http : / / linkin ghub . elsevier . com / retrieve / pii / S1388198113002199 [ 227 ] Nielsen MH , Beck - Nielsen H , Andersen MN , et al . A flow cytometric method for characterization of circu - lating cell - derived microparticles in plasma . J Extracell Vesicles . 2014 ; 3 ( 1 ) : 20795 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v3 . 20795 [ 228 ] de Gassart A , Geminard C , Fevrier B , et al . Lipid raft - associated protein sorting in exosomes . Blood . 2003 ; 102 ( 13 ) : 4336 – 4344 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 12881314 [ 229 ] Gualerzi A , Niada S , Giannasi C , et al . Raman spectro - scopy uncovers biochemical tissue - related features of extracellular vesicles from mesenchymal stromal cells . Sci Rep . 2017 ; 7 ( 1 ) : 9820 . Available from : http : / / www . nature . com / articles / s41598 - 017 - 10448 - 1 [ 230 ] Neri T , Lombardi S , Faìta F , et al . Pirfenidone inhibits p38 - mediated generation of procoagulant microparti - cles by human alveolar epithelial cells . Pulm Pharmacol Ther . 2016 ; 39 : 1 – 6 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27237042 [ 231 ] de Rond L , van der Pol E , Hau CM , et al . Comparison of generic fluorescent markers for detection of extra - cellular vesicles by flow cytometry . Clin Chem . 2018 ; 64 ( 4 ) : 680 – 689 . Available from : http : / / www . clinchem . org / lookup / doi / 10 . 1373 / clinchem . 2017 . 278978 [ 232 ] Ullal AJ , Pisetsky DS , Reich CF . Use of SYTO 13 , a fluorescent dye binding nucleic acids , for the detec - tion of microparticles in in vitro systems . Cytometry A . 2010 ; 77 ( 3 ) : 294 – 301 . [ 233 ] Sansone P , Savini C , Kurelac I , et al . Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy - resistant breast cancer . Proc Natl Acad Sci U S A . 2017 ; 114 ( 43 ) : E9066 – 75 . Available from : http : / / www . pnas . org / lookup / doi / 10 . 1073 / pnas . 1704862114 [ 234 ] Crescitelli R , Lässer C , Szabó TG , et al . Distinct RNA profiles in subpopulations of extracellular vesicles : apoptotic bodies , microvesicles and exosomes . J Extracell Vesicles . 2013 ; 2 ( 1 ) : 20677 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 24223256 [ 235 ] Nolte - ’ t Hoen EN , Buermans HP , Waasdorp M , et al . Deep sequencing of RNA from immune cell - derived vesicles uncovers the selective incor - poration of small non - coding RNA biotypes with potential regulatory functions . Nucleic Acids Res . 2012 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 22821563 [ 236 ] Villarroya - Beltri C , Gutierrez - Vazquez C , Sanchez - Cabo F , et al . Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs . Nat Commun . 2013 ; 4 : 2980 . [ 2013 / 12 / 21 ] . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 24356509 [ 237 ] Vojtech L , Woo S , Hughes S , et al . Exosomes in human semen carry a distinctive repertoire of small non - coding RNAs with potential regulatory functions . Nucleic Acids Res . 2014 ; 42 ( 11 ) : 7290 – 7304 . Available from : https : / / academic . oup . com / nar / article - lookup / doi / 10 . 1093 / nar / gku347 [ 238 ] Tosar JP , Gambaro F , Sanguinetti J , et al . Assessment of small RNA sorting into different extracellular frac - tions revealed by high - throughput sequencing of breast cell lines . Nucleic Acids Res . 2015 ; 43 ( 11 ) : 5601 – 5616 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25940616 [ 239 ] van Balkom BWM , Eisele AS , Pegtel DM , et al . Quantitative and qualitative analysis of small RNAs in human endothelial cells and exosomes provides insights into localized RNA processing , degradation and sorting . J Extracell Vesicles . 2015 ; 4 ( 1 ) : 26760 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v4 . 26760 [ 240 ] Li K , Rodosthenous RS , Kashanchi F , et al . Advances , challenges , and opportunities in extracellular RNA biology : insights from the NIH exRNA strategic workshop . JCI Insight . 2018 ; 3 ( 7 ) . Available from : https : / / insight . jci . org / articles / view / 98942 [ 241 ] Chen M , Xu R , Ji H , et al . Transcriptome and long noncoding RNA sequencing of three extracellular vesi - cle subtypes released from the human colon cancer LIM1863 cell line . Sci Rep . 2016 ; 6 ( 1 ) : 38397 . Available from : http : / / www . nature . com / articles / srep38397 [ 242 ] Lai CP , Kim EY , Badr CE . , et al . Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters . Nat Commun . 2015 ; 6 ( May ) : 7029 . [ 243 ] Ter - Ovanesyan D , Kowal EJK , Regev A , et al . Imaging of isolated extracellular vesicles using fluorescence microscopy . Methods Mol Biol . 2017 ; 1660 : 233 – 241 . Available from : http : / / link . springer . com / 10 . 1007 / 978 - 1 - 4939 - 7253 - 1 _ 19 [ 244 ] Wu Y , Deng W , Klinke DJ . Exosomes : improved methods to characterize their morphology , RNA con - tent , and surface protein biomarkers . Analyst . 2015 ; 140 ( 19 ) : 6631 – 6642 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26332016 [ 245 ] Linares R , Tan S , Gounou C , et al . High - speed centri - fugation induces aggregation of extracellular vesicles . J Extracell Vesicles . 2015 ; 4 ( 0 ) : 29509 . Available from : http : / / www . journalofextracellularvesicles . net / index . php / jev / article / view / 29509 [ 246 ] Höög JL , Lötvall J Diversity of extracellular vesicles in human ejaculates revealed by cryo - electron microscopy . J Extracell Vesicles . 2015 ; 4 : 28680 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26563734 [ 247 ] Sharma S , Rasool HI , Palanisamy V , et al . Structural - mechanical characterization of nanoparticle exosomes in human saliva , using correlative AFM , FESEM , and force spectroscopy . ACS Nano . 2010 ; 4 ( 4 ) : 1921 – 1926 . 38 C . THÉRY AND K . W . WITWER Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 20218655 [ 248 ] Treps L , Perret R , Edmond S , et al . Glioblastoma stem - like cells secrete the pro - angiogenic VEGF - A factor in extra - cellular vesicles . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1359479 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1359479 [ 249 ] Chen C , Zong S , Wang Z , et al . Imaging and intracel - lular tracking of cancer - derived exosomes using single - molecule localization - based super - resolution microscope . ACS Appl Mater Interfaces . 2016 ; 8 ( 39 ) : 25825 – 25833 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acsami . 6b09442 [ 250 ] Mehdiani A , Maier A , Pinto A , et al . An innovative method for exosome quantification and size measurement . J Vis Exp . 2015 ; 95 : 50974 . Available from : http : / / www . jove . com / video / 50974 / an - innovative - method - for - exosome - quantification - and - size - measurement [ 251 ] Tatischeff I , Larquet E , Falcón - Pérez JM , et al . Fast char - acterisation of cell - derived extracellular vesicles by nano - particles tracking analysis , cryo - electron microscopy , and Raman tweezers microspectroscopy . J Extracell Vesicles . 2012 ; 1 ( 1 ) : 19179 . Available from : https : / / www . tandfon line . com / doi / full / 10 . 3402 / jev . v1i0 . 19179 [ 252 ] Carney RP , Hazari S , Colquhoun M , et al . Multispectral optical tweezers for biochemical finger - printing of CD9 - positive exosome subpopulations . Anal Chem . 2017 ; 89 ( 10 ) : 5357 – 5363 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acs . analchem . 7b00017 [ 253 ] Smith ZJ , Lee C , Rojalin T , et al . Single exosome study reveals subpopulations distributed among cell lines with variability related to membrane content . J Extracell Vesicles . 2015 ; 4 ( 1 ) : 28533 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v4 . 28533 [ 254 ] Stoner SA , Duggan E , Condello D , et al . High sensi - tivity flow cytometry of membrane vesicles . Cytom Part A . 2016 ; 89 ( 2 ) : 196 – 206 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26484737 [ 255 ] Nolan JP , Jones JC . Detection of platelet vesicles by flow cytometry . Platelets . 2017 ; 28 ( 3 ) : 256 – 262 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 28277059 [ 256 ] Sitar S , Kej ž ar A , Pahovnik D , et al . Size characterization and quantification of exosomes by asymmetrical - flow field - flow fractionation . Anal Chem . 2015 ; 87 ( 18 ) : 9225 – 9233 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acs . analchem . 5b01636 [ 257 ] Heusermann W , Hean J , Trojer D , et al . Exosomes surf on filopodia to enter cells at endocytic hot spots , traffic within endosomes , and are targeted to the ER . J Cell Biol . 2016 ; 213 ( 2 ) : 173 – 184 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 27114500 [ 258 ] Wyss R , Grasso L , Wolf C , et al . Molecular and dimen - sional profiling of highly purified extracellular vesicles by fluorescence fluctuation spectroscopy . Anal Chem . 2014 ; 86 ( 15 ) : 7229 – 7233 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / ac501801m [ 259 ] Baietti MF , Zhang Z , Mortier E , et al . Syndecan – syn - tenin – ALIX regulates the biogenesis of exosomes . Nat Cell Biol . 2012 ; 14 ( 7 ) : 677 – 685 . [ 260 ] Erdbrügger U , Rudy CK , Etter ME , et al . Imaging flow cytometry elucidates limitations of microparticle analysis by conventional flow cytometry . Cytometry A . 2014 ; 85 ( 9 ) : 756 – 770 . [ 261 ] Headland SE , Jones HR , Asv D , et al . Cutting - edge analysis of extracellular microparticles using ImageStream ( X ) imaging flow cytometry . Sci Rep . 2014 ; 4 ( 1 ) : 5237 . Available from : http : / / www . nature . com / articles / srep05237 [ 262 ] Lee K , Fraser K , Ghaddar B , et al . Multiplexed profil - ing of single extracellular vesicles . ACS Nano . 2018 ; 12 ( 1 ) : 494 – 503 . Available from : http : / / pubs . acs . org / doi / 10 . 1021 / acsnano . 7b07060 [ 263 ] Daaboul GG , Lopez CA , Yurt A , et al . Label - free optical biosensors for virus detection and characterization . IEEE J Sel Top Quantum Electron . 2012 ; 18 ( 4 ) : 1422 – 1433 . [ 264 ] Daaboul GG , Freedman DS , Scherr SM , et al . Enhanced light microscopy visualization of virus par - ticles from Zika virus to filamentous ebolaviruses . PLoS One . 2017 ; 12 ( 6 ) : e0179728 . [ 265 ] van der Pol E , Sturk A , van Leeuwen T , et al . , ISTH - SSC - VB Working group . Standardization of extracel - lular vesicle measurements by flow cytometry through vesicle diameter approximation . J Thromb Haemost . 2018 ; 16 ( 6 ) : 1236 – 1245 . [ 266 ] Cvjetkovic A , Jang SC , Kone č ná B , et al . Detailed analysis of protein topology of extracellular vesicles - evidence of unconventional membrane protein orientation . Sci Rep . 2016 ; 6 ( 1 ) : 36338 . Available from : http : / / www . nature . com / articles / srep36338 [ 267 ] Deregibus MC , Cantaluppi V , Calogero R , et al . Endothelial progenitor cell derived microvesicles acti - vate an angiogenic program in endothelial cells by a horizontal transfer of mRNA . Blood . 2007 ; 110 ( 7 ) : 2440 – 2448 . Available from : http : / / www . bloodjour nal . org / cgi / doi / 10 . 1182 / blood - 2007 - 03 - 078709 [ 268 ] Sharma A , Mariappan M , Appathurai S , et al . In vitro dissection of protein translocation into the mammalian endoplasmic reticulum . Methods Mol Biol . 2010 ; 619 : 339 – 363 . Available from : http : / / link . springer . com / 10 . 1007 / 978 - 1 - 60327 - 412 - 8 _ 20 [ 269 ] Sung BH , Weaver AM . Exosome secretion promotes chemotaxis of cancer cells . Cell Adh Migr . 2017 ; 11 ( 2 ) : 187 – 195 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 1080 / 19336918 . 2016 . 1273307 [ 270 ] Osteikoetxea X , Sódar B , Németh A , et al . Differential detergent sensitivity of extracellular vesicle subpopulations . Org Biomol Chem . 2015 ; 13 ( 38 ) : 9775 – 9782 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26264754 [ 271 ] Parolini I , Federici C , Raggi C , et al . Microenvironmental pH is a key factor for exosome traffic in tumor cells . J Biol Chem . 2009 ; 284 ( 49 ) : 34211 – 34222 . Available from : http : / / www . jbc . org / lookup / doi / 10 . 1074 / jbc . M109 . 041152 [ 272 ] Franzen CA , Simms PE , Van Huis AF , et al . Characterization of uptake and internalization of exo - somes by bladder cancer cells . Biomed Res Int . 2014 ; 2014 : 619829 . Available from : http : / / www . hin dawi . com / journals / bmri / 2014 / 619829 / [ 273 ] Christianson HC , Svensson KJ , van Kuppevelt TH , et al . Cancer cell exosomes depend on cell - surface heparan sulfate proteoglycans for their internalization JOURNAL OF EXTRACELLULAR VESICLES 39 and functional activity . Proc Natl Acad Sci U S A . 2013 ; 110 ( 43 ) : 17380 – 17385 . Available from : http : / / www . pnas . org / cgi / doi / 10 . 1073 / pnas . 1304266110 [ 274 ] Mulcahy LA , Pink RC , Carter DRF . Routes and mechanisms of extracellular vesicle uptake . J Extracell Vesicles . 2014 ; 3 : 24641 . Available from : https : / / www . tandfonline . com / doi / full / 10 . 3402 / jev . v3 . 24641 [ 275 ] Wahlgren J , Karlson TDL , Glader P , et al . Activated human T cells secrete exosomes that participate in IL - 2 mediated immune response signaling . PLoS One . 2012 ; 7 ( 11 ) : e49723 . Available from : http : / / dx . plos . org / 10 . 1371 / journal . pone . 0049723 [ 276 ] Szabó GT , Tarr B , Pálóczi K , et al . Critical role of extracellular vesicles in modulating the cellular effects of cytokines . Cell Mol Life Sci . 2014 ; 71 ( 20 ) : 4055 – 4067 . Available from : http : / / link . springer . com / 10 . 1007 / s00018 - 014 - 1618 - z [ 277 ] Gámez - Valero A , Monguió - Tortajada M , Carreras - Planella L , et al . Size - exclusion chromatography - based isolation minimally alters extracellular vesicles ’ characteristics compared to precipitating agents . Sci Rep . 2016 ; 6 ( 1 ) : 33641 . Available from : http : / / www . nat ure . com / articles / srep33641 [ 278 ] Paolini L , Zendrini A , Di Noto G , et al . Residual matrix from different separation techniques impacts exosome biological activity . Sci Rep . 2016 ; 6 ( 1 ) : 23550 . Available from : http : / / www . nature . com / articles / srep23550 [ 279 ] Gyorgy B , Modos K , Pallinger E , et al . Detection and isolation of cell - derived microparticles are compro - mised by protein complexes resulting from shared biophysical parameters . Blood . 2011 ; 117 ( 4 ) : e39 – 48 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 21041717 [ 280 ] Benedikter BJ , Bouwman FG , Vajen T , et al . Ultrafiltration combined with size exclusion chroma - tography efficiently isolates extracellular vesicles from cell culture media for compositional and functional studies . Sci Rep . 2017 ; 7 ( 1 ) : 15297 . Available from : http : / / www . nature . com / articles / s41598 - 017 - 15717 - 7 [ 281 ] Trajkovic K , Hsu C , Chiantia S , et al . Ceramide trig - gers budding of exosome vesicles into multivesicular endosomes . Science . 2008 ; 319 ( 5867 ) : 1244 – 1247 . Available from : http : / / www . sciencemag . org / cgi / doi / 10 . 1126 / science . 1153124 [ 282 ] Figuera - Losada M , Stathis M , Dorskind JM , et al . Cambinol , a novel inhibitor of neutral sphingomyeli - nase 2 shows neuroprotective properties . PLoS One . 2015 ; 10 ( 5 ) : e0124481 . Available from : http : / / dx . plos . org / 10 . 1371 / journal . pone . 0124481 [ 283 ] Dinkins MB , Enasko J , Hernandez C , et al . Neutral sphingomyelinase - 2 deficiency ameliorates alzheimer ’ s disease pathology and improves cognition in the 5XFAD mouse . J Neurosci . 2016 ; 36 ( 33 ) : 8653 – 8667 . Available from : http : / / www . jneurosci . org / lookup / doi / 10 . 1523 / JNEUROSCI . 1429 - 16 . 2016 [ 284 ] Cruz FF , Borg ZD , Goodwin M , et al . Systemic admin - istration of human bone marrow - derived mesenchy - mal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract - induced allergic airway inflammation in immunocompetent mice . Stem Cells Transl Med . 2015 ; 4 ( 11 ) : 1302 – 1316 . [ 285 ] Villarroya - Beltri C , Baixauli F , Mittelbrunn M , et al . ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins . Nat Commun . 2016 ; 7 : 13588 . Available from : http : / / www . nature . com / doifinder / 10 . 1038 / ncomms13588 [ 286 ] Savina A , Vidal M , Colombo MI . The exosome path - way in K562 cells is regulated by Rab11 . J Cell Sci . 2002 ; 115 ( Pt 12 ) : 2505 – 2515 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 12045221 [ 287 ] Ostrowski M , Carmo NB , Krumeich S , et al . Rab27a and Rab27b control different steps of the exosome secretion pathway . Nat Cell Biol . 2010 ; 12 ( 1 ) : 13 – 19 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 19966785 [ 288 ] Hsu C , Morohashi Y , Yoshimura S - I , et al . Regulation of exosome secretion by Rab35 and its GTPase - activating proteins TBC1D10A - C . J Cell Biol . 2010 ; 189 ( 2 ) : 223 – 232 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 20404108 [ 289 ] Hyenne V , Apaydin A , Rodriguez D , et al . RAL - 1 controls multivesicular body biogenesis and exosome secretion . J Cell Biol . 2015 ; 211 ( 1 ) : 27 – 37 . Available from : http : / / www . jcb . org / lookup / doi / 10 . 1083 / jcb . 201504136 [ 290 ] Gross JC , Chaudhary V , Bartscherer K , et al . Active Wnt proteins are secreted on exosomes . Nat Cell Biol . 2012 ; 14 ( 10 ) : 1036 – 1045 . Available from : http : / / www . nature . com / articles / ncb2574 [ 291 ] Imjeti NS , Menck K , Egea - Jimenez AL , et al . Syntenin mediates SRC function in exosomal cell - to - cell communication . Proc Natl Acad Sci U S A . 2017 ; 114 ( 47 ) : 12495 – 12500 . Available from : http : / / www . pnas . org / lookup / doi / 10 . 1073 / pnas . 1713433114 [ 292 ] Sinha S , Hoshino D , Hong NH , et al . Cortactin pro - motes exosome secretion by controlling branched actin dynamics . J Cell Biol . 2016 ; 214 ( 2 ) : 197 – 213 . Available from : http : / / www . jcb . org / lookup / doi / 10 . 1083 / jcb . 201601025 [ 293 ] Jackson CE , Scruggs BS , Schaffer JE , et al . Effects of inhibiting VPS4 support a general role for ESCRTs in extracellular vesicle biogenesis . Biophys J . 2017 ; 113 ( 6 ) : 1342 – 1352 . Available from : http : / / linkinghub . else vier . com / retrieve / pii / S0006349517305714 [ 294 ] Chalmin F , Ladoire S , Mignot G , et al . Membrane - associated Hsp72 from tumor - derived exosomes med - iates STAT3 - dependent immunosuppressive function of mouse and human myeloid - derived suppressor cells . J Clin Invest . 2010 ; 120 ( 2 ) : 457 – 471 . Available from : http : / / www . jci . org / articles / view / 40483 [ 295 ] Montecalvo A , Larregina AT , Shufesky WJ , et al . Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes . Blood . 2012 ; 119 ( 3 ) : 756 – 766 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 22031862 [ 296 ] Savina A , Furlán M , Vidal M , et al . Exosome release is regulated by a calcium - dependent mechanism in K562 cells . J Biol Chem . 2003 ; 278 ( 22 ) : 20083 – 20090 . Available from : http : / / www . jbc . org / lookup / doi / 10 . 1074 / jbc . M301642200 [ 297 ] Minakaki G , Menges S , Kittel A , et al . Autophagy inhibition promotes SNCA / alpha - synuclein release and transfer via extracellular vesicles with a hybrid 40 C . THÉRY AND K . W . WITWER autophagosome - exosome - like phenotype . Autophagy . 2018 ; 14 ( 1 ) : 98 – 119 . Available from : https : / / www . tand fonline . com / doi / full / 10 . 1080 / 15548627 . 2017 . 1395992 [ 298 ] Edgar JR , Manna PT , Nishimura S , et al . Tetherin is an exosomal tether . Elife . 2016 ; 5 : 17180 . Available from : https : / / elifesciences . org / articles / 17180 [ 299 ] Atai NA , Balaj L , van Veen H , et al . Heparin blocks transfer of extracellular vesicles between donor and reci - pient cells . J Neurooncol . 2013 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 24002181 [ 300 ] Wang Q , Lu Q Plasma membrane - derived extracellular microvesicles mediate non - canonical intercellular NOTCH signaling . Nat Commun . 2017 ; 8 ( 1 ) : 709 . Available from : http : / / www . nature . com / articles / s41467 - 017 - 00767 - 2 [ 301 ] Nabhan JF , Hu R , Oh RS , et al . Formation and release of arrestin domain - containing protein 1 - mediated microvesicles ( ARMMs ) at plasma membrane by recruitment of TSG101 protein . Proc Natl Acad Sci U S A . 2012 ; 109 ( 11 ) : 4146 – 4151 . Available from : http : / / www . pnas . org / cgi / doi / 10 . 1073 / pnas . 1200448109 [ 302 ] Muralidharan - Chari V , Clancy J , Plou C , et al . ARF6 - regulated shedding of tumor cell - derived plasma mem - brane microvesicles . Curr Biol . 2009 ; 19 ( 22 ) : 1875 – 1885 . Available from : http : / / linkinghub . elsevier . com / retrieve / pii / S0960982209017722 [ 303 ] Burger D , Montezano AC , Nishigaki N , et al . Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I / NADPH oxi - dase / Rho kinase pathways targeted to lipid rafts . Arterioscler Thromb Vasc Biol . 2011 ; 31 ( 8 ) : 1898 – 1907 . Available from : http : / / atvb . ahajour nals . org / cgi / doi / 10 . 1161 / ATVBAHA . 110 . 222703 [ 304 ] Gao C , Li R , Liu Y , et al . Rho - kinase - dependent F - actin rearrangement is involved in the release of endothelial microparticles during IFN - α - induced endothelial cell apoptosis . J Trauma Acute Care Surg . 2012 ; 73 ( 5 ) : 1152 – 1160 . Available from : http : / / content . wkhealth . com / linkback / openurl ? sid = WKPTLP : landing page & an = 01586154 - 201211000 - 00017 [ 305 ] Yu X , Xu J , Liu W , et al . Bubbles induce endothelial microparticle formation via a calcium - dependent path - way involving flippase inactivation and rho kinase activation . Cell Physiol Biochem . 2018 ; 46 ( 3 ) : 965 – 974 . Available from : https : / / www . karger . com / Article / FullText / 488825 [ 306 ] Di Vizio D , Kim J , Hager MH , et al . Oncosome for - mation in prostate cancer : association with a region of frequent chromosomal deletion in metastatic disease . Cancer Res . 2009 ; 69 ( 13 ) : 5601 – 5609 . Available from : http : / / cancerres . aacrjournals . org / cgi / doi / 10 . 1158 / 0008 - 5472 . CAN - 08 - 3860 [ 307 ] Schwechheimer C , Kuehn MJ . Outer - membrane vesi - cles from Gram - negative bacteria : biogenesis and functions . Nat Rev Microbiol 2015 ; 13 ( 10 ) : 605 – 619 . Available from : http : / / www . nature . com / articles / nrmicro3525 [ 308 ] Colombo M , Raposo G , Théry C Biogenesis , secretion , and intercellular interactions of exosomes and other extracellular vesicles . Annu Rev Cell Dev Biol . 2014 ; 30 ( 1 ) : 255 – 289 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25288114 [ 309 ] Romancino DP , Paterniti G , Campos Y , et al . Identification and characterization of the nano - sized vesicles released by muscle cells . FEBS Lett . 2013 ; 587 ( 9 ) : 1379 – 1384 . [ 310 ] Booth AM , Fang Y , Fallon JK , et al . Exosomes and HIV Gag bud from endosome - like domains of the T cell plasma membrane . J Cell Biol . 2006 ; 172 ( 6 ) : 923 – 935 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 16533950 [ 311 ] Hoang TQ , Rampon C , Freyssinet J - M , et al . A method to assess the migration properties of cell - derived microparticles within a living tissue . Biochim Biophys Acta . 2011 ; 1810 ( 9 ) : 863 – 866 . Available from : http : / / lin kinghub . elsevier . com / retrieve / pii / S0304416511001061 [ 312 ] Menck K , Sönmezer C , Worst TS , et al . Neutral sphin - gomyelinases control extracellular vesicles budding from the plasma membrane . J Extracell Vesicles . 2017 ; 6 ( 1 ) : 1378056 . Available from : https : / / www . tand fonline . com / doi / full / 10 . 1080 / 20013078 . 2017 . 1378056 [ 313 ] Bobrie A , Colombo M , Krumeich S , et al . Diverse subpopulations of vesicles secreted by different intra - cellular mechanisms are present in exosome prepara - tions obtained by differential ultracentrifugation . J Extracell Vesicles . 2012 ; 1 : 18297 . [ 314 ] Peinado H , Ale č kovi ć M , Lavotshkin S , et al . Melanoma exosomes educate bone marrow progenitor cells toward a pro - metastatic phenotype through MET . Nat Med . 2012 ; 18 ( 6 ) : 883 – 891 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 22635005 [ 315 ] Kim DK , Kang B , Kim OY , et al . EVpedia : an inte - grated database of high - throughput data for systemic analyses of extracellular vesicles . J Extracell Vesicles . 2013 ; 2 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 24009897 [ 316 ] Kim D - K , Lee J , Kim SR , et al . EVpedia : a community web portal for extracellular vesicles research . Bioinformatics . 2015 ; 31 ( 6 ) : 933 – 939 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 25388151 [ 317 ] Kalra H , Simpson RJ , Ji H , et al . Vesiclepedia : a compendium for extracellular vesicles with continu - ous community annotation . PLoS Biol . 2012 ; 10 ( 12 ) : e1001450 . [ 318 ] Mathivanan S , Simpson RJ . ExoCarta : A compendium of exosomal proteins and RNA . Proteomics . 2009 ; 9 ( 21 ) : 4997 – 5000 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 19810033 [ 319 ] Subramanian SL , Kitchen RR , Alexander R , et al . Integration of extracellular RNA profiling data using metadata , biomedical ontologies and linked data technologies . J Extracell Vesicles . 2015 ; 4 : 27497 . Available from : http : / / www . ncbi . nlm . nih . gov / pubmed / 26320941 JOURNAL OF EXTRACELLULAR VESICLES 41 MISEV2018 Checklist Numbers refer to sections listed in the Table of contents from : C . Théry and K . W . Witwer , et al , ” Minimal Information for Studies of Extracellular Vesicles 2018 ( MISEV2018 ) : a posi - tion statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines ” , J Extracell Vesicles 2018 ; 7 : 1535750 . O Mandatory O Mandatory if applicable O Encouraged 1 - Nomenclature Mandatory O Generic term extracellular vesicle ( EV ) : With demon - stration of extracellular ( no intact cells ) and vesicular nature per these characterization ( Section 4 ) and function ( Section 5 ) guidelines OR O Generic term , e . g . , extracellular particle ( EP ) : no intact cells but MISEV guidelines not satisfied Encouraged ( choose one ) O Generic term extracellular vesicle ( EV ) + specification ( size , density , other ) O Specific term for subcellular origin : e . g . , ectosome , microparticle , microvesicle ( from plasma membrane ) , exosome ( from endosomes ) , with demonstration of the subcellular origin O Other specific term : with definition of specific criteria 2 - Collection and pre - processing Tissue Culture Conditioned medium ( CCM , Section 2 - a ) O General cell characterization ( identity , passage , myco - plasma check … ) O Medium used before and during collection ( additives , serum , other ) O exact protocol for depletion of EVs / EPs from addi - tives in collection medium O Nature and size of culture vessels , and volume of medium during conditioning O specific culture conditions ( treatment , % O2 , coating , polarization … ) before and during collection O Number of cells / ml or / surface area and % of live / dead cells at time of collection ( or at time of seeding with estimation at time of collection ) O Frequency and interval of CM harvest Biofluids or Tissues ( Sections 2 - b and - c ) O Donor status if available ( age , sex , food / water intake , collection time , disease , medication , other ) O Volume of biofluid or volume / mass of tissue sample collected per donor O Total volume / mass used for EV isolation ( if pooled from several donors ) O All known collection conditions , including additives , at time of collection O Pre - treatment to separate major fluid - specific con - taminants before EV isolation O Temperature and time of biofluid / tissue handling before and during pre - treatment O For cultured tissue explants : volume , nature of med - ium and time of culture before collecting conditioned mediumOFordirect tissue EV extraction : treatment of tissue to release vesicles without disrupting cells Storage and recovery ( Section 2 - d ) O Storage and recovery ( e . g . , thawing ) of CCM , bio - fluid , or tissue before EV isolation ( storage tempera - ture , vessel , time ; method of thawing or other sample preparation ) O Storage and recovery of EVs after isolation ( tempera - ture , vessel , time , additive ( s ) … ) 3 - EV separation and concentration Experimental details of the method O Centrifugation : reference number of tube ( s ) , rotor ( s ) , adjusted k factor ( s ) of each centrifugation step ( = time + speed + rotor , volume / density of centrifugation condi - tions ) , temperature , brake settings O Density gradient : nature of matrix , method of gen - erating gradient , reference ( and size ) of tubes , bottom - up ( sample at bottom , high density ) or top - bottom ( sample on top , low density ) , centrifugation speed and time ( with brake specified ) , method and volume of fraction recovery O Chromatography : matrix ( nature , pore size , … ) , loaded sample volume , fraction volume , number O Precipitation : reference of polymer , ratio vol / vol or weight / vol polymer / fluid , time / temperature of incuba - tion , time / speed / temperature of centrifugation O Filtration : reference of filter type ( = nature of mem - brane , pore size … ) , time and speed of centrifugation , volume before / after ( in case of concentration ) O Antibody - based : reference of antibodies , mass Ab / amount of EVs , nature of Ab carrier ( bead , surface ) and amount of Ab / carrier surface O Other … : all necessary details to allow replication O Additional step ( s ) to concentrate , if any O Additional step ( s ) to wash matrix and / or sample , if any Specify category of the chosen EV separation / concentra - tion method ( Table 1 ) : O High recovery , low specificity = mixed EVs and non - EV components OR O Intermediate recovery , intermediate specificity = mixed EVs with limited non - EV components OR O Low recovery , high specificity = subtype ( s ) of EVs with as little non - EV as possible OR O High recovery , high specificity = subtype ( s ) of EVs with as little non - EV as possible 4 - EV characterization Quantification ( Table 2a , Section 4 - a ) O Volume of fluid , and / or cell number , and / or tissue mass used to isolate EVs O Global quantification by at least 2 methods : protein amount , particle number , lipid amount , expressed per volume of initial fluid or number of producing cells / mass of tissue O Ratio of the 2 quantification figures Global characterization ( Section 4 - b , Table 3 ) O Transmembrane or GPI - anchored protein localized in cells at plasma membrane or endosomes O Cytosolic protein with membrane - binding or - association capacity 42 C . THÉRY AND K . W . WITWER O Assessment of presence / absence of expected contaminants ( At least one each of the three categories above ) O Presence of proteins associated with compartments other than plasma membrane or endosomes O Presence of soluble secreted proteins and their likely transmembrane ligands O Topology of the relevant functional components ( Section 4 - d ) Single EV characterization ( Section 4 - c ) O Images of single EVs by wide - field and close - up : e . g . electron microscopy , scanning probe microscopy , super - resolution fluorescence microscopy O Non - image - based method analysing large numbers of single EVs : NTA , TRPS , FCS , high - resolution flow cytome - try , multi - angle light - scattering , Raman spectroscopy , etc . 5 - Functional studies O Dose - response assessment O Negative control = nonconditioned medium , bio - fluid / tissue from control donors , as applicable O Quantitative comparison of functional activity of total fluid , vs EV - depleted fluid , vs EVs ( after high recovery / low specificity separation ) O Quantitative comparison of functional activity of EVs vs other EPs / fractions after low recovery / high spe - cificity separation O Quantitative comparison of activity of EV subtypes ( if subtype - specific function claimed ) O Extent of functional activity in the absence of contact between EV donor and EV recipient 6 - Reporting O Submission of methodologic details to EV - TRACK ( evtrack . org ) with EV - TRACK number provided ( strongly encouraged ) O Submission of data ( proteomic , sequencing , other ) to relevant public , curated databases or open - access repositoriesODatasubmission to EV - specific databases ( e . g . , EVpedia , Vesiclepedia , exRNA atlas ) O Temper EV - specific claims when MISEV require - ments cannot be entirely satisfied ( Section 6 - b ) JOURNAL OF EXTRACELLULAR VESICLES 43